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ABSTRACT 
 
Gonorrhea is caused by the human pathogen Neisseria gonorrhoeae. More than 106 
million new cases of N. gonorrhoeae infections occur each year worldwide. There is no vaccine 
available against gonococcal infections and treatment of gonorrhea with antibiotics is the only 
way to eradicate infection. The high prevalence of antibiotic resistance (AMR) in this 
microorganism makes the effective treatment of gonococcal infections increasingly problematic. 
The emergence of AMR, especially to extended spectrum cephalosporins (i.e. cefixime and 
ceftriaxone) which are the last possibilities for single dose treatment options for gonococcal 
infections, is a serious concern. Gonorrhea may become an untreatable infection in the near 
future.   
 
 Saskatchewan (SK) has one of the highest rates of gonorrhea in Canada. In order to better 
characterize the gonorrhea epidemic in SK, the objectives of the present research were to 
determine the prevalence and trends of AMR and emerging AMR mechanisms in N. 
gonorrhoeae isolates. AMR mechanisms were ascertained for the first time in SK in order to 
identify genetic causes of resistance. This was completed by determining and analyzing the DNA 
sequences of various genes - penA, mtrR, porB ponA, gyrA, parC mtrR, 23S rRNA alleles and 
erm –implicated in gonococcal AMR. The population dynamics of the N. gonorrhoeae isolates in 
SK was investigated by DNA based molecular methods to determine strain distribution, 
evolution of AMR phenotypes, and association between strain types (STs) and AMR genotypes 
and phenotypes.  
 
N. gonorrhoeae isolates (n=427) from Saskatchewan (2003-2011) were susceptible to 
antibiotics now recommended for treatment - cefixime, ceftriaxone and spectinomycin. Over 
95% of the isolates tested were also susceptible to penicillin (96%) and ciprofloxacin (95.5%), 
antibiotics no longer recommended for treatment, and azithromycin (99.4%). Tetracycline 
resistance was also high (50.1%).   
 
N. gonorrhoeae isolates that were resistant to the antibiotics tested and also those isolates 
with MICs ≥0.003 mg/L to cefixime and ceftriaxone were analyzed (n=146) to determine their 
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resistance mechanisms. This analysis revealed that reduced susceptibility to ceftriaxone and 
cefixime and resistance to penicillin is mediated by specific mutations in penicillin binding 
protein 2 (PBP2), in the promoter and dimerization domains of MtrR and porin protein (PorB). 
Novel mutations and combinations of mutations were noted. Ciprofloxacin resistant N. 
gonorrhoeae isolates carried double mutations in GyrA (S91F and D95G/N) and a S87R or S88P 
substitution in ParC. Isolates resistant to azithromycin had specific mutations in all the four 
alleles of 23S rRNA as well as in the DNA binding domain of MtrR. Most resistance was 
chromosomally mediated while plasmid-mediated resistance to penicillin (0.93% of penicillin 
resistant isolates) and tetracycline (3.3%) was low.  
 
DNA based strain typing methods such as porB-DNA sequencing, N. gonorrhoeae multi-
antigen sequence typing (NG-MAST) and multilocus sequence typing (MLST) showed that the 
gonococcal population in SK differs appreciably from both other Canadian provinces and from 
strains reported internationally. MLST analysis, which ascertains the evolution of isolates over 
time, demonstrated that penicillin and tetracycline resistant isolates in SK evolved through 
spontaneous mutations in established lineages. Ciprofloxacin and azithromycin resistant N. 
gonorrhoeae isolates, on the other hand, were introduced into SK from outside the province. 
Significant associations between particular mutation pattern combinations in resistance 
determining genes and specific NG-MAST STs were identified e.g. NG-MAST ST 25 was 
associated with specific combined mutation patterns in PBP2, MtrR and PorB and antibiotic 
susceptibility; and, NG-MAST ST 3654 was associated with another PBP2/MtrR/PorB  mutation 
pattern, chromosomal resistance to penicillin and tetracycline and elevated MICs to cefixime. 
  
This research shows the importance of regional antimicrobial susceptibility monitoring. 
In the context of SK, this means that local surveillance of gonococcal AMR may be used to 
develop policies for regional treatment guidelines which promote the prudent use of 
antimicrobials for treatment, including those antibiotics which may no longer be used in other 
regions  due to higher AMR rates. Further, the significant association between particular AMR 
mutation pattern combinations and specific STs indicates that AMR might be predicted. These 
results should assist in the development of non-culture-based tests for the diagnosis of 
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gonococcal AMR similar to nucleic acid amplification tests used to diagnose N. gonorrhoeae 
infections. 
 
Key words: Neisseria gonorrhoeae, antimicrobial susceptibility/resistance, molecular 
determinants of antimicrobial resistance, molecular epidemiology, molecular typing, strain types 
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1.1 Epidemiology and Clinical Features of Gonorrhea 
1.1.1 Prevalence of Gonorrhea Worldwide  
 
Neisseria gonorrhoeae, a Gram-negative coccus, is an obligatory human pathogen 
causing gonorrhea, which is one of the most common sexually transmitted infections (STIs) 
worldwide.  More than 106 million new cases of gonorrhea are reported annually (WHO 2012). 
Gonorrhea remains an underreported disease worldwide often because of unrecognized 
infections, inadequate laboratory diagnosis facilities, poor reporting systems and reluctance on 
the part of the patients or physicians to report the disease to public health authorities (Tapsall, 
2009). Lack of knowledge about STI prevention in populations at increased risk of the disease, 
as well as in the general population, also contributes to the high prevalence of gonorrhea and 
other STIs (Cohen et al 2000). 
 
Gonorrhea has been a notifiable disease in Canada since 1924 and is the second most 
commonly reported bacterial STI (PHAC 2010a). From 1991 to 1997, males and females 
experienced an overall decline in the reported rates of gonorrhea infection (Fig 1.1A). Between 
1999 and 2008, reported rates of gonorrhea infection among males and females increased by 
95.1% and 151.1%, respectively. Overall, the reported rate of infection was higher for males than 
for females. In Canada, gonorrhea prevalence rates have been rising since 1997 (Hansen et al 
2003). In 2009, over 11,000 cases of gonorrhea were reported in Canada, a rate of 33.1 cases per 
100,000 population, which is more than double the numbers for 1997 (14.9 cases/100,000, 
PHAC 2011a).  This steady increase in rates since 2000 presents a significant public health 
concern in Canada. The majority of the reported gonorrhea cases were in the under 30 years of 
age group, in males and females between 15 to 24 years old in 2009 (PHAC 2011b).  
 
Saskatchewan (SK) has one of the highest gonorrhea rates in all the provinces of Canada 
(PHAC 2011a). From 1991 to 1999, males and females experienced an overall decline in the 
reported rates of gonorrhea infection (Fig 1.1B). Between 2000 and 2008, reported rates of 
gonorrhea infection among males and females increased by 230% and 340%, respectively. Since 
2000, the reported rate of infection was higher for females than for males. The gonorrhea rate in 
the province was 84.9 per 100,000 people in 2009, 2.5 times higher than the national rates  
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Fig. 1.1 Prevalence of gonorrhea in Canada and Saskatchewan 
A. Gonorrhea rates in Canada 
B. Number of reported gonorrhea cases in Saskatchewan. 
Data were derived from the Public Health Agency of Canada (PHAC 2011a)
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(PHAC 2011a). In 2009, the incidence rates of gonorrhea in SK among men and women were 
71.9 and 97.8 per 100,000 population (PHAC, 2011a).  
 
The increase in prevalence of gonorrhea and other STI’s has been partly attributed to an 
increase in unprotected sex, particularly since HIV (Human Immunodeficiency Virus) infections 
are no longer considered as 100% fatal (PHAC, 2009). The use of noninvasive nucleic acid 
amplification tests (NAATs) has also increased the diagnostic efficiency for gonorrhea, resulting 
in higher levels of detection and reporting rates compared to rates using invasive specimen 
collection coupled with culture methods used in the past (Whiley et al 2006; Dillon 2011). 
 
Gonorrhea is the second most commonly reported notifiable disease in the United States 
(CDC 2011). In 2010, a total of 309,341 cases of gonorrhea were reported in the United States 
with a rate of 100.8 cases per 100,000 population. The incidence rates of gonorrhea in the United 
States in 2010 among men and women were 94.1 and 106.5 per 100,000 population. According 
to the STD Surveillance Network (SSuN), 23.2% of the reported cases of gonorrhea in the 
United States were estimated to be in men who have sex with men (MSM; CDC 2011). 
 
According to World Health Organization (WHO 2011) 87.65 million new cases of 
gonorrhea were reported worldwide in 2005 with an overall incidence of 25.6 per 1000 
population. In females incidence rates were 23.38 per 1000 population with 39.91 million new 
cases in 2005, whereas in males the incidence estimates were 27.47 per 1000 population with 
47.74 million new cases. The gonorrhea incidence estimates for the year 2005 were highest for 
African region (49.14 per 1000 population) and lowest for European region (10.12 per 1000 
population) (Fig 1.2). The incidence of gonorrhea was higher in males compared to females in 
African region, region of Americas, South-East Asian region and East Mediterranean region. In 
the European and Western Pacific  regions higher numbers of cases were recorded in females 
than males. 
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Fig. 1.2 Incidence of gonorrhea in different WHO regions in 2005.   
Data were derived from the World Health Organization (WHO 2011). 
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1.1.2 History and Identification of Neisseria gonorrhoeae 
 
Neisseria are cocci 0.6-1.0 µm in diameter. These occur singly but more often in pairs. 
The species N. weaver, N. elongate and the proposed new species, N. baclliformis sp. nov. are 
exceptions, often arranged as diplobacilli or in short chains (Elias et al 2011). The genus 
Neisseria includes at least 21 members (Knapp 1988). N. gonorrhoeae and N. meningitidis are 
obligatory human pathogens. Other members of the genus are non-pathogenic commensal 
species, although some of them can cause opportunistic infections in humans (i.e. N. lactamica). 
These non-pathogenic species are important because of their occasional diagnostic confusion 
with gonococci or meningococci (Sparling 2008). High rates of homologous recombination 
between Neisseria spp. result in the evolution of Neisseria spp. with mosaic alleles i.e. alleles 
generated in a recipient strain by recombination of regions of similar genes from closely related 
donor species. The genetic characters of these newly evolved species remain unclear (Hange et al 
2005).  
N. gonorrhoeae was the first discovered species of genus Neisseria. Gonococci were 
initially observed by Albert Ludwig Sigesmund Neisser in 1879. The organisms were 
demonstrated within polymorphonuclear leucocytes (PMNs) in pus smears from patients with 
gonorrhea. Neisseria gonorrhoeae was successfully cultivated by Bumm and by Lestikow and 
Loeffler in 1882 (Morse & Genco 1998). 
 
N. gonorrhoeae is a Gram-negative diplococcus, which produces oxidase (Elias et al 
2011). N. gonorrhoeae produces acid from carbohydrates by oxidation and utilizes glucose only 
(Morse and Genco 1998). It is a fastidious organism and grows on selective media under specific 
conditions. It requires an energy source such as glucose, pyruvate and lactate to grow. All N. 
gonorrhoeae strains require cysteine for the growth. Glutamine and cocarboxylase are required 
for the growth of the majority of strains during primary isolation. Because of these specific 
growth requirements, complex media are required for the primary cultivation of this organism 
(Morse and Genco 1998). Selective media used for N. gonorrhoeae cultivation includes the 
addition of antibiotics such as vancomycin, colistin and nystatain to prevent growth of 
commensal bacteria and yeast (Elias et al 2011).  
 
7 
 
Isolates are usually grown in nutrient rich media containing glucose, glutamine, thiamine, 
cysteine, cystine, adenine, vitamin B12, p-aminobenzoic acid and ferric nitrate.  N. gonorrhoeae 
inoculated media are incubated at 35
o
C for 24-72 hr under humid conditions and in an 
environment containing 5-7% CO2. The colonies of N. gonorrhoeae are approximately 1mm in 
diameter, opaque, glistening and convex. The colonies expressing pili and opacity proteins have 
well defined edges, whereas non-pliated colonies have a more diffused edge and are more 
glistening (Elias et al 2011). Gonococci occur in multiple colony types when grown on a clear 
agar medium and viewed under obliquely transmitted light. Small convex glistening colonies 
type 1 and type 2 colonies can be distinguished from larger flattened type 3 and type 4 colonies. 
Small colonies are known to be piliated (P
+
) and large colonies are nonpiliated (P
-
) (Kellogg et al 
1963).  
 
N. gonorrhoeae can be differentiated from other Neisseria species through enzymatic 
action on chromogenic substrates. The presence of the enzyme proline iminopeptidase (Pip) is 
specific to gonococci, Pip negative N. gonorrhoeae strains have also been identified (Tapsall 
2007). The presence of such strains can result in false negative reactions. GonoCheck II and 
Neisseria PET are the two commercially available kits for identifying and differentiating N. 
gonorrhoeae on the basis of enzymatic reaction (Elias et al 2011).  
 
Tests based on a combination of carbohydrate utilization tests and direct enzyme 
detection assays e.g. Api NH and RapID NH are available commercially for the rapid 
confirmation of Neisseria spp. The Api NH comprises four sugar utilization tests (glucose, 
fructose, maltose and sucrose), eight enzyme substrates and an acidimetric penicillinase test. The 
RapID NH has two carbohydrate utilization tests (glucose and sucrose), 10 enzyme tests and one 
resazurin reduction test (Elias et al 2011).  
 
All immunological tests used for identification of N. gonorrhoeae detect outer membrane 
porin protein, PorB (PorB IA and PorB IB) of N. gonorrhoeae by a pool of monoclonal 
antibodies (Knapp et al 1984). The Phadebact Monoclonal GC test is a co-agglutination test 
(Carlson et al 1987; Dillon et al 1988).  The test utilizes inactivated Staphylococcus aureus cells 
coated with antibodies bound to Fc portions through staphylococcal protein A. The Fab part of 
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the antibody is free to react with N. gonorrhoeae. GonoGen II is a colorimetric test in which 
antibodies are adsorbed on metal-sol particles and give red color as positive test (Dillon et al 
1988). The Micro Trak Culture Confirmation Test uses fluorescein isothiocyanate labeled 
antibody for confirmation of N. gonorrhoeae (Dillon et al 1988). Positive specimens are 
identified as diplococci with apple green fluorescence (Elias et al 2011).  
 
  The non-culture N. gonorrhoeae diagnostic tests are based on detection of N. 
gonorrhoeae nucleic acids from non-invasive clinical specimens i.e. urine (Hook and Handsfield 
2008).  These tests provide rapid and sensitive detection of the N. gonorrhoeae and are in use 
since 1990s. The non-culture N. gonorrhoeae tests can be classified as hybridization assays and 
nucleic acid amplification tests (NAATs) (Whiley et al 2006).   
 
  NAATs for the detection of N. gonorrhoeae became available in the early 1990s. These 
assays use a specific oligonucleotide probe to hybridize directly to N. gonorrhoeae nucleic acid 
present within a specimen (Whiley et al 2006). NAATs have additional advantages of providing 
performance similar to that of endocervical swabs when voided urine or vaginal swabs are used 
as specimens (Whiley et al 2006; Hook and Handsfield 2008). This simplifies specimen 
collection and permits gonorrhea screening in settings where genital examination is not possible 
and disease prevalence is high. In addition, a single specimen collected for NAATs can be tested 
for both N. gonorrhoeae and Chlamydia trachomatis (Whiley et al 2006; Hook and Handsfield 
2008). Amplicor CT/NG, ProbeTec and Gen-probe APTIMA are the commercially available 
NAATs. The test format includes amplification of target DNA from the specimen; the amplified 
DNA is hybridized to oligonucleotide to target specific probes and detection of the probe bound 
amplified DNA by colorimetric determination (Elias et al 2011). 
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1.1.3 Synopsis of Pathobiology of N. gonorrhoeae 
 
A number of virulence factors have been identified that allow N. gonorrhoeaeto 
successfully adapt to variable microenvironments within its host. The steps involved in the 
pathogenesis of the gonococci are adherence to epithelial cells, internalization, invasion and 
dissemination (Sparling 2008). Multiple gonococcal surface molecules independently or 
collectively contribute to the mechanism involved in the adherence to human epithelial cells. 
Two well documented adherence ligands are pili and opacity associated (Opa) outer membrane 
proteins (Edwards and Apicella 2004; Sparling 2008). 
 
 Gonococci appear to be able to multiply and divide intracellularly and some gonococci 
can exit from the cell by exocytosis. The invasion by N. gonorroheae is dependent on expression 
of PorB, Opa proteins and lipooligosaccharide (LOS) (Edwards and Apicella 2004; Sparling 
2008).  
 
In addition to these adhesion and invasion factors, a number of gonococcal components 
undergo phase and antigenic variation, resulting in greater antigenic variability in the molecules 
on the surface of the cells during the course of the disease (Edwards and Apicella 2004; Edwards 
and Butler 2011). The major virulence factors involved in the pathogenesis of N. gonorrhoeae 
are briefly reviewed below. 
 
Pili play an important role in initial attachment of the gonococci with host cells and also 
provide the ability to ascend mucosal surfaces by twitching. The exact mechanism of this 
twitching motility is not clear (Wall & Kaiser 1999). This twitching can be the result of a random 
alternation due to thermal motion, between hydrophilic surface interactions and hydrophobic 
surface interactions. It has also been suggested that twitching can be due to forceful retraction 
and extension of pili from one cell to another that will result in a twitch (Wall & Kaiser 1999). 
The I-domain of α1 β1 or α2 β1 integrin on epithelial cells of urethral mucosa and the I-domain of 
complement receptor 3 (CR3) in cervical mucosa act as receptors for the gonococcal pilus 
(Edwards et al 2002; Edwards & Apicella 2005). Pilus-host cell interaction causes calcium flux 
which results in exocytosis of host cell lysosomal contents and redistribution of lysosome-
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associated membrane protein 1 (LAMP1) (Ayala et al 2001). LAMP1 is one of the proteins 
required for maturation of gonococci containing vacuoles and gonococcal killing inside the host 
cell (Binker et al 2007). Pilus attachment also causes rearrangement of the host cell cytoskeleton, 
facilitating entry of N. gonorrhoeae (Griffiss et al 1999). 
 
Opa proteins are structurally and functionally related proteins encoded by 11 
independently expressed opa genes (Bhat et al 1991). Opa proteins as represented by Opa50 and
 
Opa52. Opa50 adheres to heparin sulfate proteoglycans (HPSG). Opa52 binds to the 
carcinoembryonic antigen-related family of cell adhesion molecules (CEACAMs or CD66) 
(Edwards & Apicella 2004; Edwards & Butler 2011). Opa50-HPSG interaction releases 
diacylglycerol which activates spingomyelinase. Spingomyelinase produces ceramide from 
spingomyelin and ceramide causes cytoskeletal disruption of host cells (Grassme et al 1997). 
Opa-CAECAM interactions result in the activation of a series of tyrosine kinases resulting in 
cytoskeletal changes in host cells which facilitate the entry of gonococci (Hauck et al 1998). Opa 
proteins are not required for an interaction with epithelial cells but they do play a role in the 
interaction of gonococci with neutrophils (Rest et al 1982; Edwards & Butler 2011; Johnson & 
Criss 2011). 
 
Neisseria carry LOS molecules in their outer membranes, which mimic mammalian cell 
sugar moieties called glycosphingolipids. LOS does not possess repeating the O-antigen sugar 
that comprises the polysaccharide side chain of lipopolysacchride (LPS) present on other Gram- 
negative bacteria. This structural similarity between LOS and mammalian glycosphingolipid 
protects the bacterium from the host-derived immune system (Edwards and Apicella 2004; 
Edwards & Butler 2011). LOS also serves as a site for the deposition of sialic acid. Deposition of 
sialic acid occurs through sialyltransferase using host cytidine monophosphate (CMP)-N-
acetylneuraminic acid. The presence of sialic acid on gonococcal LOS also confers serum 
resistance to N. gonorrhoeae (Smith et al 1995). LOS is an important virulence factor in N. 
gonorrhoeae pathogenesis and binds asialoglycoprotein receptor (ASGP-R) on the urethral 
epithelium (Harvey et al 2001; Edwards & Butler 2011).  Sialylation of LOS impairs LOS-
ASGP-R binding (Harvey et al 2001; Shell et al 2002).  
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Gonococcal porins, as PorB are water-filled channels through which small molecules can 
cross the outer membrane. PorB serves as a secondary adhesion protein, binding to the I-domain 
of CR3 along with the pilus, resulting in a tighter gonococcus-receptor interaction (Edwards et al 
2001; Edwards & Butler 2011). Gonococcal porin has the ability to translocate into eukaryotic 
cell membranes (Edwards & Apicella 2004). N. gonorrhoeae has been shown to induce apoptotic 
cell death in epithelial cells and phagocytes in vitro (Muller et al 1999). Cells treated with 
purified porin respond with an immediate, transient uptake of extracellular Ca
2+
 and cells start to 
form extensive membrane blebs. PorB isoform, (PIB) has been shown to increase the expression 
of the anti-apoptotic genes in male urethral epithelial cells, which aids survival of the bacterium 
in the protected intracellular environment (Binnicker et al 2003, 2004). Porin also causes 
cytoskeletal rearrangements through fragmentation and remodeling of actin filaments, which 
facilitates the entry of gonococci in the host cell and inhibits phagosome maturation (Wen et al 
2000; Mosleh et al 1998). 
 
Approximately 45% of women with gonococcal cervicitis develop an ascending infection 
(Edwards & Apicella 2004). Expression of CR3 decreases from the ectocervix to the fallopian 
tubes with the progressive increase in expression of the lutropin receptor (LHr) (Edwards et al, 
2001). Adherence to the LHr by gonococcal ribosomal protein L12 is proposed to mediate 
gonococcus-fallopian tube interaction (Chen et al 1991; Spence et al 1997). Human chorionic 
gonadotropin (hCG) is a natural ligand for the LHr and can competitively inhibit the LHr-
gonococcal interaction (Gorby et al 1991). Gonococcal-LHr interaction could possibly result in 
serious complications with increased risk of spontaneous abortions associated with N. 
gonorrhoeae infections (Edwards & Apicella 2004) 
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1.1.4 Control, Transmission, Clinical Manifestations and Complications of Gonorrhea 
 
Gonorrhea control strategies include safe sex practices and early diagnosis followed by 
antibiotic treatment. Contact tracing and primary diagnosis on the basis of clinical symptoms and 
laboratory diagnosis are also important to check the spread of infection in a population. There is 
no vaccine available against N. gonorrhoeae, therefore, the prevention and treatment of 
gonorrhea relies primarily on early diagnosis and treatment with antibiotics. Important strategies 
for managing gonorrhea infections include preventing the misuse or inappropriate use of 
antibiotics, evaluation of appropriate treatment for gonorrhea, monitoring of antimicrobial use, as 
well as ensuring the supply of the right drugs in appropriate quantity at the right time and at the 
right dose (Tapsall et al 2009a).  
 
Transmission: Patterns of STI transmission depend upon sexual partners, within sexual 
networks. A sexual network is a social network  defined by the sexual inter-relationships within a 
defined group of people (Kretzschmar 2000). STI’s are “network diseases” because the links 
established through sexual contact, and each contact is significant in defining a sexual network 
(Day et al 1998).  
 
 Gonorrhea transmission primarily occurs through small groups of high risk people, called 
“core groups” (Yorke et al 1978; Jolly & Wylie 2002). Core groups are joined directly or 
indirectly through sexual contact and transmit infection within the population through their 
sexual partners (Yorke et al 1978; Potterat et al 1985; Anderson & May 1992; Jolly & Wylie 
2002). Bridging populations, the individuals in the lower-risk group act as a link between the 
core infected groups and the general population (Fig 1.3) (WHO 2007). Therefore, effective 
identification of core groups is critical for the proper and effective control of STIs (WHO 2007). 
It has been recommended that intervention strategies should focus on high-risk (core groups) and 
bridging populations and not the low risk general population (WHO 2007). Sexual networks 
appear densely connected through core groups in early epidemic phases and therefore, 
interventions focusing core groups should have a large population effect during epidemics (Ward 
2007).  
 
13 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3 Transmission dynamics of sexually transmitted infections at the population levels. 
Source: WHO 2007.  
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In endemic regions, interventions focusing on a larger proportion of people will have greater 
impact (Ward 2007). 
 
 A combination of epidemiological and molecular biological methods can work to 
establish a much better view of sexual networks in gonorrhea transmission (Day et al 1998), 
when contrasted to the traditional contact tracing methods for the identification of sexual 
networks in STI studies. The latter consist of STI surveillance and screening, identification of 
index cases, partner notification, and contact tracing through extended interviews. The local 
transmission networks of STI’s can be identified by combining the molecular information of 
strain types (STs) with demographic data (Ward et al 2000; Choudhury et al 2006; Risley et al  
2007). 
 
 Two types of transmission components within a large sexual network have been 
identified for STIs, radial and linear, (Wylie and Jolly 2000). Radial components are 
characterized by the presence of a central individual with a partner range of 5 to 13 people. In 
linear components, the partner range is 1 to 4 people with a larger number of distinct geographic 
locations. Linear components represent an important reservoir for gonorrhea maintenance and 
spread (Wylie and Jolly 2001). The linear component has extensive interconnections present 
within a large sexual network, resulting in frequent bridging events between different 
demographic groups (Wylie et al 2005).    
 
Clinical Manifestations and Complications: The primary infection sites of N. gonorrhoeae are 
the mucous membranes lined with noncornified columnar or cuboidal epithelial cells of the 
urogenital tract (the urethra in males and the uterine cervix in females), the rectal mucosa, the 
conjunctiva and pharynx (Sparling 2008; Hook & Handsfield 2008). Over 50% of women and 
10% of men who have gonorrhea are asymptomatic (Hook & Handsfield 2008). This 
consequently delays the treatment and facilitates the spread of the pathogen (Sparling 2008; 
Hook & Handsfield 2008).  
 
In men, acute anterior urethritis is the most common manifestation of gonococcal 
infection. The incubation period of gonorrhea ranges between 1 to 14 days but the majority of 
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men develop symptoms within 2-5 days. Clinical disease is primarily manifested by urethral 
discharge or dysuria. Urethral discharge is initially scanty and mucopurlent in appearance and 
usually becomes frankly purulent and profuse within 24 hr of the onset of the infection. Patients 
complain of a urethral itch and pain or burning sensation when passing urine (Sparling 2008; 
Hook & Handsfield 2008). 
 
In women, the endocervical canal is the primary site of urogenital gonococcal infection 
followed by the urethra. The incubation period of urogenital gonorrhea is variable in women but 
symptoms usually appear within 10 days of infection. The most common symptoms include 
increased vaginal discharge, dysuria and intermenstrual bleeding. There may be a strong 
smelling vaginal discharge which is often thick and yellow/green. Many infected women have 
cervical abnormalities such as mucopurulent cervical discharge, cervical erythema and edema 
and endocervical bleeding. Purulent discharge may also be expressed from urethra and 
periurethral gland or Bartholin’s duct (Sparling 2008; Hook & Handsfield 2008). 
 
Gonococci causing cervicitis may also spread to the rectal mucosa in women. The rectal 
mucosa is also a frequent site of infection in homosexual men. Rectal gonorrhea is usually 
asymptomatic in women and in MSM can be associated with overt proctitis. Other symptoms of 
rectal gonorrhea include anal erythema and edema, painless mucopurulent discharge, scant rectal 
bleeding, severe rectal pain, tenesmus, and constipation (Sparling 2008; Hook & Handsfield 
2008). 
 
Pharyngeal gonorrhea is transmitted to the pharynx by orogenital sexual contact and is 
acquired by fellatio (Hook & Handsfield 2008). Pharyngeal gonorrhea is common in MSM. 
Gonoccoccal infection can cause pharyngitis or tonsillitis but over 90% of pharyngeal infections 
are asymptomatic. The transmission of pharyngeal gonorrhea to sex partners is rare because of 
low bacterial loads in pharynx but can increase the risk of disseminated gonococcal infection 
(DGI) in individuals (Bissessor et al, 2011).  
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In men, ascending infection of N. gonorrhoeae causes epididymitis that can lead to 
infertility and acute or chronic prostatitis. Other complications in men include seminal vasiculitis 
and infections of Cowper’s and Tyson’s glands (Bolan et al 1999; Hook & Handsfield 2008). 
 
In women, the most common consequence of untreated gonorrhea is pelvic inflammatory 
disease (PID), which includes salpingitis, endometritis, tubo-ovarian abscess or pelvic peritonitis 
(Hook & Handsfield 2008). PID causes scar tissue formation in the fallopian tubes. A fertilized 
egg may not be able to pass into the uterus through scarred fallopian tube. This may cause 
implantation of embryo in the tube leading to tubal (ectopic) pregnancy. In addition to ectopic 
pregnancies, tubal and peritubal damage after PID may result in chronic pain, miscarriage, 
gynecological morbidity and possibly death of the mother (Morse & Beck-Sague 1999; 
Paavonen et al 2008; Hook & Handsfield 2008). Apart from PID, Bartholin’s gland abscess is 
the most common urogenital complication of gonorrhea in women (Hook & Handsfield 2008).  
 
Untreated gonorrhea can spread through the bloodstream causing DGI. It is manifested 
by acute arthralgia, arthritis, tenosynovitis, dermatitis or a combination of all these findings 
resulting in joint pain and skin lesions as necrotic pustules. Patients with DGI can develop 
endocarditis with valvular damage or may suffer with meningitis (Sparling 2008; Hook & 
Handsfield 2008). 
 
Gonococcal ophthalmia neonatorum, an infection in the eyes of the newborn, is acquired 
during passage through the birth canal of an infected mother. The initial conjunctivitis rapidly 
progresses and, if untreated, results in blindness due to corneal ulceration and perforation (Morse 
& Beck-Sague 1999; Kohlhoff and Hammerschlag, 2008).  
 
Infection with N. gonorrhoeae has been associated with increased susceptibility to and 
enhanced incidence rates of infections with the sexually transmitted human immunodeficiency 
virus (HIV) (Galvin & Cohen 2004; Ding et al 2010). The findings of clinical trials and 
epidemiological studies has shown role of STIs, including gonorrhea, in HIV transmission 
(Wasserheit 1992; Galvin & Cohen 2004; Ding et al 2010). Gonorrhea enhances the 
infectiousness of HIV due to several pathophysiological factors including increased HIV viral 
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load in the urethra, semen, and cervical fluid due to a high degree of inflammation, as well as 
increased HIV replication due to the influx of polymorphonuclear cells (PMNs) during 
gonococcal infections (Galvin & Cohen 2004). Gonorrhea also makes a person more susceptible 
to HIV infection due to damage of the columnar epithelial barriers and increased infiltration of 
HIV co-receptor (CCR-5) containing cells (Wasserheit 1992; Galvin & Cohen 2004). In response 
to N. gonorrhoeae infection, genital epithelial cells produce cytokines, chemokines and defensins 
to modulate HIV infection and infectivity (Galvin & Cohen 2004; Jarvis & Chang et al 2012). N. 
gonorrhoeae infected women have more endocervical T cells and monocyte-derived dendritic 
cells providing more targets for HIV (Levine et al 1998; Zhang et al 2005). Antimicrobial 
peptides, such as human defensin 5 and 6, induced by gonococcal infection, also promote HIV 
infectivity (Klotman et al 2008). Infection with N. gonorrhoeae also enhances HIV-1 infection of 
primary resting CD4+T cells through TLR2 activation (Ding et al 2010). All these interactions 
are of great concern because the majority of HIV infections are sexually transmitted (Cohen 
2004).  
 
1.2 Surveillance of Antimicrobial Resistance in Neisseria gonorrhoeae  
1.2.1 Antimicrobial Resistance in N. gonorrhoeae  
 
N. gonorrhoeae has developed antimicrobial resistance (AMR) against most classes of 
antibiotics. According to the accepted definition of gonococcal treatment efficacy, a cure rate of 
over 95% is required for an antibiotic to be recommended for gonorrhea treatment (Handsfield et 
al 1992; WHO 1989, 2001; CDC 1987). Thus, an antibiotic should not be used in situations 
where resistance is observed in greater than 5% of gonococcal isolates tested (PHAC 2006; 
Newman et al 2007). AMR in N. gonorrhoeae is increasing in prevalence, and resistance to new 
classes of antibiotics has spread globally (Dillon 2011; Ohnishi et al, 2011a,b; Unemo et al, 
2010, 2011, 2012a,b; Bolan et al, 2012). 
 
N. gonorrhoeae strains have developed high levels of resistance against several 
antimicrobial agents including sulfonamide drugs (1940s), penicillin [chromosomal (associated 
with changes to existing and non-plasmid-borne genes), 1950s; plasmid mediated (resistance 
plasmid acquisition by bacteria), 1976], tetracycline [chromosomal, late1950s; plasmid 
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mediated, 1986] and quinolones (late 1990s) globally (Tapsall 2005; Stathi et al 2006; Wang et 
al 2006; Enders et al 2006; Bala et al 2007; Lewis 2010; Shafer et al 2010; Bolan et al 2012). 
This has resulted in the removal of these oral antimicrobials from gonorrhea treatment guidelines 
(Tapsall et al 2009a; Lewis 2009; Bala et al 2010; Dillon 2011).  
 
After the worldwide development of quinolone resistant N. gonorrhoeae (QRNG), 
extended spectrum cephalosporins have been widely recommended for treating gonococcal 
infections and are considered the last single-dose bullet against the disease (HPA 2005; PHAC 
2006; Japanese Society for sexually transmitted infections 2006; Wang and Zhang 2007; CDC 
2010).  
 
The recent reports of the emergence of N. gonorrhoeae strains with resistance or reduced 
susceptibility to extended spectrum cephalosporins (cefixime and ceftriaxone) and treatment 
failures with extended spectrum cephalosporins are a serious concern worldwide (Ameyama et al 
2002; Ito et al 2004; Tapsall et al 2009a,b; Unemo et al 2010; Allen et al 2011, 2013; Ohnishi et 
al 2011a, b; Unemo et al 2011; Dillon 2011; Martin et al 2011, 2012; Bolan et al 2012). Small 
minimum inhibitory concentration (MIC) increases (i.e. MIC creep) to third generation 
cephalosporins has been widely reported from different parts of world (Chisholm et al 2010; 
Ross and Lewis 2011; Dillon 2011; Martin et al 2011). The WHO has a global alert on 
untreatable gonococcal infections (WHO 2012). It is speculated that emergence and subsequent 
spread of N. gonorrhoeae strains resistant to extended spectrum cephalosporins will render 
gonorrhea untreatable in future, at least with the single antibiotics in single doses, which has 
been the best practice for over half a century.  
 
The incidence of antibiotic resistant N. gonorrhoeae has also increased in Canada (PHAC 
2008a; Martin et al 2011). Gonococcal resistance to penicillin and tetracycline is long established 
in Canada (PHAC, 2008b). In Canada, tetracycline resistance was observed in the early 1970s 
(Dillon et al 1978a) and was highly prevalent in gonococcal isolates tested in the 2000s (Greco et 
al 2003). Penicillin and tetracycline resistance decreased from 14.2% and 23.3% in 2000 to 5.6% 
and 14.3% in 2003 in Canada and increased again after 2003 (Martin et al 2011; PHAC 2013). 
Similar trends were observed for erythromycin resistance (Martin et al 2011; PHAC 2013). The 
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prevalence of ciprofloxacin resistance in Canada increased from 1.3% of cultured isolates in 
2000 to 36.0% in 2010 (Martin et al 2011; PHAC 2013). Azithromycin resistance has remained 
sporadic in Canada since 2000 (Martin et al 2011; PHAC 2013). N. gonorrhoeae isolates with 
reduced susceptibility to extended spectrum cephalosporins have been also been reported from 
Canada (Allen et al 2011; Martin et al 2012; PHAC 2013). A shift in the modal MICs of 
currently recommended antibiotics, azithromycin (0.25 mg/L in 2000 to >2.0 mg/L in 2011) and 
ceftriaxone (0.016 mg/L in 2000 to 0.063 mg/L in 2011), has been observed in Canada (Martin et 
al 2011; PHAC 2013). 
 
1.2.2 Antimicrobial Resistance Mechanisms in N. gonorrhoeae 
 
Over their long history of evolution, bacteria have developed various ways to protect 
themselves from antimicrobial agents. These mechanisms can be generally categorized into four 
groups (Jayaraman 2008, 2009): 1) restriction of intracellular drug concentration by influx and 
efflux, 2) chemical modifications or destruction of drugs, 3) alterations of drug targets in 
bacteria, and 4) bacterial tolerant states which are associated with persistence, biofilm formation, 
and swarming. Some mechanisms mediate cross-resistance to multiple unrelated drugs, whereas 
more than one resistance mechanism can co-exist in a microorganism against a particular 
antibiotic.   
 
A systematic understanding of gonococcal AMR mechanisms is critical for the 
development of new and effective antimicrobial agents. Mechanisms of antibiotic resistance in 
N. gonorrhoeae include mutation of the antibiotic target, enzymatic breakdown of antibiotics, 
decreased permeability of the bacterial membrane and, the presence of active efflux systems (Fig 
1.4) (Alekshun and Levy 2007; Shafer et al 2010). AMR in N. gonorrhoeae develops due to 
genetic changes, which can occur by spontaneous mutation, and or due to horizontal transfer 
(DNA uptake and homologous recombination) of the genetic material from other bacteria
 
(Shafer 
et al 2010).  
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Fig. 1.4 Mechanisms of penicillin, tetracycline and ciprofloxacin resistance in N. 
gonorrhoeae. 
Pen resistance (Pen
R) is due to actions of β-lactamase, decreased influx and increased efflux of the 
antibiotic and modifications of penicillin binding proteins (PBP), PBP 1 and PBP 2.Tetracycline 
resistance (Tet
R
) is attributed to modifications in influx and efflux mechanisms. High level of Tet
R 
is due 
to attachment of TetM protein to ribosomes which prevents tetracycline binding to ribososmes. A 
substitution at Val-57 to Met in ribosomal protein S10 along with decreased influx and increased efflux of 
the antibiotic provides chromosomal tetracycline to N. gonorrhoeae. Ciprofloxacin resistance (Cip
R
) is 
due mutations in DNA gyrase (GyrA) and topoisomerase IV (ParC). 
Source: Shafer et al 2010.  
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The antimicrobial resistance determinants in N. gonorrhoeae can be both plasmid 
mediated and chromosomally mediated. Plasmid-mediated resistance may confer resistance to 
penicillin (i.e. penicillinase-producing N. gonorrhoeae, PPNG), or to tetracycline  
 (i.e. tetracycline resistant N. gonorrhoeae, TRNG). Penicillinase production in PPNG is 
mediated by a TEM1-type β-lactamase encoded by the TnA transposon Tn2, which is truncated 
and includes 84% of tnpR, noncoding sequences, the entire bla gene, and the right inverted 
repeat (IR-R) (Chen and Clowes, 1987; Dillon & Yeung 1989; Pagotto et al 2000). These 
plasmids were most likely acquired by conjugal transfer from Haemophilus parainfluenzae 
which carries a similar plasmid (Elwell et al 1977; Roberts et al 1977). 
 
The β-lactamase-producing plasmids of N. gonorrhoeae are named Asia, Africa, Toronto, 
Rio, Nimes, New Zealand and Johannesburg types (Dillon et al 1999; Pagotto et al 2000) (Muller 
et al 2011). Only the Asia, Africa and the Toronto-type plasmids have been associated with 
epidemic outbreaks
 
(Dillon and Yeung 1989). These plasmids are related and the structural 
diversity seen in gonococcal β-lactamase producing plasmids is due to the presence of several 
deleted or repeated sequences (Pagotto et al 2000). A novel β-lactamase-producing plasmid, a 
variant of prototype Asia plasmid was identified in gonococcal isolates from Johannesburg, 
South Africa (Fayemiwo et al 2010; Muller et al 2011).  
 
 Plasmid-mediated tetracycline resistance in N. gonorrhoeae isolates is due to the 
presence of the tetM gene. This plasmid is the result of the insertion of a streptococcal tetM-like 
sequence into the endogenous gonococcal 24.5-MDa conjugative plasmid to produce 25.2-MDa 
plasmid (Morse et al 1986; Knapp et al 1988). The TetM protein binds to the ribosome resulting 
in release of tetracycline from the ribosome and conferring a high level of resistance to 
tetracycline (Burdett 1986, 1991; Knapp et al 1988). tetM plasmids are differentiated into 
American (1600bp) or Dutch type (700bp) on the basis of the size of polymerase chain reaction 
(PCR) product (Ison et al 1993; Xia et al 1995; Greco et al 2003).  
 
Chromosomally-mediated resistance (CMR) of N. gonorrhoeae is more complex and 
caused by mutations or modifications in various genes (Table 1.1). The accumulation of 
chromosomal mutations may confer resistance to multiple antibiotics or confer higher levels of  
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Table 1.1 Genes with selected mutations commonly implicated for antimicrobial resistance in N. 
gonorrhoeae 
 
*: A-;G45D- adenine deletion in mtrR promoter and G45D substitution in MtrR DNA binding domain are present 
together. 
a: clinical level of penicillin resistance is due to additive effect of mutations in penA, mtrR, porB, ponA and pilQ2 
b: reduced susceptibility or resistance to extended spectrum cepahlosporins requires combined presence of penA, 
mtrR and porB 
c & d: resistance to erythromycin and azithrmycin is due to mtrR and 23S rRNA 
c: tetracycline resistance is due to combined presence of mutations in penA, mtrR, porB and rspJ 
d:quinolone resistance requires mutations both in gyrA and parC 
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resistance to single antibiotic (Sparling et al 1975; Dillon and Pagotto et al 1999; Ropp et al 
2002). Generally, these mutations alter structure and function of the cell envelope (Shafer and 
Folster 2006). 
 
Penicillin resistance: Penicillin resistance in N. gonorrhoeae develops after sequential 
acquisition of resistance determinants through homologous recombination with commensal 
Neisseria or DNA uptake from closely related species (Fig   1.5). Of the four penicillin binding 
proteins (PBPs) identified in N. gonorrhoeae, PBP1 (ponA) and PBP2 (penA) are essential for 
cell viability and are the targets of β-lactam antibiotics action (Barbour 1981).  PBP1 and PBP2 
both possess transpeptidase activity and catalyze the formation of peptide cross-links between 
adjacent glycan strands of peptidoglycan (Barbour 1981; Powell et al 2009). PBP1 also has an N-
terminal transglycosylase domain that polymerizes glycan strands (Barbour 1981; Powell et al 
2009). PBP2 is a primary target of penicillin and inhibited at 10-fold lower penicillin 
concentrations compared to PBP1 (Barbour 1981; Powell et al 2009). A codon insertion of 
aspartic acid at amino acid position 345 and four (F504L, A510V, A516G, H541N) to eight 
mutations (F504L, A510V, A516G, H541N, P552V, K555Q, I556V, I566V) clustered in the C 
terminus of the PBP2, were found to lower the rate of acylation of PBP2 by penicillin G 16-fold 
which, in turn, resulted in reduced susceptibility to penicillin (Whiley et al 2007a; Powell et al 
2009; Ohnishi et al 2011b).   
 
  mtrR encodes the multiple transfer resistance repressor (MtrR) which represses the 
expression of the MtrC–MtrD-MtrE efflux pump. The MtrC-MtrD-MtrE efflux pump exports 
hydrophobic agents, such as macrolide antibiotics, Triton-X 100 and capric and cholic acids 
outside the cell. It is also implicated in high level penicillin resistance (Veal et al 2002). 
Mutations in the promoter and structural gene of mtrR result in overexpression of the efflux 
pump and increased efflux activity. The most common mutations associated with MtrR are: 
adenine deletion (A-) in the 13bp inverted repeat region between the -10 and -35 hexamers of the 
mtrR promoter, and A39T or G45D mutations in the structural gene of mtrR (Hagman et al 1995; 
Warner et al 2008). The mutation in the promoter abrogates mtrR transcription and RNA 
polymerase is not able to interact with the mtrR promoter (Lucas et al 1997). This overexpresses 
the efflux action of the MtrC–MtrD-MtrE pump. 
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Fig. 1.5 Stepwise acquisition of penicillin resistance genes in N. gonorrhoeae 
Source: Ropp et al 2002.  
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A helix–turn–helix (HTH) DNA binding motif exists between amino acid residues 32–
53; missense mutations at residues 39 (A39T) or 45 (G45D) can enhance gonococcal resistance 
to antimicrobials such as macrolides, β-lactams, tetracyclines and quinolones. Presumably these 
substitutions abrogate MtrR binding to the target DNA upstream of mtrR (Hagman and Shafer, 
1995; Shafer et al 1995). Other mutations that cause radical amino acid replacements in the 
centre of coding sequence (H105Y) or the C-terminal domain can also impact MtrR function, 
possibly by altering MtrR multimer formation (Warner et al 2008). Although, the roles mtrR 
mutations have been described in conferring AMR, the effects of combinations of mutations 
present together in the different regions of mtrR e.g. promoter (A-) or DNA binding motif 
(G45D) or multimeric region (H105Y) have not been experimentally proven to determine their 
contribution to gonococcal AMR. 
 
 The gene porB encodes a major outer membrane porin protein. Mutations in PorB cause a 
decrease in the influx of antibiotics to the periplasm
 
(Fig 1.6) (Olesky et al 2002). PorB allows 
the passage of small molecules, such as β-lactams and tetracyclines, through the outer membrane 
(Danielsson et al 1986). PorB proteins are vital for cell viability, pathogenesis (Hook and 
Handsfield 1999) and antimicrobial susceptibility (Olesky et al 2002, 2006). Gonococcal PorB is 
a transmembrane protein comprising eight highly variable loops separated by nine conserved 
regions (van der Lay et al 1991; Carbonetti & Sparling 1987). 
 
The surface exposed-loop regions of PorB have a high frequency of amino acid variations 
(Ison et al 1988; Smith et al 1995).  N. gonorrhoeae has two porB alleles, porB1a (PIA) and 
porB1b (PIB) (Cooke et al 1998; Gill et al 1994). These alleles encode one of the two PorB 
proteins, either PorB1a or PorB1b, which are singly present in the bacterium (Fig 1.6) 
(Gotschlich et al 1987).  Hybrid PI forms have occasionally been identified from clinical isolates 
by serological testing (Shinners & Catlin 1988). porB1a lacks sequence fragments in the loop 5 
coding regions (van der Ley et al 1991; Derrick et al 1999). 
 
Amino acid substitutions at Gly-120 and Ala-121 of loop 3 of PIB are associated with 
decreased susceptibility to β-lactams and tetracycline (Olesky et al 2002). The identical  
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Fig. 1.6 Schematic presentation of N. gonorrhoeae PorB.  
The length of PorB differs between PIB (~348 amino acids) and PIA (~328 amino acids), respectively. 
There are 8 surface exposing loops (1– 8) spanned by inter-space regions (van der Lay et al 1991). The 
amino acids G120 and A121 locate at loop 3.  DNA sequences used in phylogenetic analysis include 
coding regions of loop 1 to 7. DNA sequences in N. gonorrhoeae multi-antigen sequence typing (NG-
MAST) analysis included coding sequences for Loop III to Loop VII. 
Source: Posada et al 2000.  
 
 
 
 
Extracellular 
Intracellular 
G120; 
A121 
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mutations in PIA do not significantly change the susceptibility of N. gonorrhoeae to penicillin 
(Olesky et al 2002). The increase in resistance due to the porB allele occurs only in those strains,  
which already harbor mtrR mutations
 
(Cooke et al 1998). A limited number of population studies 
of N. gonorrhoeae strains have determined the potential role of the specific mutations in  porB, 
i.e. substitutions with charged amino acids at G120 and A121, in imparting penicillin resistance 
(Malakhova et al 2006; Allen et al 2011). Sun et al (2010) in a population study reported that 
deletions of A121 and N122 in PIB are associated with high levels (MIC=4-8 mg/L) of 
chromosomal penicillin resistance.   
 
A single amino acid substitution in ponA (ponA1 allele; L421P) produced a PBP1 with 
reduced affinity for penicillin (Ropp et al 2002).  The presence of L412P alone does not affect 
the penicillin susceptibility of N. gonorrhoeae (Ropp et al 2002). ponA1 contributes to high-level 
penicillin resistance in N. gonorrhoeae
 
when present along with other penicillin resistance 
determinants such as  penA, mtrR and porB (Ropp et al 2002). The significance of ponA1 
mutations in contributing to the observed clinical levels of penicillin resistance is not established 
through N. gonorrhoeae population studies and requires investigation (Allen et al 2011). 
 
PilQ, a member of the secretin family of proteins, is a major component of the 
gonococcal outer membrane (Newhall et al 1980). PilQ is required for formation of the type IV 
pilus, which is involved in twitching motility, cell attachment and invasion of epithelia, and 
DNA transformation (Tonjum and Koomey 1997). PilQ multimers form a pore around the pilus 
in the outer membrane of N. gonorrhoeae allowing antibiotics to diffuse into the periplasm. A 
pilQ2 missense mutation (E666K) alters pilQ multimeriazation, thereby blocking the entry of 
antibiotics by destabilizing the pore (Zhao et al 2005). The pilQ2 mutation appears to increase 
cellular resistance to hydrophilic antibiotics (penicillin and tetracycline) but not to hydrophobic 
antibiotics (erythromycin and azithromycin)
 
(Ropp et al 2002; Sparling et al 1975).  
 
The presence of all of the resistance determinants (penA, mtrR, penB, ponA1 and pilQ2) 
is essential for conffering a clinical level of penicillin resistance (MIC≥2mg/L) in N. 
gonorrhoeae isolates (Ropp et al 2002). The recipient susceptible strains of N. gonorrhoeae i.e 
FA19 transformed with all the known resistance determinants present in N. gonorrhoeae strains 
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with high-level penicillin resistance do not have the same penicillin MICs as associated with 
donar resistant gonococci (Lindberg et al 2007). This suggests that the individual resistance 
determinants are incapable of effecting high level resistance and therefore complex interactions 
between them are required to exert resistance effects (Shafer et al 2010).  In essence, penicillin 
resistance mechanisms in N. gonorrhoeae require further understanding.    
 
Reduced susceptibility to extended spectrum cephalosporins: The known molecular 
determinants of reduced susceptibility to extended spectrum cephalosporins are the same as those 
conferring penicillin resistance (Table 1.1). But, the exact mechanisms in N. gonorrhoeae of 
reduced susceptibility to extended spectrum cephalosporins remain undetermined. The 
mechanism(s) of reduced susceptibly of N. gonorrhoeae to extended spectrum cephalosporins 
are complex, since different combinations of mutations, within a gene or in different genes, have 
been observed in these isolates (Tanaka et al 2006; Lindberg et al 2007; Zhao et al 2009; Lee et 
al 2010; Liao et al 2011; Allen et al 2011; Ohnishi et al 2011b). Mutations in penA (PBP2) can 
provide reduced susceptibility to extended spectrum cephalosporins. The transpeptidase domain 
of PBP2 is a hyper-variable region (amino acid residues 340 to 581). On the basis of mutations 
present in this region, different mutation pattern numbers have been assigned to PBP2 (Ito et al 
2005; Whiley et al 2007a; Lee et al 2010; Liao et al 2011; Allen et al 2011; Ohnishi et al 2011b). 
Thirty-nine polymorphism patterns (I-XXIX) of PBP2 between AA340-AA575 have been 
described (Ito et al 2005; Lee et al 2010; Whiley et al 2007a, b; Ohnishi et al 2011b; Martin et al 
2012).  
 
The decreased susceptibility to extended spectrum cephalosporins in gonococci is due to 
alterations of penA (Fig 1.7) The acquisition of a penA mosaic alleles, which are thought to be 
acquired by gonococci from commensal Neisseria strains by in vivo transformation and 
homologous recombination, is considered as the most common mechanism of decreased 
susceptibility to extended spectrum cephalosporins (Spratt 1988; Ameyama et al 2002; Ito et al 
2005 Allen et al 2011; Tomberg et al 2010; Ohnishi et al 2011b; Unemo et al, 2010, 2011, 
2012a,b). The amino acid alterations A501V/T in PBP2 increase MICs to cephalosporins 
(Tomberg et al 2010; Ohnishi et al 2011b; Unemo et al 2010, 2011, 2012a,b).  
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Fig. 1.7 Schematic presentation of non-mosaic and mosaic patterns of Penicillin Binding 
Protein (PBP2) in N. gonorrhoeae. Arrangements of point mutations on C-terminal transpeptidase 
domain of PBP2 were shown (Dougherty et al 1980). A) Non-mosaic PBP2 pattern I & IX and B) mosaic 
PBP2 pattern X. (Ito et al 2004; Whiley et al 2007; Ohinishi et al 2011b). 
Adapted and modified: Powell et al 2009.  
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The first report of a N. gonorrhoeae strain with reduced susceptibility to cefixime 
demonstrated that the bacterium possessed a penA allele with 50-60 amino acid changes in 
PBP2. These were later described as mosaic PBP2 pattern X (Ameyama et al 2002; Ito et al 
2005). N. gonorrhoeae strain H041 isolated in Japan, which is associated with high level of 
resistance to cefixime and ceftriaxone as well as to multiple antibiotics and treatment failure with 
ceftriaxone, was shown to carry mosaic allele penAH041. This new PBP2 pattern has 8 new amino 
acid substitutions not observed in other mosaic penA alleles (Ohnishi et al 2011b; Goire et al 
2011).   
 
The oro-pharynx is thought to be a key site for the development of novel mechanisms of 
gonococcal resistance as a result of genetic exchange between commensal Neisseria spp. and N. 
gonorrhoeae (Barry & Klausner 2009). The mosaic alleles of penA, are generated by 
recombination of regions of N. gonorrhoeae penA genes with the penAs of other Neisseria 
spp.colonizing the oro-pharynx, such as N. sicca, N. perflava, N. cinerea, and/or N. flavescens 
(Ameyama et al 2002; Ito et al 2005; Whiley et al 2007a).  
 
Various population studies showed that both penA non-mosaic patterns and the mosaic 
patterns are associated with reduced susceptibility to extended spectrum cephalosporins (Ito et al 
2005; Whiley et al 2007a, 2010a; Lee et al 2010; Liao et al 2011; Allen et al 2011; Ohnishi et al 
2011b). The importance of non-mosaic patterns, or mosaic patterns, other than pattern X and 
penAH041 was not verified (Zhao et al 2009; Ohnishi et al 2011b).  
 
Evidence for the role of ponA in susceptibility to extended spectrum cephalosporins is 
conflicting. Transformation studies of N. gonorrhoeae showed that ponA (PBP1) did not 
contribute to reduced susceptibility to extended spectrum cephalosporins (Zhao et al 2009). Liao 
and others (2011) did not observe any significant association of ponA with extended spectrum 
cephalosporin reduced susceptibility. In contrast, other population study reports for  gonococcal 
AMR showed that ponA mutations were present in N. gonorrhoeae isolates with reduced 
susceptibility to cephalosporins (Lindberg et al 1997, Lee et al 2010; Allen et al 2011). 
Therefore, the role of ponA in contributing to reduced susceptibility to extended spectrum 
cephalosporins remains to be determined. 
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Population studies of AMR in N. gonorrhoeae isolates have shown that mtrR mutations 
A-, A-;G45D, and A39T;H105Y and G45D;H105Y are associated with reduced susceptibility to 
extended spectrum cephalosporins (Lindberg et al 2007; Lee et al 2010; Allen et al 2011; Liao et 
al 2011). Transformation studies have indicated that the mtrR mutation combinations A-;G45D 
contributed to reduced susceptibility to cefixime and ceftriaxone (Zhao et al 2009). 
Transformation studies are required to determine the role of other mtrR mutation combinations 
such as A39T;H105Y, G45D;H105, A-;H105 in conferring reduced susceptibility to extended 
spectrum cephalosporins.  
 
PorB mutations (G120K;A121D and G120K;A121N) known to confer penicillin 
resistance also contribute to  reduced susceptibility to extended spectrum cephalosporins in N. 
gonorrhoeae  strains (Lindberg et al 2007; Lee et al 2010; Allen et al 2011).  Also 
G120K;A121D mutations together with MtrR mutations (A-;G45D) have been experimentally 
demonstrated to contribute to reduced susceptibility to extended spectrum cephalosporins (Zhao 
et al 2009). However, in a recent study, Liao et al (2011) reported no significant association 
between specific PorB mutations and reduced susceptibility to extended spectrum 
cephalosporins. Alterations in pilQ2 have not been shown to contribute to the reduced 
susceptibility of N. gonorrhoeae isolates to extended spectrum cephalosporins (Whiley et al 
2010b). 
 
The mechanisms of reduced susceptibility to extended spectrum cephalosporins appear to 
differ for the oral extended spectrum cephalosporin, cefixime and parenteral extended spectrum 
cephalosporin, ceftriaxone.  It has been suggested that cefixime does not diffuse into the 
periplasm through porin channels of N. gonorrhoeae. This can be attributed to the double 
negative net charge on cefixime compared to a single negative in ceftriaxone (Zhao et al 2009). 
The increase in net negative charge may affect the permeation of cefixime into N. gonorrhoeae 
(Zhao et al 2009). The majority of cefixime resistance is conferred by the penA allele, with only 
small contributions attributable to mtrR and porB, whereas ceftriaxone resistance is nearly 
equally dependent upon mtrR and porB (Zhao et al 2009). 
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Quinolone resistance: The quinolones (e.g. ciprofloxacin; ofloxacin) block DNA replication 
and repair in bacteria by targeting DNA gyrase (gyrA) and topoisomerase IV (parC) (Walsh, 
2003). Quinolone resistance in N. gonorrhoeae is caused by point mutations arising in gyrA and 
parC within their quinolone resistance-determining regions (Table 1.1) (QRDRs, Belland et al 
1994; Deguchi et al 1995, 1996; Trees et al 1998; Yang et al 2006; Starnino et al 2010). Drug 
permeability and drug efflux mechanisms also confer cross-resistance to structurally unrelated 
antibiotics (Nikaido 1994). In N. gonorrhoeae mutations affecting drug permeation and drug 
efflux, such as mtrR mutations, contribute to fluoroquinolone resistance (Starnino et al 2010).  
 
  Mutations in gyrA alone provide low (MIC=0.25mg/L) to intermediate (MIC=0.5mg/L) 
levels of resistance to ciprofloxacin (Belland et al 1994). A high level of quinolone resistance 
(MIC=4.0-16.0mg/L) also requires parC mutations (Belland et al 1994). A number of GyrA and 
ParC amino acid alteration patterns have been identified (Trees et al 1999; Yang et al 2006; 
Starnino et al 2010; Uehara et al 2011). The GyrA Ser91Phe/Asp95Ala and ParC Asp86Asn 
patterns are most commonly reported around the world (Trees et al 1999; Yang et al 2006; 
Starnino et al 2010). 
 
Mutations in mtrR, along with QRDR mutations, have been observed in ciprofloxacin 
resistant (MIC= 1->32mg/L) N. gonorrhoeae isolates (Starnino et al 2010; Chen et al 2010). 
However, no genetic study has been conducted to determine the role of mtrR mutations in 
quinolone resistance. Quinolone resistance in N. gonorrhoeae has been limited primarily to 
QRDR mutations but the contribution of efflux pumps such as MtrC-MtrD-MtrE in decreasing 
N. gonorrhoeae susceptibility to quinolones is not fully established. 
 
Azithromycin resistance: Azithromycin is effective against N. gonorrhoeae but the 
recommended dose (2g) is not well tolerated and causes gastrointestinal distress (Tapsall et al 
1998a; CDC 2002, 2010). Clinical strains displaying intermediate susceptibility or resistance to 
azithromycin emerged first in the 1990’s and new variants continue to be found (Dillon et al 
2001a; Dillon et al 2001b; Sosa et al 2003; Dillon et al 2006; Palmer et al 2008; Galarza et al 
2009; Starnino et al 2009; Chisholm et al 2009, 2010). Azithromycin resistance in N. 
gonorrhoeae can arise by a number of mechanisms: mutations either in the promoter region 
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(adenine deletion, A- or a dinucleotide insert, TT+) of mtrR or in the mtrR structural gene 
(A39T, G45D and H105Y), are known to cause low-level macrolide resistance in gonococcal 
strains (Table 1.1) (Zarantonelli et al 1999; Cousin et al 2003; Warner et al 2008). The presence 
of mef gene encoding a membrane-bound efflux protein, MacA-MacB efflux pump system, in N. 
gonorrhoeae can confer azithromycin resistance (Luna et al 2000). Alterations in 23S rRNA or 
the presence of methylase enzymes (encoded by ermA/ermB/ermC/ermF) prevents azithromycin 
binding to 23S rRNA, the target for azithromycin (Chung et al 1999; Roberts et al 1999; Ng et al 
2002; Galarza et al 2010; Chisholm et al 2010). Recent reports suggest that emerging low 
(MIC=8 mg/L) to high (MIC≥ 256mg/L) azithromycin resistance in N. gonorrhoeae is due to 
mutated 23SrRNA alleles (Table 1.1) or the presence of rRNA methylases (Galarza et al 2010; 
Chisholm et al 2010; Katz et al 2012). These reports are important, particularly since 
azithromycin is one of the antibiotics in the recommended combination therapy for the treatment 
of gonorrhea (CDC 2012; HPA 2011; PHAC 2011c). 
 
Spectinomycin resistance: Spectinomycin is used to treat infections due to -lactamase 
producing N.
 
gonorrhoeae or in treating the patients who cannot tolerate cephalosporins and 
quinolones (Boslego et al 1987; Kubanova et al 2010; CDC 2010). Frequent use of 
spectinomycin may lead to the emergence of resistance. Therefore monitoring of its use and of 
the treated patients is crucial (Boslego et al1987; Kubanova et al 2010). Spectinomycin  acts on 
the 30S ribosomal subunit, inhibiting translocation of peptidyl tRNA (WHO 2003). 
Spectinomycin resistance can develop due to mutations G1064C and C1192U in helix 34 of 16S 
rRNA (Galimand et al 2000; Dillon 2007). Recently, a deletion of codon 27 and a K28E 
alteration in the ribosomal protein 5S has also been shown in N. gonorrhoeae isolated with high 
level of spectinomycin resistant (MIC>1024 mg/L) (Unemo 2012b). The role of other resistance 
mechanisms or mutations such as mtrR mutations, which contribute to clinical levels of 
resistance to different antibiotics in N. gonorrhoeae, may also be worth investigating in 
spectinomycin resistance.  
 
Tetracycline resistance: Some of the resistance determinants implicated for chromosomal 
penicillin resistance also impart resistance to tetracycline. Intermediate levels of tetracycline 
resistance (MIC≥1 mg/L) may develop due to mutations in the promoter or structural gene of 
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mtrR. Substitution of charged amino acids (i.e. arginine, lysine, aspartic acid and histidine) at 
positions G120 and A121 position in PorB may also cause tetracycline resistance (Table 1.1) 
(Olesky et al 2002; Pan and Spratt 1994). High-level chromosomal resistance to tetracycline 
(MIC=6 mg/L) may be caused by a mutation in rpsJ1 together with mtrR and porB mutations 
(Hu et al 2005). A mutation (V57M) in the rpsJ gene encoding ribosomal protein S10 modulates 
the rRNA-binding site for tetracycline, thus lowering the affinity of the antibiotic for the 
ribosome (Table 1.1) (Hu et al 2005; Allen et al 2011). Deletions at positions A121 and N122 in 
PIB were shown to be associated with MICs of 4-16 mg/L of chromosomal tetracycline 
resistance (Sun et al 2010).  
 
1.2.3 Impact of Antimicrobial Resistance on Treatment Guidelines for Gonococcal 
Infections 
 
Sulfanilamides, introduced in 1936, were the first effective anti-gonococcal antibiotics 
(Lees 1946). Subsequent studies showed that sulphanilamides cure 80 to 90% of gonorrhea cases 
(Kampmeier 1983). However, by the end of the 1950, over 90% of N. gonorrhoeae isolates were 
resistant to sulphonamides (Kampmeier 1983; Lewis 2010). A combination of trimethoprim and 
sulfamethoxazole was used to treat gonorrhea till the 1970’s (Austin et al 1973; Lawrence et al 
1973) until resistance developed to these agents. 
 
Penicillin was first used to treat gonococcal urethritis in 1943 (Van Slyke et al 1943). 
Penicillin remained the antibiotic of choice for the treatment of gonorrhea for the next 40 years 
(Van Slyke et al 1943; Lewis 2010). The emergence of high-level, plasmid-mediated resistance 
to penicillin in 1976 marked the end of the use of penicillin for the treatment of gonorrhea 
(Percival et al 1976; CDC 1976). Eventually, treatment with penicillin was discontinued in 1985 
in most regions (Dillon & Pagotto 1999).  
 
Tetracyclines were used initially to treat gonorrhea in patients who were allergic to 
penicillin. Tetracycline is still in use today for treating suspected, or proven, chlamydial co-
infection (PHAC 2008b, 2010b; CDC 2010). However, gonococci became less susceptible to 
tetracycline shortly after it was introduced to gonorrhrea treatment guidelines. This occued due 
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to rapid emergence and spread of gonococcal strains with plasmid mediated tetracycline 
resistance (Reyn et al 1958). This antibiotic was no longer recommended for the treatment of 
gonorrhea when plasmid-mediated tetracycline resistant isolates were identified (Roberts et al 
1988; CDC 1985; Dillon & Pagotto 1999; Greco et al 2003). Plasmid-mediated tetracycline 
resistant N. gonorrhoeae (TRNG) were first reported in the USA in 1985 and then in the 
Netherlands (CDC 1985; Roberts et al 1988). TRNG are now widespread, probably as a result of 
widespread use of tetracyclines in STI management (Lewis 2010). 
 
Erythromycin has limited activity against N. gonorrhoeae and is not recommended for 
the treatment of gonorrhea (Brown et al 1977) except if penicillin is not tolerated and in pregnant 
women (Dillon et al 1998). Azithromycin is more active against gonococci and has the 
advantage of single-dose oral treatment. Azithromycin has been used in some Latin American 
countries for the primary treatment of N. gonorrhoeae infections (Starnino et al 2012), however 
in North America, azithromycin is not recommended as a first-line treatment option for 
gonorrhea owing to concerns over development of resistance and side effects of the 
recommended 2 g dose (Young et al 1997; WHO 2003). The earliest reports of decreased 
susceptibility and resistance to azithromycin came from Latin America in the mid to late 1990s 
(Dillon et al 2006; Sosa et al 2003; Dillon et al 2001a). Azithromycin resistant gonococci were 
isolated from Canada and the USA (Ng et al 2002; Johnson et al 2003). High-level azithromycin 
resistance (MIC>256 mg/L) to N. gonorrhoeae has been reported from Scotland (Palmer et al 
2008), Argentina (Galarza et al 2009; 2010), the UK (Chisholm et al, 2009 & 2010) and Italy 
(Starnino et al 2009).   
 
Fluoroquinolones, such as ciprofloxacin and ofloxacin, were widely used to treat 
gonorrhoea from the mid-1980s onwards (Lewis 2010). In 1993, oral fluoroquinolones were 
recommended for gonorrhea treatment in the USA (CDC 1993). Trends in treatment 
recommendations for gonorrhea in Canada have been similar to those in the USA (PHAC 2006). 
Initially, low doses of 250 mg were prescribed but, by 1990, treatment failures were reported and 
recommended treatment dose was raised to 500 mg (Gransden et al 1990; Ison et al 1998; Ray et 
al 2005). However, the emergence of quinolone-resistant N. gonorrhoeae (QRNG) became a 
concern in 1991 in the US and in the Asia-Western Pacific regions (Iverson et al 2004; Tapsall et 
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al 1998b; Tapsall 2002, 2005, 2006). Since then, the rates of QRNG have continuously increased 
and have been reported internationally (Yang et al 2006; Cole 2010, 2011; CDC 2009, 2011; 
Starnino et al 2010; Uehara et al 2011; Tanaka et al 2011; WHO-WPR 2012). Quinolones were 
not recommended as first-line gonococcal treatment in most Asia-Pacific countries in the mid-to-
late1990s (Dan 2004; Lewis & Marumo 2009). In 2006, the US CDC abandoned quinolones as a 
drug of choice for treatment of gonorrhea (CDC 2007). Due to the rapid increase in rates of 
QRNG, quinolones such as ciprofloxacin and ofloxacin were shifted from the class of 
recommended drugs to the alternative options for the treatment of gonococcal infections in 
Canada (PHAC 2008a, b, 2011c). 
 
Spectinomycin is an aminocyclitol antibiotic, closely related to the aminoglycosides and 
is a bacteriostatic agent. It was developed and marketed specifically for the treatment of 
gonorrhoea in the early 1960s (Lewis 2010). Spectinomycin resistance was first reported in a 
penicillin susceptible N. gonorrhoeae isolate in the Netherlands in 1967, and subsequently in a 
PPNG isolate acquired in the Philippines in 1981(Stolz et al 1975; Ashford et al 1981). However, 
shortly after its introduction and wide use in the mid-1980s, clinical treatment failures caused by 
spectinomycin resistant strains began to be appear in US military personnel in the Republic of 
Korea (Boslego et al 1987). Gonococcal resistance to spectinomycin has also been reported from 
the Western Pacific regions (WHO-WPR 2001) and from the Latin American countries (Dillon 
et al 2006). 
 
Cephalosporins were first discovered in 1945 and modern variants are chemical 
modifications of this prototypic molecule (Barry & Klausner 2009). Because of global spread of 
QRNG and resistance to penicillin and tetracycline, extended-spectrum cephalosporins were 
recommended effective treatment of gonorrhea (Lewis 2010).  Many countries recommend orally 
administered cefixime or injectable ceftriaxone as the antibiotics of choice, including Canada 
(2008a, b), the United States (CDC 2006, 2007, 2010), the United Kingdom (HPA 2005), China 
(Wang & Zhang 2007) and Japan (Jpn Soc STD 2006).  
 
The recent reports of the emergence of strains with resistance or reduced susceptibility to 
extended spectrum cephalosporins, as well as treatment failures with this class of antibiotics, 
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have raised concerns about the use of extended spectrum cephalosporins (cefixime and 
ceftriaxone) as the first line of treatment for uncomplicated gonococal infections (Ito et al 2004, 
Tapsall et al 2009b; Ohinishi et al 2011; Unemo et al 2011b, 2012a,b; Martin et al 2012; Bolan et 
al 2012; Camara et al 2012; WHO 2012; Allen et al 2013). The spread of resistant N. 
gonorrhoeae strains, such as those isolated from Japan with high-level resistance to both 
cefixime and ceftriaxone as well as multiple antibiotics, may render N. gonorrhoeae untreatable 
in the near future (Ohinishi et al 2011; Dillon 2011). Ceftriaxone is essentially the last remaining 
treatment option and, worryingly, there have been cases of confirmed failure treating pharyngeal 
gonorrhea with ceftriaxone in Australia, Sweden and France (Tapsall et al 2009b; Unemo et al 
2011c, 2012a, 2012c). 
 
All these findings have led to a change in gonorrhea treatment recommendations in 
various countries. In Japan, cefixime has been replaced by ceftriaxone as a 1g dose given 
intravenously (Ohnishi et al 2011a). The CDC, USA, the Health Protection Agency (HPA), UK 
and Public Health Agency of Canada (PHAC) are now recommending ceftriaxone with at an 
increased dose of 250-500mg and 1g azithromycin as dual therapy for treatment of gonorrhea 
(CDC 2012; HPA 2011; PHAC 2011c).  
 
Historically, thiamphenicol has been suggested in some countries as a viable alternate 
therapy regimen to penicillin in the treatment of infections with N. gonorrhoeae. It has not 
commonly been used in the treatment of N. gonorrhoeae since because cross-resistance to 
thiamphenicol was common in penicillin resistant isolates. Further, thiamphenicol can produce 
erythroid suppression (Dillon et al 1978a,b). 
 
Aminoglycosides, kanamycin and gentamicin are rarely used for the treatment of 
gonorrhea because of their low activity against N. gonorrhoeae and their toxicity (Dillon 1992; 
WHO 2003). Kanamycin has been used to treat gonorrhea in Indonesia (Ieven et al 2003; 
Donegan et al 2006). Gentamicin is the national first-line treatment for gonorrhoea in Malawi 
and has also been used to treat gonococcal infections in Mongolia (Daly et al 1997; Lkhamsuren 
et al 2001; Brown et al 2010).  Studies in Malawi have confirmed that gonococci remain 
susceptible to gentamicin after over 14 years of first-line use (Brown et al 2010). In vitro studies 
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had demonstrated that the European gonococcal population is also susceptible to gentamicin 
(Chisholm et al 2011). Resistance to other antibiotics does not confer resistance to gentamicin 
since its mechanism of action differs from other antibiotics recommended for the treatment of 
gonorrhea (Vakulenko & Mobashery 2003; Dowell & Kirkcaldy 2012). Gentamicin is widely 
available and inexpensive but requires parenteral administration. The risks of ototoxicity and 
nephrotoxity with a single-dose therapy (240-280 mg) appear to be minimal and are not observed 
in gonorrhea patients treated with a single dose of gentamicin (Barclay & Begg 1994; Dowell & 
Kirkcaldy 2012). Although the efficacy of gentamicin does not meet recommended treatment 
efficacy criteria (≥ 95% treatment efficacy), it could potentially prove to be a valuable treatment 
option for gonorrhea patients showing cephalosporin resistance or severe cephalosporin allergy 
(Dowell and Kirkcaldy 2012). 
 
The new parenterally administered antimicrobial agents, ertapenem, a carbapenem and 
tigecycline, a glycylcycline (derived from tetracycline) are active against gonococci but require 
further testing against multidrug-resistant strains (Unemo et al 2012d; Livermore et al 2004; 
Deshpande et al 2001). Furthermore, a new fluoroketolide, solithromycin (CEM-101), has also 
been shown to have high in vitro activity against gonococci (Putnam et al 2010; Golparian et al 
2012). 
 
Gonococcal resistance to penicillin and tetracycline has been prevalent for several 
decades in Canada
 
resulting in their elimination as treatment options (PHAC 2010b). Due to the 
rapid increase in QRNG, quinolones such as ciprofloxacin are no longer preferred drugs for the 
treatment of gonococcal infections in Canada. All these findings led to a change in Canadian 
treatment guidelines from ciprofloxacin to cefixime as the recommended drug for the treatment 
for gonorrhea, with ceftriaxone or spectinomycin as the alternative treatment (PHAC, 2008). In 
view of emergence of strains with resistance or reduced susceptibility to extended spectrum 
cephalosporins and treatment failures in other parts of the world, the Canadian treatment 
guidelines for gonorrhea were revised in 2011 (PHAC 2011c). In new treatment guidelines, 
Public Health Agency of Canada (PHAC 2011c), recommends the use of ceftriaxone (250 mg 
intramuscularly) or cefixime (800 mg
 
orally) to treat gonococcal infections. Ceftriaxone is now 
being recommended as the preferred treatment for gonococcal infections in MSM. New 
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treatment guidelines also recommend use of single oral dose (1 gm) of azithromycin along with 
the recommended doses of extended spectrum cephalosprins to be used as empirical treatment to 
treat Chlamydia and gonococcl co-infections. It is important to note that PHAC still recommends 
that quinolones (ciprofloxacin 500 mg or ofloaxcin 400 mg as single dose orally) can be used as 
alternative treatment in those cases where the quinolone susceptibility of gonococcal isolates is 
demonstrated through antimicrobial susceptibility testing, or the QRNG prevalence is under 5%. 
Treatment guidelines issued by PHAC are followed all over Canada. Therefore, as per new 
recommendations ceftriaxone and azithromycin will be the drugs of choice to treat gonorrhea in 
SK and cefixime and ciprofloxacin can be used as alternatives drugs.  
 
1.3 Understanding Transmission of Neisseria gonorrhoeae through Molecular 
Epidemiology  
1.3.1 Overview of Typing Methods for N. gonorrhoeae 
 
One of the important components of gonorrhea control programs is identification of 
sexual networks and strain clusters to understand transmission of N. gonorrhoeae in a 
population. A number of phenotypic and genotypic typing methods have been applied to 
determine the molecular epidemiology of gonorrhea (Sarafian and Knapp 1989; Unemo & Dillon 
2011). The phenotypic characterizations of N. gonorrhoeae (Unemo & Dillon 2011) have 
included auxotyping (A) (Carifo & Catlin 1973; Ng & Dillon 1993), serovar determination (S) 
(Knapp et al 1984; Sandström et al 1982, 1984; Dillon et al 1987a, b), and the combination of A/S 
(Ng & Dillon 1993), as well as antibiogram determination, or a combination of these methods 
(Ng et al 1995). The use of phenotype based typing methods is limited due to the unavailability 
of reagents e.g. sera, the degree of technical expertise required e.g. auxotype, the relatively high 
cost and lack of discrimination (Unemo & Dillon 2011). 
 
An ideal typing approach for epidemiological studies should have the characteristics of : 
1) being able to type all strains in a species, 2) having enhanced discriminatory power while 
preserving the ability to demonstrate strain linkages, 3) reproducibility, 4) feasibility and 
applicability, 5) easy to perform and 6) cost (Olive & Bean, 1999; Unemo & Dillon 2011).  
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The discriminatory power of a typing method is its ability to distinguish unrelated strains. 
The “index of discrimination” (ID) indicates the probability of a typing method to differentiate 
two different isolates and has been used to characterize discriminatory abilities of different 
typing methods (Hunter & Gaston 1988). An ID of higher than 95% has been considered to be 
desirable in differentiating N. gonorrhoeae isolates with critical assessment of the confidence 
interval (Dillon et al 1993; Unemo & Dillon 2011). This index is influenced by sample size and 
the heterogeneity and clonality of the bacterial populations tested (Unemo & Dillon 2011). 
 
Phenotypic Differentiation of N. gonorrhoeae Isolates 
 
Antimicrobial susceptibility testing: This method involves the determination of MICs of N. 
gonorrhoeae isolates against one or many antibiotics. Strains are differentiated on their 
susceptibility or resistance profiles. Antimicrobial susceptibility testing is used for monitoring 
antibiotic susceptibility and for determining appropriate treatment recommendations (Dillon et 
al1978b, Dillon & Carballo, 1990; Dillon & Pagotto 1999). The results of the antimicrobial 
susceptibility testing can vary between different laboratories since uniformity does not exist in 
terms of susceptibility interpretation criteria, use of reference strains and lot numbers of 
antibiotics, and culture media used for testing. The antibiograms have low discriminatory power 
and are inappropriate for epidemiological studies of gonorrhea (Dillon et al 1993; Ng et al 1995; 
Unemo & Dillon, 2011). However, they are absolutely required for surveillance as this is the 
only way that AMR can be determined. 
 
Auxotyping (A): Auxotypes of N. gonorrhoeae isolates are based on their different nutritional 
requirements for amino acids, purines, pyrimidines, and vitamins (Catlin 1973). Some nutritional 
components (e.g. cystine, cysteine) are required for all isolates of N. gonorrhoeae to grow, 
whereas other components are required by some isolates (Carifo & Catlin, 1973). Auxotyping 
differentiates N. gonorrhoeae isolates into various nutrient-requiring phenotypes, e.g. non-
requiring (NR) or prototrophic, proline-requiring (P), arginine-hypoxanthine-uracil-requiring 
(AHU), and proline-citrulline-uracil-requiring (PCU) (Dillon et al 1986, 1987b). This method of 
typing also has low discriminatory ability, is time consuming and laborious, and requires higher 
41 
 
levels of training in both technical aspects and for interpretation of the test results (Dillon et 
al1987b, 1993, Unemo & Dillon 2011).  
 
Serotyping (S) and Auxo/Sero (A/S) typing: Serotyping is based on the antigenic diversity of 
the major outer membrane porin proteins, known as the protein I (PI) molecules or PorB 
(Sandstrom et al 1982). Serovars are determined using coagglutination techniques (Sandstrom & 
Danielsson 1980) for detecting interactions between gonococcal antigens and panels of specific 
monoclonal antibodies (MAbs) (Knapp et al 1984). Two typing schemes were developed based 
on monoclonal antibodies (MAbs) generated against specific PI (Knapp et al 1984). One of these 
typing systems is the use of the Genetic system (GS) series of MAbs (Knapp et al 1984). Another 
set of PI-specific MAbs was designed as the Ph panel (Pharmacia; Bygdeman et al 1983; Kohl et 
al 1990). The utilization of the series of MAbs generated for this purpose, produces serotyping 
schemes with high discriminatory ability, especially when this is used in combination with 
auxotyping methods (Dillon et al 1987a, b, 1993; Unemo & Dillon 2011). However, use of this 
approach is limited by inconsistency in the interpretation of weakly positive results for some 
MAbs, the inaccessibility of some MAbs (GS), and the prevalence of non-serotypeable strains 
(Unemo et al 2003). Serovar determination has better discriminatory ability than auxotyping. It is 
fast, easy to perform, and relatively cost-efficient. The disadvantages include a reduction in the 
discriminatory ability compared to genotypic methods; this is largely due to the subjective 
interpretation of results, the low specificity of some MAbs, the increasing prevalence of non-
serotypeable strains, and the emergence of new serovars over time due to the ongoing evolution 
of PorB (Unemo & Dillon 2011).  
 
Multiple Locus Enzyme Electrophoresis: Multiple locus enzyme electrophoresis (MLEE) 
involves analysis of electrophoretic mobilities of housekeeping enzymes on starch gels (Selander 
et al 1986; Ng & Dillon 1993; De la Fuente & Vazquez 1992). MLEE indexes allelic variations 
based on banding patterns of multiple housekeeping enzymes. It may not be highly 
discriminatory (Ng & Dillon 1993; De la Fuente & Vazquez 1992). Differences in cultural 
growth conditions and enzyme productivity can make interpretation of results by MLEE 
difficult, especially if isolates tested are clones (Unemo & Dillon 2011).  
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DNA- Based Differentiation of N. gonorrhoeae Isolates 
 
Genotypic methods, i.e. DNA sequencing methods, are currently the methods of choice 
for typing gonococcal isolates. Genetic methods are more discriminatory, reproducible, 
objective, and reliable compared to those based on phenotypes (Unemo & Dillon 2011). 
Selection for molecular typing systems is based on typeability (i.e. target sequence from each 
isolate can be amplified and analyzed), reproducibility, ease of interpretation, ease of use and 
greater discriminatory power (Maslow et al 1993). DNA-based typing methods include 
characterizing plasmids as well as determining polymorphisms in either a single locus or 
multiple loci over the entire genome, using a number of methods (Unemo & Dillon 2011). 
 
DNA-based typing methods for characterizing N. gonorrhoeae strains can be broadly 
divided into two groups (Unemo & Dillon 2011): gel-based DNA-based typing methods and 
DNA sequence-based typing methods.  
 
Gel based DNA typing methods 
 
Gel based DNA typing methods include plasmid content analysis, restriction 
endonuclease (RE) analysis,  restriction fragment length polymorphism (RFLP) determination 
using pulsed-field gel electrophoresis (PFGE), ribotyping, and Opa typing.  
 
Plasmid Content Analysis: Analysis of plasmid content involves the characterization of either 
all plasmid content in the organism, or specifically targeted plasmids in N. gonorrhoeae isolates. 
Specific plasmids have been classified based on their phenotypes, molecular weights, or DNA 
sequences, including cryptic (no known phenotype) and conjugative plasmids, as well as 
resistance determinant-containing plasmids such as the tetM-carrying conjugative plasmid and 
the family of β-lactamase-producing plasmids (Unemo & Dillon 2011). 
Most gonococcal strains carry a 2.6 megadalton (MDa) plasmid that is cryptic (i.e. no 
known function) and a 24.5 MDa transfer plasmid (Sox et al 1978). Plasmid analysis has been 
used to differentiate plasmid-mediated antimicrobial resistance including penicillinase-producing 
N. gonorrhoeae (PPNG) and plasmid-mediated tetracycline resistant N. gonorrhoeae (TRNG) 
43 
 
(Dillon & Yeung 1989; Ison et al 1993, Xia et al 1995; Greco et al 2003). β -lactamase plasmids 
can be typed by PCR (Dillon et al 1999).  β -lactamase plasmids of N. gonorrhoeae can be 
detected in non-cultured specimens through real time PCR (Goire et al 2011). TRNG can be 
differentiated through PCR ((Ison et al 1993; Xia et al 1995; Greco et al 2003). The Uruguay 
TetM type exhibits a unique restriction pattern (Marquez et al 2002).  
 
Typing methods based on analysis of plasmid content are easy to perform and are useful 
for investigating antimicrobial resistance and outbreak of plasmid-harbouring N. gonorrhoeae 
strains (Dillon et al 1993). However, plasmid content analysis has low discriminatory ability and 
may lack reproducibility, if plasmids are acquired or lost from isolates, hence it is not 
recommended as a routine typing method.  
 
Restriction Endonuclease (RE) Analysis: Restriction endonuclease (RE) analysis involves 
cleavage of chromosomal DNA with type II (homodimers generating undivided and palindromic 
sites with 4–6 nucleotides in length) restriction endonucleases (REs; SmaI, AvaII or HindIII) and 
the resulting restriction fragments are analyzed by gel electrophoresis (Li & Dillon 1995).  Type 
II REs cleave DNA into a unique set of fragments and provide a unique band pattern or 
restriction pattern or finger print of DNA examined (Southern 1979). RE analysis is highly 
specific in differentiating strains of bacteria but is both laborious and expensive (Li & Dillon 
1995).   
 
Restriction Fragment Length Polymorphism analysis and Pulsed Field Gel Electrophoresis: 
Restriction fragment length polymorphism (RFLP) analysis is based on digestion of the entire 
genome by low-frequency-cutting restriction endonucleases followed by separation of fragments by 
polyacrylamide gel electrophoresis (PAGE) (Falk et al 1984). This method is no longer commonly 
used because it is laborious and not suitable for high-throughput analysis since the results obtained 
require visual interpretation, leading to problems with reproducibility and inter-laboratory 
comparisons (Unemo & Dillon 2011). 
 
 The discrimination ability of RFLP analysis improves when combined with pulsed-field 
electrophoresis (PFGE) involving repeated change in the orientation of the electric field in gel 
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electrophoresis. It can resolve DNA fragments ranging in size up to 2000 kb (Li & Dillon 1995; Sor 
1988). PFGE is based on digestion of the entire bacterial genome by rare-cutting restriction 
endonucleases (SpeI and/or BglII)  has followed by separation of the resulting large (5 to 10 kb) 
DNA fragments in an agarose gel subjected to pulsed-field electrophoresis (Schwartz & Cantor 
1984; Vollrath & Davis 1987; Li & Dillon 1995; Ng et al 1995; van Looveren et al 1999). PFGE is 
reproducible, increases discrimination between isolates in specific situations, and all N. 
gonorrhoeae isolates are typeable by this method (Unemo & Dillon 2011). However, PFGE lacks 
standard methods of comparison (Unemo & Dillon 2011). 
 
Ribotyping: Ribotyping is based on the RFLP analysis of rRNA genes (Li & Dillon 1995; Ng & 
Dillon 1993). Ribotyping involves enzymatic digestion of the bacterial genome, electrophoresis, and 
visualization of the resulting banding patterns after hybridization with a ribosomal RNA probe 
(rRNA) (Pace et al 1986). Ribotyping has been evaluated for typing of N. gonorrhoeae strains (Li & 
Dillon 1995). However, this method has little applicability for N. gonorrhoeae strains, as it is 
laborious, has low discrimination, involves subjective interpretation of results, and therefore, not 
practical for use outside reference laboratories (Unemo & Dillon 2011).  
 
Opa-typing: Opa-typing involves analysis of up to 11 opa genes coding for the neisserial colony 
opacity-associated (Opa) proteins (O’Rourke et al 1995; Palmer et al 2001; Ison 1998; Ward et al 
2000). In Opa-typing, opa genes are PCR-amplified; PCR products are subjected to RE digestion 
with TaqI and HhaI and separation of fragments by gel electrophoresis; banding patterns are 
compared after gel electrophoresis (O’Rourke et al 1995). Opa-typing has high typeability, 
reproducibility and high discriminatory ability (Unemo & Dillon 2011). It has been used to define 
gonococcal populations, identification of strain clusters and in tracking strain transmission, and 
strain clustering in N. gonorrhoeae (Bilek et al 2007; Khaki et al 2009; Viscidi et al 2000; 
O’Rourke et al 1995; Unemo & Dillon 2011). Opa-typing is labor intensive and it is difficult to 
standardize and compare results obtained in different laboratories (Unemo & Dillon 2011).  
 
Other typing methods: In amplified ribosomal DNA gene restriction analysis (ARDRA), a 
ribosomal gene fragment including part of the 16S rRNA gene, the 16S-23S rRNA spacer region 
and part of the 23S rRNA gene is PCR amplified, followed by digestion of PCR products with a 
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high-frequency-cutting restriction enzyme and subsequent gel electrophoresis analysis (Gu¨rtler 
and Stanisich 1996; van Looveren et al 1999).  
 
 Amplified fragment length polymorphism (AFLP) analysis is a PCR-based genome 
sampling technique that reproducibly generates fragment profiles of bacterial clones. Using each 
fragment size as an individual character, data can be reduced to binary form that can be stored in 
a database (Palmer & Arnold 2001; Spaargaren et al 2001).  
 
Arbitrarily primed PCR (AP-PCR) or randomly amplified polymorphic DNA (RAPD) 
relies on annealing a single random primer at anonymous sites in the bacterial genome where it 
may be a perfect or an approximate match. AP-PCR results give an indication of genetic 
relatedness between isolates at multiple unknown locations in the bacterial chromosome (Hobbs 
et al 1999; Lawung et al 2010).  
 
Multilocus variable-number tandem repeat (VNTR) analysis (MLVA) is gel based 
method and utilizes the variation in the number of tandem repeat sequences in different loci 
dispersed over the total genome (Schouls et al 2006). This variation is expressed in strain-
specific numerical DNA profiles. MLVA results have good congruence with DNA sequence 
based typing methods (Heymans et al 2011, 2012). The advantage of MLVA analysis is that 
genetic data are translated into numerical profiles without the loss of valuable information 
(Kushnir et al 2012). The ID for MLVA is high and is comparable to DNA sequence based 
typing methods (Heymans et al, 2012; Kushnir et al 2012). 
 
DNA sequence-based typing methods 
 
DNA sequence analysis of various gene(s) is currently the method of choice for 
distinguishing N. gonorrhoeae isolates as it provides unambiguous and reproducible information, 
has high discriminatory power, and enables data to be stored or shared electronically, permitting 
reliable comparisons to be made between data obtained in different laboratories (Maiden 2006; 
O’Rouke et al 1995; Viscidi et al 2000).  
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Currently DNA sequence based molecular typing schemes are based on PCR 
amplification of either a single gene or multiple genes (Stefani and Agodi 2000; Dillon and 
Unemo 2011). These methods have greater discriminatory power, reproducibility, rapidity and 
high throughput facilitating inter-laboratory comparisons of results nationally and 
internationally. DNA sequence based typing methods coupled with sophisticated analysis of raw 
sequences such as phylogenetic analysis provide more comprehensive information of genetic 
relatedness of different STs (Unemo & Dillon 2011). DNA sequence based typing methods have 
been used to trace the transmission of individual N. gonorrhoeae strains within a community, to 
identify suspected clusters of cases of gonorrhea; to confirm epidemiological connections 
between patients (Hobbs et al 1999; Unemo et al 2002; Viscidi & Demma 2003; Choudhury et al 
2006; Martin et al 2004, 2005; Lundba¨ck et al 2006; Liao et al 2008, 2009; Golparian et al 
2010; Ilina et al 2010; Unemo & Dillon et al 2011), to investigate treatment failure (Ota et al 
2009; Tapsall et al 2009b; Unemo et al 2010), to study population genetics (Fudyk et al 1999; 
Pe´rez-Losada et al 2007; Tazi et al 2010), tracing sexual contacts (Martin et al 2004; Unemo et 
al 2007; Bilek et al 2007; Abu-Rajab et al 2009), in medico-legal cases (Martin et al 2007), and, 
predicting antimicrobial resistance (Palmer et al 2008).  DNA sequence-based typing methods 
routinely used for N. gonorrhoeae include full- or extended-length porB sequence analysis, N. 
gonorrhoeae multi-antigen sequence typing (NG-MAST), and multilocus sequence typing 
(MLST). 
 
porB-based DNA Sequence Typing: porB-based DNA sequence analysis is based on DNA 
sequence analysis of either full, or an extended length. of porB, that comprises most polymorphic 
segments, or the full length (up to nearly 1,000 bp) of the gene (Vicsidi et al 2000; Unemo et al 
2002; Liao et al 2008; Unemo & Dillon 2011). This method has high discriminatory power when 
full-length or partial porB sequences are used (Unemo & Dillon 2011; Liao et al 2008). The cost 
for using this method is low as compared to other DNA sequence-based methods used and two 
DNA sequencing reactions of the amplicon are required (Hunter & Gaston 1988; Dillon et al 
1993; van Looveren et al 1999). However, international standardization of the reference strain 
for full- or extended-length porB sequence-based methods and an appropriate database for these 
porB sequences, to permit international comparison, is lacking (Unemo & Dillon 2011).  
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Neisseria gonorrhoeae Multi-Antigen Sequence Typing: NG-MAST involves analysis of 
variable internal fragments of two highly polymorphic loci of N. gonorrhoeae: porB (490 bp) 
and tbpB (390 bp), which encodes subunit B of the transferrin binding protein (Martin et al 
2004). The combination of two hyper-variable loci ensures that the NG-MAST method has a 
very high discriminatory power. NG-MAST has been widely used because it is easy to perform 
and the availability of a public database (http://www.ng-mast.net) for comparing sequence types 
of N. gonorrhoeae isolates from different laboratories and geographical areas around the world. 
NG-MAST is most often used with cultured specimens, and the method must be optimized for 
potential use in all types of NAAT specimens (Whiley et al 2006; Unemo & Dillon 2011). 
Recently, Whiley et al (2009) demonstrated that NG-MAST can be applied to the non-cultured 
urogenital specimen but authors reported cross-reactions with commensal Neisseria for throat 
swabs. 
 
Multiple Locus Sequence Typing: MLST evolved from the MLEE (De la Fuente & Vazquez 
1992) and is based on DNA sequences of internal fragments of the alleles of seven or more 
chromosomal housekeeping genes (Maiden et al 1998; Bennett et al 2007). Housekeeping genes 
are conserved, slowly evolving, evolutionarily more neutral, and are distributed throughout the 
genome (Enright & Spratt 1999). For MLST analysis, different sequences for each locus are 
assigned divergent allele numbers, and the combination of alleles at the seven loci defines an 
allelic profile (Enright & Spratt 1999; Unemo & Dillon 2011). The MLST scheme for N. 
gonorrhoeae was originally adapted from MLST for N. meningitides [using abcZ (ATP-binding 
protein), adk (adenylate kinase ), aroE (shikimate dehydrogenase), gdh (glucose-6-phosphate 1-
dehydrogenase), pdhC (pyruvate dehydrogenase), pgm (phosphoglucomutase), mtg  (myeloid 
translocation gene), pilA (regulatory protein PilA), pip (proline iminopeptidase), ppk 
(polyphosphate kinase) and serC (3-phosphoserine aminotransferase)] (Viscidi & Demma 2003; 
Maiden et al 1998). A slight modification of the “meningitidis” scheme with the addition of one 
gene [abcZ, adk, aroE, gdh, pdhC, pgm, fumC (fumarate hydratase class II)] has been used 
recently for molecular epidemiology of N. gonorrhoeae (Bennett et al 2007). A similar MLST 
scheme targeting seven loci [gdh, fumC, pilA, serC, pyrD (dihydroorotate dehydrogenase), gnd 
(6-phosphogluconate dehydrogenase) and glnA (glutamine synthetase)] has been used in 
studying gonococcal population dynamics (Viscidi & Demma 2003; Tazi et al 2010). MLST is 
48 
 
most useful for studying bacterial genomic evolution in bacterial populations (Viscidi & Demma 
2003) since the house-keeping genes are under neutral selection and evolve slowly (Pérez-Losada 
et al 2005).  
 
The main advantage of MLST over other existing N. gonorrhoeae typing schemes is that 
concatenated sequences (sequences from different genes linked in series) of the housekeeping 
genes (MLST) retain the phylogenetic uniqueness and genetic stability of gonococcal strains. 
Thus, MLST can help identify strains over a longer period of time, compared to DNA sequences 
of hyper-variable genes such as porB and tbpB, which can be subjected to frequent mutations and 
recombination, thereby, leading to a failure to identify the predominant related strains of N. 
gonorrhoeae (Vidovic et al 2011). MLST appears to be a more suitable method for long term 
epidemiological investigations to monitor the spread and distribution of gonococcal isolates 
(Vidovic et al 2011).  
 
Lip-based DNA Sequence Typing: Lip-typing (Trees et al 2000) characterizes the number and 
sequences of repeats (encoding a five amino acid sequence, AAEAP) in the gene encoding an 
outer membrane lipoprotein (Woods et al 1989). By PCR-amplifying lip and subsequently 
differentiating the sizes of PCR products, the number of the repeat-coding sequences can be 
predicted. DNA sequence analysis of the amplicons further differentiates N. gonorrhoeae strains 
with the same number of repeats, thus identifying Lip subtyping patterns (Trees et al 2000).  
 
Whole Genome Sequencing of N. gonorrhoeae: Bacterial strains can be differentiated through 
whole genome sequencing to investigate strain lineages and their transmission patterns (Harris et 
al 2010). This method can provide better discrimination compared to existing typing schemes 
and data generated from whole genome sequencing can be applied for short or long term 
epidemiological analysis. Comparative genome analysis for differentiating N. gonorrhoeae 
strains can be useful in the investigation of evolution of gonococci especially antimicrobial 
resistant strains and their determinants (Unemo & Dillon 2011). N. gonorrhoeae strains FA1090 
(GenBank Accession #AE004969), NCCP11945 (GenBank Accession # CP001050) and TCDC-
NG08107 (GenBank Accession # NC_017511) have been completely sequenced (Chung et al 
2008; Chen et al 2011). The genome of N. gonorrhoeae FA1090 is 2.15 million nucleotides 
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(Mbp) in length with a GC content of 52.0%. There are 2002 protein-coding sequences and 67 
structural RNA-coding sequences in the N. gonorrhoeae FA1090 genome. Sequencing of the N. 
gonorrhoeae NCCP11945 genome was completed in July 2008 (Chung et al 2008); it contains 
2.232023 Mbps with a GC content of 52.0%. There are 2662 protein-coding sequences and 67 
structural RNA-coding sequences in the N. gonorrhoeae NCCP11945 genome. In addition to 
these complete N. gonorrhoeae genomes, shotgun sequences of 16 N. gonorrhoeae strains are 
available from National Cenre for Biotechnology Information (NCBI. 
http://www.ncbi.nlm.nih.gov/nuccore) 
 
Four N. gonorrhoeae plasmids have been completely sequenced, pJD4 (Pagotto et al 
2000), pSJ5.2 (Scharbaai-Vázquez et al 2007), pCmGFP (GenBank Accession #FJ172221), 
pNGK (GenBank Accession #CP001051) and pEM1 (Muller et al 2011).  These plasmids are 7.4 
(pJD4), 5.16 (pSJ5.2), 6.1 (pCmGFP), 4.2 (pNGK) and 4.8 kbp (pEM1) long, respectively. The 
GC contents were variable, ranging from 38% to 51%.  
 
1.3.2 Molecular Epidemiology of Gonorrhea 
 
Epidemiology identifies factors that determine disease distribution in time and place, as 
well as factors that determine disease transmission, manifestation, and progression. The term 
“molecular epidemiology” was coined by Kilbourne in 1973 (Kilbourne 1973).  Molecular 
epidemiology involves the use of the techniques of molecular biology to characterize nucleic 
acid or amino acid-based content, and “Epidemiology,” the study of the distribution and 
determinants of disease (Foxman & Riley 2001). Riley (2004) defined molecular epidemiology 
of infectious diseases as “the study of the distribution and determinants of infectious diseases 
that utilize molecular biology methods.” Molecular epidemiology helps to elucidate observations 
made in the biological world to formulate new concepts and make predictions. Molecular 
epidemiology determines the dynamics of disease transmission and identifies risk factors 
including genetic determinants.  
 
Molecular techniques help to stratify and to refine data by providing more sensitive and 
specific measurements that facilitate epidemiologic analyses. This can, include disease 
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surveillance; outbreak investigations; identification of transmission patterns and risk factors 
among apparently disparate cases; characterization host-pathogen interactions; detecting 
uncultivatable organisms; providing clues for possible infectious causes of communicable and 
non-communicable diseases; and, providing better understanding of disease pathogenesis at the 
molecular level (Foxman & Riley 2001). porB-based DNA sequence analysis, NG-MAST and 
MLST have been used for studying the molecular epidemiology of N. gonorrhoeae (Unemo and 
Dillon 2011).   
 
Gene markers for porB typing and NG-MAST evolve rapidly, owing to immune 
selection, which makes these typing methods virtually inapplicable in long-term epidemiological 
studies. The limitation of the NG-MAST and porB typing methods was overcome by introducing 
MLST (Maiden et al 1998). Unlike NG-MAST or porB typing methods, MLST provides clonal 
stability, while retaining a high-resolution power (Klint et al 2007; Meats et al 2003; Ilina et al 
2010; Vidovic et al 2011). MLST schemes have been used to study gonococcal population 
structure, and emergence and evolution of antimicrobial resistance in N. gonorrhoeae (Viscidi & 
Demma 2003; Pe´rez-Losada et al 2005, 2007a, b; Bennett et al 2007; Tazi et al 2010, Ilina et al 
2010; Mavroidi et al 2011; Vidovic et al 2011).  
 
1.4 Population Dynamics and Emerging AMR Mechanisms of Neisseria gonorrhoeae: 
Saskatchewan as a Model 
 
N. gonorroheae isolates collected from different clinics and hospitals across the province 
are subjected to antimicrobial susceptibility testing at the Saskatchewan Disease Control 
Laboratory (SDCL; Regina, SK) yet very limited information is available on the status of AMR 
in N. gonorroheae isolates from SK (PHAC 2011; Dillon 1990). This is primarily because fewer 
and fewer cases are diagnosed with cultures compared to NAATs. In a national study conducted 
in 1988/89, low prevalence of resistance to penicillin (0-0.9%) and tetracycline (0-2.7%) was 
recorded in SK (Dillon 1990). The treatment guidelines for gonorrhea in Canada have been 
changed since 1988/89 and no study has been conducted to determine the status of N. 
gonorrhoeae AMR in SK after 1988/89 (PHAC 2006; 2011c). Therefore, determination of the 
status of AMR in N. gonorroheae isolates from SK is relevant. No studies  have been conducted 
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to determine the mechanisms of antimicrobial resistance in gonococcal isolates from SK. 
Reduced susceptibilities to extended spectrum cephalosporins and treatment failure with 
cefixime have been reported in Canada (Allen et al 2011, 2013; Martin et al 2012). It is 
worthwhile to explore AMR mechanisms in N. gonorroheae isolates from SK especially for 
extended spectrum cephalosporins. 
 
Molecular epidemiological investigations conducted on N. gonorroheae isolates from the 
province are limited to a study conducted in 1988/89 determining the distribution of the 
auxotypes (A) and serovars (S) and A/S classes in the province (Dillon 1990). The most 
prevalent auxotypes in the province were; NR (59.7%), proline-uracil-hypoxanthine requiring 
(PUH, 12.1%) and proline-citruline-uracil requiring (PCU, 8.1%). The most prevalent (93%) 
serovars included; IB-3 (52.9%), IB-1 (19.2%), IB-2 (11.4%), and IA-2 (9.4). The majority 
(61.7%) of isolates were A/S classes NR/IB-3 (46.9%), PUH/IB-1 (8.6%) and PCU/IB-2 (6.2%). 
The prevalence of predominant A/S classes detected in this study was different from those for 
the rest of Canada (Dillon 1990). 
 
No molecular epidemiological studies were conducted in province using DNA-based 
typing methods such as porB typing, NG-MAST and MLST.  Use of these DNA-based typing 
methods will provide higher levels of discrimination and a better understanding of distribution 
and transmission of N. gonorroheae strains, emergence and evolution of AMR and for 
developing improved public health control measures, and preventive interventions. These would 
include contact tracing, identification of core groups, correlation with risk behaviors, and use of 
effective antimicrobial treatment in the province. The use of DNA based typing methods will 
help in developing baseline data on N. gonorroheae STs in SK. Based on such database, N. 
gonorroheae strain distribution, new strains and epidemiological parameters, and novel 
associations of antibiograms with specific strains/STs observed in SK can be compared 
internationally. 
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1.5 Hypothesis and Objectives 
 
This study focuses on the investigation of the prevalence of antimicrobial resistance, 
mechanisms of antimicrobial resistance and the molecular epidemiology of N. gonorrhoeae 
isolated in the province of SK, Canada between 2003 and 2011. 
 
Hypotheses:  
 
1. Trends of antimicrobial resistance of N. gonorrhoeae in SK can differ temporally and 
geographically from Canada and worldwide, since isolates with raised MICs and 
decreased susceptibility to extended spectrum cephalosporins are emerging. 
2. Specific genetic variations in various loci are associated with gonococcal antimicrobial 
resistance and will reflect a unique distribution in SK. These can be observed in targeted 
genes i.e. penA, mtrR, porB, and ponA for penicillin and extended spectrum 
cephalosporins resistance, gyrA and parC for quinolone resistance and mtrR, 23SrRNA 
and erm for azithromycin. 
3. DNA-based typing schemes, based on unique AMR profiles can be used to determine 
whether N. gonorrhoeae strains from SK differ from gonococcal STs identified in other 
Canadian studies. Temporal and geographical differences will be observed between 
gonococcal STs in SK. Specific STs will be associated with specific resistance 
phenotypes or mutation patterns in potential resistance determinants in gonococcal 
isolates from SK .  
 
Objectives: 
 
The objectives of the present research are: 
1. To ascertain the prevalence, patterns and trends of AMR in N. gonorrhoeae isolates in 
SK by: 
a) determining and analyzing antimicrobial susceptibility profiles to cefixime, 
ceftriaxone, azithromycin, spectinomycin, ciprofloxacin, penicillin and tetracycline or 
isolates collected from SK (2003-2011). 
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b) comparing SK trends to national and international data 
2. Emerging AMR mechanisms will be ascertained by amplifying and analyzing DNA 
sequences of: 
a) penA, mtrR, porB and ponA for reduced susceptibility to extended spectrum 
cephalosporins and penicillin resistance.  
b) gyrA and parC quinolone resistance determinant regions (QRDR) and mtrR for 
ciprofloxacin resistance. 
c) mtrR, 23S rRNA alleles and erm encoding  rRNA methylase enzymes for azithromycin 
resistance. 
3.  Investigating the distribution of N. gonorrhoeae STs in SK by molecular typing 
methods, specially ascertaining:  
a) strain distribution based on porB DNA sequence analysis, NG-MAST and MLST, 
b) phylogenetic relationships between STs, 
c) evolution of AMR phenotypes by MLST analysis, 
d) associations between specific STs and AMR phenotypes and genotypes. 
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CHAPTER TWO 
 
MATERIALS AND METHODS 
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2.1 Collection and Identification of Neisseria gonorrhoeae Isolates 
 
  Cultures of N. gonorrhoeae (n=427) were consecutively collected at the Saskatchewan 
Disease Control Laboratory (SDCL), Regina, SK between 2003 and 2011. None of the isolates 
tested were duplicate specimens from the same patient at the same time period. Primary 
isolations of N. gonorrhoeae were made at the SDCL on Thayer Martin medium (OXOID, ON, 
Canada) containing 1% IsovitaleX (Becton Dickinson, ON, Canada) (Knapp 1988). The isolates 
were identified as N. gonorrhoeae at the SDCL. 320 of these isolates were shipped in Amies 
transport medium (Becton Dickinson, Mississagua, ON, Canada) to the University of 
Saskatchewan. They were stored at –80oC in Brain Heart Infusion medium (Difco BD 
Biosciences, Oakville, ON, Canada) containing 20% glycerol. Frozen N. gonorrhoeae isolates 
were streaked onto GC Agar Medium Base (GCMB, Difco BD Biosciences, Oakville, ON, 
Canada) supplemented with 1% modified Kellogg’s supplement (GCMBK, Kellogg et al 1963) 
and incubated at 35C with 5-7% CO2 in a humid environment for 20-24 hours (Knapp 1988; 
CLSI 2009). Isolates were reconfirmed as N. gonorrhoeae using the oxidase test and Gram 
staining
 
(WHO 2003).  Information such as city of isolation, age and sex of the patient was 
available for each isolate.  
 
2.2 Antimicrobial Susceptibility  
2.2.1 Determination of Minimal Inhibitory Concentrations 
 
 The antimicrobial susceptibility of the N. gonorrhoeae isolates was determined using the 
agar dilution method of the Clinical and Laboratory Standards Institute (CLSI 2009).World 
Health Organization (WHO) reference strains B, C, F and K and ATCC 49226 (Table 2.1) were 
used as reference strains for antimicrobial susceptibility testing (CLSI 2009; WHO-WPR 1997; 
Unemo et al 2009). The antimicrobial susceptibility of 427 N. gonorrhoeae isolates was 
determined to penicillin (0.002–128.0 mg/L), tetracycline (0.06–256.0 mg/L), ciprofloxacin 
(0.001–64.0 mg/L), azithromycin  (0.016–32.0 mg/L), cefixime (0.00025-2.0 mg/L), ceftriaxone 
(0.000125–2.0 mg/L) and spectinomycin (4.0–256.0 mg/L) (CLSI 2009). Of the minimum 
inhibitory concentration (MIC) data in this study, 320 N. gonorrhoeae isolates (2003-2008) were 
tested by me including susceptibility to azithromycin and data for a further 107 isolates (2009- 
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Table 2.1 Strains and plasmid used in this study as reference strains and positive controls  
 
 
a: penA, mosaic pattern X with I312M, V316T& G545S; ponA, L421P; mtrR, deletion of A (promoter) & G45D in coding sequence;  gyrA, S91F; parC,S87R 
&S88P; porB, G120K & A121D; b: penA, D345a & A501V;  parC, D86N &S88P; c: gyrA,S91F & D95N; d: mtrR, truncated mtrR; e: mtrR, A to C substitution 
(promoter) & insertion of T at bp 60; f: Phenotypes-Pen
I
-penicillin intermediate susceptibility, Tet
I
-tetracycline intermediate susceptibility, TRNG-tetracycline 
resistant N. gonorrhoeae, Ery
R
-erythromycin resistant, CMRNG; chromosomally mediated resistant N. gonorrhoeae, Cip
R
-ciprofloxacin resistance, 
 
Cef
NS- 
not 
susceptible to cefixime, Cro
NS
-not susceptible to ceftriaxone, PPNG-penicillinase producing N. gonorrhoeae, Ery
R
-erythromycin resistance, Azi
R
-azithromycin 
resistance; g: NML- National Microbiological Laboratory; h: SDCL- Saskatchewan Disease Control Laboratory. 
 
5
6
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2011) was obtained from the SDCL. For testing performed in Saskatoon, all antimicrobial agents 
were purchased from Sigma Aldrich (Oakville ON, Canada). Minimum Inhibitory 
Concentrations (MICs) were determined in duplicate on GCMBK agar, and included reference 
strains for each time performed. Antimicrobial susceptibly/resistance criteria (Table 2.2) were 
those of CLSI (CLSI 2009). For azithromycin, since no breakpoints have been established by the 
CLSI, interpretative criteria were based on the Gonococcal Isolate Surveillance Project (GISP), 
USA (CDC 2010b). Gonococcal inocula were prepared by suspending an overnight culture 
grown on GCMBK plates in Muller-Hinton broth (Difco, BD Biosciences, Oakville, ON, 
Canada) to a 0.5 McFarland turbidity standard (Remel, Lenexa KS, USA), which equilibrates to 
10
8
 colony forming units (CFU) per milliliter. This suspension was diluted 1:10 with Muller-
Hinton broth, resulting in a cell density of ~10
7 CFU/mL. Approximately 2 μL of the cell 
suspension containing 200 CFU was delivered onto antibiotic- containing and control GCMBK 
plates using a multispot Steers inoculator (Steers et al 1959) and incubated for 18-24 hours at 
35
o
C with 5-7% CO2 in a humid environment. The MIC was considered to be the lowest 
concentration of antibiotic producing complete inhibition of growth (CLSI 2009). As per the 
CDC, the alert values for cefixime and ceftriaxone are MICs 0.125 mg/L and 0.25 mg/L and are 
defined as elevated MICs (CDC 2012). β-lactamase production was determined using the 
chromogenic nirocefin test (Calbiochem, EMD Chemicals Inc., Darmstadt, Germany). All 
isolates with penicillin MICs ≥ 2.0 mg/L were tested for β-lactamase production. 
 
The resistance phenotypes classified in this study included: PPNG (β-lactamase 
positive);TRNG (tetracycline MIC ≥16 mg/L and β-lactamase negative); PP/TRNG (β-lactamase 
positive and tetracycline MIC ≥16 mg/L); PenR (non PPNG; penicillin MIC ≥ 2.0 mg/L);CMTR 
(non-PPNG; non-TRNG, penicillin MIC < 2.0 mg/L and tetracycline MIC ≥ 2.0-8.0 mg/L); CipR 
(ciprofloxacin MIC ≥ 1.0 mg/L); AziR (azithromycin MIC ≥ 2.0mg/L); SpecR (spectinomycin 
MIC ≥ 128.0 mg/L); CMPR (non-PPNG, tetracycline MIC < 2.0 mg/L and penicillin MIC ≥2.0 
mg/L);,and,  CMRNG (non-PPNG, non-TRNG, penicillin MIC ≥ 2.0 mg/L and tetracycline MIC 
≥ 2.0 mg/L). An isolate can exhibit more than one resistance phenotype. For example, the 
phenotype of CMTR/Azi
R
/PPNG indicates an isolate of N. gonorrhoeae with chromosomal 
resistance to tetracycline, azithromycin, which is also β-lactamase positive. 
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Table 2.2 Determination of minimal inhibitory concentrations and interpretation criteria 
for N. gonorrhoeae
a
 
 
a: Interpretative criteria for MIC classification were those described by the CLSI (CLSI 2009). MICs 
are classified into susceptible (S), intermediate (I) and resistant (R) for each antimicrobial agent. 
b: Interpretative criteria for azithromycin MIC classification are not described by CLSI, therefore 
standards (alert values) followed by Gonococcal isolate surveillance project (GISP), USA were used 
(CDC 2010b). 
c: Alert values for cefixime and ceftriaxone are MICs 0.125 mg/L and 0.25 mg/L (CDC 2012). 
d: Break points are not defined. 
 
 
 
 
Antimicrobial  
agent 
Antibiotic concentration 
Testing range (mg/L) 
Interpretative criteria (mg/L)
a
 
S  I R 
 
Penicillin 
 
 
0.002 – 128.0 
 
≤ 0.06 
 
0.12 – 1.0 
 
≥ 2.0 
Tetracycline 0.06 – 256.0 ≤ 0.25 0.5 – 1.0 ≥ 2.0 
 
Ciprofloxacin 0.001 – 64.0 ≤ 0.06 0.12 – 0.5 ≥ 1.0 
 
Azithromycin
b
 0.016 – 32.0 
 
≤ 1.0 NDd ≥ 2.0 
 
Cefixime 0.00025 – 2.0 
 
≤ 0.25c ND ND 
 
Ceftriaxone 0.00125 – 2.0 ≤ 0.25c ND ND 
 
Spectinomycin 4.0 – 256.0 ≤ 32.0 64.0 ≥ 128.0 
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For cefixime and ceftriaxone, the susceptible breakpoint is defined as having MICs ≤ 
0.25 mg/L (CLSI 2009; CDC 2010b). Breakpoints for intermediate-levels of susceptibility and 
resistance have not been defined for cefixime and ceftriaxone. The CLSI defines reduced 
susceptibility to cefixime and ceftriaxone as having MICs > 0.25 mg/L, whereas the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) defines reduced susceptibility to 
cefixime MIC > 0.25 mg/L and ceftriaxone MIC > 0.125 mg/L (Cole et al 2010). In the USA, 
alert values for cefixime and ceftriaxone reduced susceptibility are MICs 0.125 mg/L and 0.25 
mg/L (CDC 2012). 
 
2.3 Molecular Mechanisms of Antimicrobial Resistance in N. gonorrhoeae 
2.3.1 Chromosomal DNA Isolation  
 
DNA isolation was performed using overnight N. gonorrhoeae growth from 
approximately one half of a GCMBK plate and suspendeding it in 1 mL of 0.9% saline. After 
centrifugation at 10,000 X g for 1 min the supernatant was removed and genomic DNA was 
extracted using a Qiagen DNeasy Tissue Kit (Qiagen Inc., Valencia, California) according to the 
manufacturer’s instructions. DNA was eluted in sterile distilled water and stored at -20oC. The 
chromosomal DNA of WHO reference strains K, L, M, N and P used as positive controls for 
various resistance genotypes (Unemo et al 2009) (Table 2.1).  
 
2.3.2 Amplification of penA, mtrR, porB, ponA, gyrA, parC, 23SrRNA and erm by the 
Polymerase Chain Reaction 
 
The DNA sequences of penA, mtrR, ponA1 and porB were analyzed for 146 [2003 (n=24, 
40%), 2004 (n=37, 62%), 2005 (n=29, 55%), 2006 (n=18, 33%), 2007 (n=22, 42%) and 2008 
(n=16, 39%)] isolates to determine the emerging molecular mechanisms of extended spectrum 
cephalosporin susceptibility. This subset of isolates included all the Pen
R
 (n=15), Cip
R
 (n=5), 
Azi
R
 (n=2) and 50% (n=90) of Tet
R
 isolates observed from 2003 through 2008 in this study. No 
isolates with” reduced susceptibility” (i.e. CLSI value MIC≥0.25 mg/L) to cefixime and 
ceftriaxone were observed in this study. In order to ascertain  the emerging mechanisms of 
reduced susceptibility or resistance to extended spectrum cephalosporins these isolates were 
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divided into two susceptibility groups: isolates with MIC 0.0005-0.016 mg/L (cefixime & 
ceftriaxone susceptibility group 1; n=123) and isolates with MICs 0.03-0.06 mg/L (cefixime & 
ceftriaxone susceptibility group 2; n=23). 23S rRNA and mtrR DNA sequences were analyzed in 
52 isolates for azithromycin resistance. Presence of erm (rRNA methylase genes) was also 
determined in these isolates. gyrA, parC and mtrR DNA sequences for 41 N. gonorrhoeae 
isolates were analyzed for ciprofloxacin resistance. All the resistant isolates detected in this study 
were analyzed for the molecular mechanisms of resistance. 
 
 Primers used for polymerase chain reaction (PCR) and DNA sequencing reactions are 
listed in Table 2.3. Primers were purchased from Invitrogen Canada (Burlington, ON). Primer 
stock solutions were prepared by dissolving individual primers in sterilized distilled water at a 
concentration of 100 μM. Antibiotic resistance genes were amplified using the following primer 
pairs: penA-F/penA-R for penA (Ochiai et al 2007; Lee et al 2010); mtrR-F/mtrR-R for the mtrR 
promoter and coding sequences (Xia et al 2000);  porB-F/porB-R for porB (Martin et al 2004; 
Unemo et al 2003); ponA-F/ponA-R
 
for ponA (Ropp et al 1997, 2002); gyrA-F/gyrA-R for gyrA; 
and, parC-F/parC-R for parC (Belland et al 1994).  The DNA sequences of an internal segment 
of the porB gene are also used for N. gonorrhoeae Multi-Antigen Sequence Typing (NG-MAST) 
(Martin et al 2004). Primer pair tbpB-F/tbpB-R was used to amplify an internal segment of tbpB 
for NG-MAST analysis (Martin et al 2004).  
 
Four alleles of the 23S rRNA gene were amplified individually using primer pairs 
gonrRNA-F/23S rRNAR-allele1 for allele 1; gonrRNA-F/23S rRNAR-allele2 for allele 2; 
gonrRNA-F/23S rRNAR-allele3 for allele 3; gonrRNA-F/23S rRNAR-allele4 for allele 4; and, 
gonrRNA-F/gonrRNA-R2 for the 23S rRNA peptidyltransferase loop (Ng et al 2002). 
Amplification reactions for the detection of rRNA methylase genes, ermA, ermB, ermC and  
ermF conferring resistance to macrolides were performed using primer pairs; AF/AR for ermA, 
BF /BR for ermB, and CF/CR for ermC and F1/ F2 for ermF (Chung et al 1999).  
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Table 2.3 Primers used for PCR and DNA sequencing reactions for penA, mtrR, porB, ponA, gyrA, parC, 23SrRNA and erm 
 
 
a: nt- nucleotide positions; b: AA- amino acid position 
 
6
1
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Table 2.3 continued…….. 
 
a: nt- nucleotide position
 
6
2
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  The PCR mixture (50 μL) for all reactions contained 2 μL of genomic DNA, 2.5 U of 
dreamTaq DNA polymerase (Fermentas, Burlington, ON, Canada L7N 3N4), 1 x PCR buffer 
with 1.5 mM MgCl2, 0.25 mM dNTPs and 0.5 μM of each primer. Amplification (MyCycler; 
Applied Biosystems, Streetsville, Ontario, Canada) was performed as follows: an initial 
denaturing step at 94
o
C for 4 min, followed by 30 sequential cycles of 94
o
C for 1 min, 55
o
C for 
45 s, 72
o
C for 45 s (for tbpB, gyrA and parC) or 1 min (for porB, mtrR, penA and ponA), and a 
final extension phase at 72
o
C for 10 min (Liao et al 2008, 2011).  
 
23S rRNA was amplified using the following conditions: 1 min of denaturation at 94°C, 
1.5 min at 66°C (for alleles 2 and 3) or 68°C (for alleles 1 and 4) for annealing, and 2.5 min at 
72°C for elongation for 30 cycles (Ng et al 2003). The amplicons obtained were then used as 
templates in a second PCR using gonrRNA-F and gonrRNA-R2 primers to amplify the 
peptidyltransferase loop for sequence determination (Ng et al 2003). The conditions for this PCR 
reaction were 94°C at 1 min for denaturing, 59°C for 1 min for annealing, and 72°C at 1 min for 
elongation for 35 cycles (Ng et al 2003).  
 
Amplification conditions for ermB and ermF were as follows (Roberts et al 1999; Chung 
et al, 1999): denaturing at 94°C for 30 s; annealing at 50°C for 30 s; and elongation at 72°C for 2 
min. The cycle was repeated 35 times. ermA amplification consisted of denaturing at 94°C for 30 
s, annealing at 48°C for 1 min, and elongation at 72°C for 2 min. Amplification 
of  ermC consisted of denaturing at 94°C for 30 s, annealing at 43°C for 1 min, and elongation at 
72°C for 2 min. Staphylococcus aureus RN1389, S. pyogenes AC1, S. aureus RN4220 and E. 
coli V831 (Table 2.1; provided by Irene Martin, National Microbiology Laboratory, Winnipeg, 
Canada) were used as positive controls for PCR amplifications of ermA, ermB, ermC and ermF ) 
(Roberts et al 1999; Chung et al 1999; Ng et al 2002). 
 
 Amplified DNA products were analyzed by agarose gel (1%) electrophoresis followed by 
ethidium bromide (0.5 µg/mL) staining and visualization under UV light (Universal Hood II, 
Biorad, Mississauga, ON, Canada) (Shambrook & Russel 2001). They were examined for purity 
and size as compared to DNA standards (1kb Plus DNA ladders, New England Biorad, 
Mississauga, ON, Canada). All PCR products were purified using the Qiagen PCR Purification 
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Kit according to the manufacturer’s instructions (Qiagen, Mississauga, ON, Canada). DNA was 
eluted in 50 μL sterilized ddH2O and stored at -20
o
C for use in subsequent DNA sequencing 
analysis. 
 
2.3.3 Determination of β lactamase and tetM Plasmid Type  
 
 β-lactamase producing plasmids were typed by PCR assay using the primer pair 
JDA/JDB ( (Dillon et al 1999; Table 2.3). Purified DNA of pJD4 (Asian β-lactamase plasmid), 
pJD5 (African β-lactamase plasmid) and pJD7 (Toronto β-lactamase plasmid) (Table 2.1), 
available in the  Dillon laboratory were positive controls and a β-lactamase negative (WHO G) 
isolate and sterilized distilled water were negative controls (Table 2.1; Dillon et al
 
1999; Unemo 
et al 2009). tetM plasmid types were determined for isolates with tetracycline MICs ≥ 16 mg/L 
by PCR using primer pairs RM4/G1 (Table 2.3; Xia et al 1995). Strain WHO G with Dutch type 
tetM plasmid was used as a TRNG positive control
 
(Table 2.1; Unemo et al 2009). PCR 
conditions were the same as described in Section 2.3.2, except for an extension time of 5 min for 
β-lactamase and 2 min for tetM in the reaction cycles (Table 2.3; Xia et al 1995; Dillon et al 
1999). Amplified DNA products were analyzed by and visualized as described in Section 2.3.2. 
The sizes of PCR products of pJD4, pJD5, and pJD7 were 4.9 kb, 3.1 kb, and 2.6 kb, respectively 
(Dillon et al 1999). The America-type tetM-containing plasmid has an amplicon size of 1.6 kb 
and the Dutch-type tetM-containing plasmid exhibits a fragment of 0.7 kb (Xia et al 1995).  
 
2.3.4 DNA Sequencing 
 
  In total, 1540 DNA sequences of genes implicated in AMR of N. gonorrhoeae [penA 
(n=292); mtrR (n=292); porB (n=292); ponA (n=292); gyrA (n=82); parC (n=82) and, 23S RNA 
(n=208)] were amplified and analyzed.  Primers used for DNA sequencing reactions of the 
targeted loci were the same as the primers used in PCR reactions except for 23SrRNA where 
primer pair gonrRNA-F/ gonrRNA-R2 (Table 2.3) was used. DNA sequences of both strands for 
each locus amplified were determined using an Applied Biosystems 3730x1 DNA Analyzer 
(Plant Biotechnology Institute, National Research Council of Canada, Saskatoon, SK). DNA 
sequences were verified and edited using online programs. Chromas Lite 
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(http://www.softpedia.com/get/Science-CAD/Chromas-Lite.shtml) was used to view and edit 
chromatograms. The ClustalW program (http://www.ebi.ac.uk/Tools/clustalw2/index.html) was 
used to align DNA sequences of both complementary strands (Larkin et al 2007). Aligned DNA 
sequences were viewed and edited using the Jalview program (Clamp et al 2004). A reference 
sequence for each locus was used for trimming DNA sequences (Table 2.4).  Flanking sequences 
corresponding to the reference sequence were removed or trimmed. After removing gaps 
introduced during alignment, DNA sequences were output in a FASTA format. DNA sequences 
were copied and pasted in Notepad, creating DNA sequence databases for subsequent analysis.  
 
Predicted amino acid sequences for each gene were obtained using the Proteomics and 
Sequence Tools (http://ca.expasy.org/, last accessed on December 12, 2012). To identify 
mutations, amino acid sequences were aligned with their respective wild type prototype 
reference sequences for which GenBank accession numbers and sequence lengths were shown in 
Table 2.4.  
 
Amino acid sequence patterns of PBP2 (penA) were classified and numbered according to 
criteria used by others (Ito et al 2005; Whiley et al 2007a; Ohinishi et al 2011b). Mutations in 
mtrR, porB, ponA1 and were classified as described previously (Warner et al 2008; Olesky et al 
2002; Ropp et al 2002). Novel sequences or mutations identified in this study have been 
submitted to the National Center for Biotechnology Information (NCBI) 
(http://www.ncbi.nlm.nih.gov/WebSub/?tool=genbank). 
 
A comprehensive data base on antimicrobial susceptibility, molecular mechanisms of 
resistance and STs has been generated on N. gonorrhoeae isolates analyzed during this study and 
is consistent with earlier studies conducted in Dillon laboratory (Yang et al 2006; Liao et al 
2008, 2011).  
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Table 2.4 Reference DNA sequences used in this study
a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a: porB (NG-MAST) and tbpB sequences are the prototypes used for NG-MAST typing (Martin et al 
2004). All other DNA sequences are wild type prototypes and were used as reference sequences for the 
determination of mutations in different resistant determinants.  
b: NG-MAST- Neisseria gonorrhoeae multi-antigen sequence typing. 
c: nt-nucleotide positions. 
d: AA-amino acid. 
e: QRDR-quinolone resistance determinant region. 
f: PBP- penicillin binding protein. 
 
 
 
Locus Nucleotide position 
GenBank accession 
 number 
 
porB1a (N. gonorrhoeae 
MS11, Extended-length  
nt
c
72-983, gaps included  J03029  
    
porB1b
a
 (N. gonorrhoeae 
FA 1090, Extended-length) 
nt
c
72-933, gaps included J03017  
porB (for NG-MAST
b
) 
 
Start at nt350 extended for 490 bp, 
 gaps removed during alignment  
M21289  
    
tbpB
a Start at nt1098 extended for 390 bp, 
 gaps removed during alignment 
2286066  
    
gyrA nt220-360, QRDR
d
 coding sequences U08817  
    
parC nt210-390, QRDR coding sequences U08907  
    
mtrR (N. gonorrhoeae 
FA1090) 
nt-1 to -120 promoter sequences and 
sequences coding for full-length MtrR  
(nt1-630)    
Z25796  
    
penA 
nt1017-1725, coding for AA
e
340-575  
of PBP2
f
 (full-length PBP2 581 AAs) 
M32091  
    
ponA1 
nt1050-1890 coding AA350-630 of 
PBP1 (full-length PBP1 798 AAs) 
U72876  
    
23S rRNA nt1-611 
AF450074- 
AF450081 
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2.4  Population Dynamics of Neisseria gonorrhoeae in Saskatchewan by Analysis of porB, 
NG-MAST and MLST 
 
 The molecular epidemiology of isolates of N. gonorrhoeae from SK was determined 
using the porB sequence typing, N. gonorrhoeae Multi-Antigen Sequence Typing (NG-MAST) 
and multilocus sequence typing (MLST). porB sequence typing and NG-MAST was performed 
on 320 isoltes collected between 2003 and 2008. A subset of 193 isolates recovered between 
2005 and 2008 were analyzed by MLST. In all, 3982 sequences [porB typing (n=640), 
NGMAST (n=640, for tbpB) and MLST (n=2702)] were amplified and analyzed to ascertain the 
population dynamics of N. gonorrhoeae in SK. 
 
The porB DNA sequences determined in this study comprised a fragment (765bp, ≈77% 
of porB sequence) containing 7 polymorphic regions encoding the surface-exposed loops (Loops 
I - VII) and 6 conserved interspace regions (II - VII) (Liao et al 2008, 2009). The sequences of 
these regions were determined for 320 N. gonorrhoeae isolates collected between 2003 and 
2008. ). porB loci were amplified and  sequenced (Table 2.3) as described earlier in Section 2.3.2 
(Table 2.3). N. gonorrhoeae porB1a (GenBank #J03029), and porB1b (GenBank #J03017) 
(Table 2.4) were used as prototype to edit the amplified porB sequences.  porB strains types were 
assigned numbers consistent with the typing criteria used in the Dillon laboratory 
(http://www.usask.ca/biology/dillon/) (Liao et al 2008, 2009). 
 
The NG-MAST database and programs for assigning STs of N. gonorrhoeae isolates are 
available online (www.ng-mast.net, Martin et al 2004). tbpB and porB loci were amplified by 
PCR and amplicons were sequenced as described in Section 2.3.2 (Table 2.3). An allele type was 
assigned to either porB or tbpB of each isolate, and a ST was assigned to the isolate based on 
porB and tbpB types online (www.ng-mast.net). Previously identified alleles of porB and tbpB, 
and STs were obtained by interrogating the NG-MAST website. The unrecognized NG-MAST 
STs were identified as novel STs on the basis of new alleles and ST numbers.  
 
193 gonococcal isolates (2005-2008) were typed by using multilocus sequence typing 
(MLST). Partial regions of 7 housekeeping genes abcZ, adk, gdh, glnA, gnd, fumC and pyrD 
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were amplified using primers listed in Table 2.5. PCR conditions included an initial 95
0
C 
denaturation step for 4 min, followed by 30 cycles of: denaturation at 95
0
C for 60 s, annealing at 
55
0
C for 30 s, amplification at 72
0
C for 30 s and a final extension step at 72
0
C for 10 
min. Amplicons were purified and sequenced as described in Section 2.3.2 and 2.3.4. All 
sequences for each locus were compared and every unique sequence was assigned as a distinct 
allele using Sequence Output (www.mlst.net). Each unique combination of allele numbers was 
assigned as a different ST.  
 
Grouping of porB and NG-MAST STs with less than 1% base pair difference: The alleles 
associated with most predominant porB and NG-MAST STs, were compared against all the 
alleles observed in this study for 320 isolates to determine similarity between different STs. It 
was done by multiple alignments using ClustalW, followed by individual pair wise alignment 
against most frequent alleles. All the porB STs with ≥99% similarity (≤7 bp difference for 
porB) were grouped together and such groups were named after predominant porB STs. NG-
MAST STs were grouped as one NG-MAST group if one identical allele (porB and tbpB) was 
shared and showed ≥99% similarity in other allele (≤5bp difference for porB and ≤4bp for tbpB) 
(Chisholm et al 2013). The NG-MAST groups were named after predominant NG-MAST ST in 
each group. 
 
2.4.1 Phylogenetic Analysis of Sequences Analyzed for porB Typing, NG-MAST and MLST 
 
porB DNA sequences in FASTA format were converted into a NEXUS format using the 
ClustalX program (http://bips.u-strasbg.fr/fr/Documentation/ClustalX; Thompson et al 1997) for 
use in TreeView program. Branch nodal support was assessed via bootstrapping (1,000 
pseudoreplicates). Trees were figured and viewed in Treeview (Page 1996; 
http://taxonomy.zoology.gla.ac.uk/rod/treeview.html). 
 
MEGA4 was used to construct phylogenetic trees from concatenated sequences of the 
housekeeping genes amplified for MLST (Tamura et al 2007). The evolutionary distances were 
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Table 2.5 Primers used for PCR and DNA sequencing reaction in multilocus sequence typing 
a: bp-base pair  
 
 
 
Locus Putative function 
Fragment 
amplified  (bp)
a 
Primer 
name 
 
Sequence (5′ to 3′) 
 
abcZ ATP-binding protein  498 
abcZ F AATCGTTTATGTACCGCAGG 
abcZ R GAGAACGAGCCGGGATAGGA 
     
adk Adenylate kinase 522 
adk F CGTTCGGCATTCCGCAAATCTCT 
adk R CGACTTTGATGTATTTCGGCGC 
     
gdh 
Glucose-6-phosphate 1-
dehydrogenase 
631 
gdh F ATGTTCGAGCCGCTGTGGAACAA 
gdh R CTTCAACGGCCTTGCCCAAATCC 
     
glnA Glutamine synthetase 537 
gln F GTTTGAAAACGGACCGGCGTTTGA 
gln R TTCCATTTGGCTGCCGGTACCGAC 
     
gnd 
Phosphogluconate  
dehydrogenase 
549 
gnd F GAGAAAATCCTCGATACGGCAGGGCA 
gnd R GGTCGTATAGCCGTCCAAGAACGT 
     
fumC Fumarate hydratase class II 
535 fumC F GCCATCCCGAATACGCTGAAATAG 
 fumC R CGATTTTGCGGTTTAACGCAGTAAC 
     
pyrD Dihydroorotate dehydrogenase 592 
pyrD F GATGATGCCGTCCATTTCGACGGA 
pyrD R TATAAAACTGATGGGTATGGATTTGC 
6
9
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computed using the Maximum Composite Likelihood method (Tamura et al, 2004). The 
Neighbor-joining algorithm (Saitou and Nei 1987) was used to generate the initial tree.  
 
To predict the ancestral profiles and clonal complexes, each genotype identified in this 
study was analyzed by eBURST (Feil et al 2004). eBURST groups were formed by the isolates 
with similar AMR phenotype. An eBURST group is defined as a collection of STs that are 
placed together according to the selected group definition. The STs within an eBURST group 
obtained with the most stringent (exclusive) group definition were closely related and belong to a 
single clonal complex. A clonal complex refers to a biologically meaningful cluster of STs that 
have diversified very recently from a common founder. Clonal complexes are defined as a 
cluster of STs in an eBURST diagram in which all STs are linked as single locus variances 
(SLVs) to at least one other ST. The primary founder of the clonal complex was predicted as the 
ST that has the largest number of SLVs in the group or clonal complex. Statistical confidence in 
each of the assigned primary founders was made by a bootstrap resampling (1,000) procedure. 
For an ST which was SLV of both primary and subgroup founders, the ST was assigned to the 
primary founder. When an ST was an SLV of two or more subgroup founders, then the ST was 
grouped with the largest subgroup.  
 
For identification of clonal complexes, the most stringent default group definition was 
used, where all STs have to be single locus variants of at least one ST in the clonal complex. The 
initial eBURST diagrams were created at http://eburst.mlst.net and edited as required to produce 
the final figure. Editing was done to improve the clarity of the diagram and not to change any of 
the links between the STs and it. The minimum sum of the weights of the edges (genetic 
distances) was used to create a minimum-spanning tree from MLST profile data. Prim’s 
algorithm was implemented to determine the links between different STs (Prim 1957). The 
highest priority was given to STs with the most numerous single locus variants. The two STs 
with the greatest number of single locus and then double locus variants were linked first, 
preferably using intermediate STs.   
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2.5 Statistical Analyses 
 
Yates’ Chi-square tests were performed on differences of percentage distribution (Ury & 
Fleiss
 
1980; Yates 1934). Significance was set at a p value of < 0.05. The Yates' correction 
prevents overestimation of statistical significance for small data sets. This reduces the chi-square 
value obtained and thus increases its p-value.  Yates' correction is typically used in Chi-square 
analysis with 1 degree of freedom where expected frequencies of less than 5.  
 
MLST data were analyzed with SAS (SAS Institute Inc., Cary, NC) by using the marascuilo 
procedure test to determine if there is a significant difference between the ratios for every pair of 
STs. The trend of change of the prevalence for the gonococcal strains over a four-year period 
was evaluated using the Chi-square multiple hypothesis test.  
 
Simpson’s index of diversity (ID) was used to determine the discriminatory abilities of 
the molecular typing methods (Hunter & Gaston 1988; Dillon et al 1993). The numerical index is 
based on the probability that two unrelated isolates would be placed into different typing groups 
(Hunter & Gaston 1988). The calculation formula is: ID = 1 – [1/N(N-1)] [Σni(ni-1)] where N 
equals the sum of all of the isolates, and ni is the size of the i
th
 group. ID is expressed as a 
percentage. An ID of 90% or greater is desirable for a typing scheme (Hunter & Gaston 1988), 
depending on the objectives of molecular epidemiological studies. 
 
2.6 DNA Sequence Deposit 
 
DNA sequences were submitted to the National Center for Biotechnology Information 
(NCBI) GenBank (http://www.ncbi.nlm.nih.gov/WebSub/?tool=genbank). GenBank accession 
numbers were reported for different housekeeping genes extended from HM359017 to 
HM359073. The DNA sequences of porB and tbpB for NG-MAST analysis were stored in the 
NG-MAST database (http://www.ng-mast.net; Martin et al 2004). 
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CHAPTER THREE 
 
RESULTS 
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3.1 Clinical, Demographic and Geographic Profiles of N. gonorrhoeae Isolates 
 
N. gonorrhoeae isolates investigated in this research were collected in Saskatchewan 
(SK) between 2003 and 2011. Of the 427 N. gonorrhoeae isolates evaluated, 58.5% (n=250) 
were isolated from male patients and 177 (41.5%) were from female patients (Fig 3.1). These 
isolates were 5.1% (356/6965) of the total number of gonorrhea cases reported between 2003 and 
2009. The data on number of cases reported in SK is available until 2009 (PHAC 2011a).  
 
Among males, 78.4% (n=196) of the reported isolations were from the urethra, followed 
by the penis (n=45, 18%) and the throat (n=4, 1.6%). Two gonococcal isolates were recovered 
from the rectum (0.8%) and one each was isolated from the knee (0.4%) and eye (0.4%). The 
isolation site for one gonococcal isolate from a male patient was not known. In females, 70% 
(n=124) of gonococcal isolations were from the cervix followed by 25.4% (n=45) recovered 
from the vagina. One N. gonorrhoeae isolate each was recovered from knee, rectum, throat and 
bartholin gland in females; 2 gonococcal isolations were made from the peritoneum; and, for two 
isolates, the sites of isolation were unknown in females (Fig 3.1). 
 
Of the 427 N. gonorrhoeae isolates, 422 were collected from 22 known locations across SK 
(Table 3.1) and for five isolates locations were unknown. Gonococcal cultures were highest from 
Regina (31%, n=139) followed by Prince Albert (23%, n=99) and Saskatoon (22%, n=96). In 
both sexes, the highest numbers of gonorrhea cases were recorded for the 20-24 years age group 
(Fig 3.2). A total of 124 (29%) gonorrhea cases were recorded in this age group comprising 78 
(31.2%) male and 46 (26%) female patients. Twenty percent and 17% of cases were grouped 
under age categories 25-29 and 15-19 years, respectively. The numbers of male gonorrhea 
patients were higher than female patients in age groups as follows; 20-24 (males: 78/124, 63%; 
females: 46/124, 37%), 30-34 (males: 30/39, 77%; females: 9/39, 23%), 40-44 (males: 14/19, 
74%; females: 5/19, 26%), 45-49 (males: 17/17, 100%; females: 0/17, 0%), 50-54 (males: 8/9, 
89%; females: 1/9, 11%), 55-59 (males: 5/5, 100%; females: 0/5, 0%) and above 60 (males: 
10/11, 91%; females: 1/11, 9%) years of age. The female patients were more in younger age 
groups; <1 (females: 1/1, 100%; males: 0/1, 0%), 10-14 (females: 10/10, 100%; males: 0/10, 
0%), 15-19 (Females: 47/72, 65.3%; males: 25/72, 34.7%) years of age (Fig 3.2).  
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Table 3.1 Geographic distribution of 427 clinical N. gonorrhoeae isolates from Saskatchewan 
 
 
a: 38 isolates were recovered from 24 different locations across the province. 
M: male 
F: female 
 
 
 
 
 
 
 
 
Geographic 
Locations 
2003 
(n=60) 
2004 
(n=59) 
2005 
(n=52) 
2006 
(n=55) 
2007 
(n=53) 
2008 
(n=41) 
2009 
(n=36) 
2010 
(n=34) 
2011 
(n=37) 
Total 
(n=427) 
Grand Total 
(n=427) 
M F M F M F M F M F M F M F M F M F M F M + F 
Ile a la Crosse 0 0 0 4 0 0 0 1 0 1 0 2 0 1 1 0 0 0 1 9 10 
La Ronge 1 3 0 4 1 1 0 3 3 1 1 3 0 1 0 0 0 0 6 16 22 
Nipawin 0 3 0 1 0 0 0 0 0 0 0 1 0 4 0 1 0 0 0 10 10 
Prince Albert 12 6 9 2 1 3 11 7 12 1 9 2 7 4 5 2 4 2 70 29 99 
Regina 15 6 15 12 10 7 6 4 3 3 4 5 7 3 18 3 8 10 86 53 139 
Saskatoon 7 4 4 4 12 9 12 5 11 5 5 3 5 1 0 0 9 2 65 33 98 
Yorkton 0 0 0 2 1 0 0 0 3 1 0 2 1 0 0 1 0 0 5 6 11 
Other locations
a 
1 2 0 2 5 2 3 3 2 7 2 2 1 1 1 2 2 0 17 21 38 
Total 36 24 28 31 30 22 32 23 34 19 21 20 21 15 25 9 23 14 250 177 427 
7
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The number gonococcal cultures isolated from gonorrhea patients in the province is 
decreasing (Fig 3.3). In 2003, 11% (n=60) of 544 reported gonorrhea cases were cultured and 
this decreased to 3.2% (n=41) of reported cases (n=1334) in 2008. In 2009, 36 (4.1%) 
gonococcal isolates were cultured and reported cases of gonorrhea in SK for the year 2009 were 
875. 
 
3.2 Temporal and Geographic Trends of Antimicrobial Resistance in Neisseria 
gonorrhoeae in Saskatchewan (2003-2011) 
 
 (Please see tables A.1 to A.7 from page 241 to 247 of appendix-I. These tables show raw 
data on penicillin, tetracycline, ciprofloxacin, azithromycin, spectinomycin, cefixime and 
ceftriaxone susceptibility of N. gonorrhoeae isolates from SK between 2003 and 2011). 
 
The antimicrobial susceptibility of 427 clinical N. gonorrhoeae isolates consecutively 
collected from SK (2003-2011) was examined against penicillin, tetracycline, ciprofloxacin, 
azithromycin, spectinomycin, cefixime and ceftriaxone (Table 3.2). Penicillin MICs ranged 
between 0.001 and 32 mg/L, with 4.0% (n=17) of the tested isolates being resistant (MIC 2 
mg/L) to penicillin. Penicillin had MICs50 (n=271) and MICs90 (n=410) values of 0.25 mg/L and 
1.0 mg/L. 
 
Tetracycline MICs ranged from 0.008 to 256 mg/L and the total burden of tetracycline
 
resistance during 2003-2011 was 50% (n=214/427) (Table 3.2). MICs50 (n=211) and MICs90 
(n=413) values for tetracycline were 1.0 mg/L and 8.0 mg/L.  
 
Ciprofloxacin MICs ranged from 0.001 mg/L to 32 mg/L and 19 (4.4%) N. gonorrhoeae 
isolates were resistant to ciprofloxacin (Table 3.2). Isolates had ciprofloxacin MICs50 (n=256) 
and MICs90 (n=405) values of 0.004 mg/L and 0.016 mg/L. 
 
 Azithromycin
 
resistance was found in 0.54% (n=2) of 320 isolates tested (2003-2008). 
MIC values for azithromycin ranged between 0.016 to 8.0 mg/L (Table 3.2). The MIC50 (n=225) 
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Table 3.2 Antibiotic susceptibility of 427 N. gonorrhoeae isolates from Saskatchewan (2003-2011)
a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a: Interpretative criteria for MIC classification were those described by the CLSI (CLSI 2009). Azithromycin MIC classification criteria 
are not described by CLSI, therefore standards followed by Gonococcal Isolate Surveillance Project (GISP), USA were used (CDC 
2010b). 
b: Break points are penicillin≥2 mg/L; tetracycline≥2 mg/L; ciprofloxacin≥1 mg/L; azithromycin≥2 mg/L; spectinomycin ≥ 128 
mg/L. Break points are not available
 
for cefixime and ceftriaxone and MICs below 0.25 mg/L are considered susceptible. 
c: N. gonorrhoeae  isolates from 2003 to 2008 (n=320) were tested for azithromycin susceptibility.  
d: Break points are not defined. 
 
 
 
 
Antibiotic 
% Susceptible 
(n) 
%Intermediate 
(n) 
% Resistant
b
 
(n) 
MIC range 
(mg/L) 
MIC50 
(mg/L) 
MIC90 
(mg/L) 
Penicillin  25.0 (105) 71.0 (305) 4.0 (17) 0.001-32.0 0.25 1.0 
Tetracycline  29.9 (128)  20.0 (85) 50.1 (214) 0.008-256.0 1.0 8.0 
Ciprofloxacin 95.0 (406) 0.5 (2) 4.5 (19) 0.001-32.0 0.004 0.016 
Azithromycin
c  99.5 (318) 0 (0) 0.5 (2) 0.016-8.0 0.25 0.5 
Spectinomycin  96.7 (413) 3.3 (14) 0 (0) 4.0-64.0 16.0 32.0 
Cefixime
 100 (427) ND
d
 ND
 
0.0005-0.125 0.008 0.016 
Ceftriaxone
 100 (427) ND ND 0.00025-0.025 0.008 0.03 
7
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and MIC90 (n=304) values of N. gonorrhoeae isolates to azithromycin were 0.25 mg/L and 0.5 
mg/L. 
 
All isolates were susceptible to spectinomycin (MIC<128 mg/L; MIC range 4.0–64.0 
mg/L) (Table 3.2). 3.3% (n=14) of the tested gonococcal isolates had intermediate (MIC=64 
mg/L) levels of resistance. MIC50 (n=344) and MIC90 (n=413) values for spectinomycin were 
16.0 mg/L and 32.0 mg/L.  
 
All isolates were susceptible to cefixime (MIC range 0.0005-0.125 mg/L) (Table 3.2). 
One isolate with a cefixime MIC of 0.125 mg/L was isolated in 2006. The MIC50 (n=281) and 
MIC90 (n=399) values for cefixime were 0.008 mg/L and 0.016 mg/L. Ceftriaxone MICs ranged 
between 0.00025 and 0.25 mg/L (Table 3.2). Ceftriaxone had MIC50 and MIC90 values of 0.008 
mg/L (n=286) and 0.03 mg/L (n=410). 
 
No penicillin resistant isolate was detected in 2006, 2007 and 2010 (Fig 3.4). Penicillin 
resistance ranged from 2.7% in 2009 (1/36) and 2011 (1/37) to 6.8% in 2003 (4/60) and 2004 
(4/59). Penicillin resistance in the province remained below 5% from 2006 to 2011. One PPNG 
isolate was detected in each of 2003, 2005, 2009 and 2011. 
 
The prevalence of CMTR (n=200/427) was 47%. TRNG (Tet MIC ≥16 mg/L; n=14/427) 
constituted 3.3% of the total tetracycline resistance (Fig 3.5). CMTR contribution to tetracycline 
resistance was 76.3% (42/55) in 2006 followed by 85% (45/53) in 2007. In 2008, 73% (30/41) of 
the isolates recovered that year were resistant to tetracycline. This declined to 0% in 2009 and 
2010.  
 
Ciprofloxacin
 
resistant isolates were not observed between 2003 and 2005 and in 2009 
(Fig 3.6). Ciprofloxacin resistance in the province remained below 5% till 2009.  In 2010 and 
2011, 26.5% (9/35) and 13.5% (5/37) isolates were resistant to ciprofloxacin.  
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Azithromycin resistant isolates were recovered in 2004 (1.7%, 1/59) and 2007 (1.9%, 
1/53) (Fig 3.7).  
 
No cefixime MIC creep was observed and no clear trend was detected for cefixime 
susceptibility (Fig. 3.8). More than 52% (n=220) of the N. gonorrhoeae isolates had cefixime 
MICs lower than 0.008 mg/L with a further 118 (28%) isolates having MICs of 0.016 mg/L. 
 
 One isolate each with ceftriaxone MIC between 0.25 mg/L and 0.125 mg/L was 
recovered in 2010 and 2011 (Fig. 3.9). Around 24% (104/427) of the isolates each had 
ceftriaxone MICs between 0.004 mg/L and 0.008 mg/L and other 19% (83/427) were with 
ceftriaxone MIC 0.016 mg/L. 
 
Overall 10 resistance phenotypes were found in 427 isolates from SK. The resistance 
phenotypes included: susceptible (n=194, 45%), CMTR (n=183, 43%), ciprofloxacin resistance 
(Cip
R
, n=16, 3.75), CMRNG (n=13, 3%), TRNG (n=13, 3%), PPNG (n=3, 0.7%), CMTR; Cip
R
 
(n=2, 0.4%), PPNG (n=1, 0.2%), TRNG; Cip
R
 (n=1, 0.2%), azithromycin resistance (Azi
R
, n=1, 
0.2%). 
 
The majority of N. gonorrhoeae isolates resistant to different antibiotics detected in this 
study were from 3 cities of SK; Saskatoon, Regina and Prince Albert (Fig 3.10).  Seventy-nine 
percent (195/247) of the total resistant isolates were from Saskatoon, Regina and Prince Albert.  
A higher percentage of total penicillin (71%, 12/17; P=0.0016), ciprofloxacin (53%, 10/19; 
P=0.096) and tetracycline (29%, 62/214; P=0.14) resistant N. gonorrhoeae isolates were from 
Regina compared to the other locations. One of the two azithromycin
 
resistant isolates was also 
recovered from Regina. Isolates from Saskatoon contributed 24% (4/17; P=0.095), 32% (6/19; 
P=0.52) and 26% (55/214; P=0.2) to penicillin, ciprofloxacin and tetracycline resistance, 
respectively in SK. No penicillin resistant gonococcal isolate was detected in Prince Albert. 
Eleven percent (2/19; P=0.29) and 20% (42/214; P=0.1027) of total ciprofloxacin and 
tetracycline resistant N. gonorrhoeae isolates in SK detected during 2005-2008 were from Prince 
Albert. One PPNG and ciprofloxacin resistant isolate was recovered from Yorkton and 
Lloydminster. 
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Fig. 3.8 Cefixime minimum inhibitory concentration wise distribution N. gonorrhoeae isolates from 
Saskatchewan: 2003-2011. 220 (52%) N. gonorrhoeae isolates each were grouped under cefixime MIC 0.008 mg/L 
followed by 118 (28%) under MIC 0.016. All the isolates from 2009, 2010 and 2011 had cefixime MIC 0.008 mg/L . 
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3.3    DNA Sequence Analysis of Genes implicated in Antomicrobial Resistance in Neisseria   
gonorrhoeae 
3.3.1 DNA Sequence Analysis of penA, porB, ponA and mtrR implicated in Reduced 
Susceptibility to Cephalosporins  
 
DNA sequences of penA (PBP2), porB (PorB) ponA (PBP1) and mtrR (MtrR and its 
promoter) were analyzed in 146 N. gonorrhoeae isolates to determine emerging molecular 
mechanisms of extended spectrum cephalosporin susceptibility. Isolates were divided into two 
groups: isolates with MICs 0.0005-0.016 mg/L (cefixime group 1; n=122 & ceftriaxone group 1; 
n=123) and isolates with MICs 0.03-0.06 mg/L (cefixime group 2; n=24 & ceftriaxone group 2; 
n=23). 
 
i) penA (PBP2) Analysis  
 (Please see table A.8 in appendix-I showing raw data on PBP2 mutations in N. 
gonorrhoeae isolates analyzed for resistance determinants of extended spectrum cephalosporins). 
 
  Analysis of the transpeptidase domain (amino acids 340 to 575) (Dougherty et al 1980) of 
PBP2 (581 amino acids) revealed nine patterns in 146 N. gonorrhoeae isolates.  Seven of which 
were non-mosaic (spontaneous mutations) penA patterns (I, II, V, IX, XII, XIV, XXII). One 
PBP2 pattern, XXXIV, was mosaic with more than 30 amino acid substitutions (Table 3.3). This 
mosaic pattern has been reported to arise due to homologous recombination between N. 
gonorrhoeae penA and penA of commensal Neisseria (Pandori et al 2009). The majority of 
isolates investigated (86%, 126/146) were associated with patterns IX (n=50, 34%), I (n=41, 
28%), and XXII (n=35, 24%).  
 
  All non-mosaic PBP2 patterns detected in this study had an Asp-346 insertion (Fig 3.11). 
Amino acid substitutions (F504, A510 & A516) between AA340 and AA540 of PBP2 were 
identical in penA pattern II, V, IX, XII, XIV and XXII. Pattern IX was significantly associated 
with ceftriaxone group 2 isolates (MIC range 0.03-0.06 mg/L; 14/23, 61%; P=0.007) (Fig 3.12). 
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Table 3.3 Mutation patterns of gonococcal PBP2 in isolates from Saskatchewan 
 
 
PBP2 patterns
a
 n
b
(%) Amino acid substitutions at the transpeptidase domain 
I 41 (28.0) D345a 
II 
c 7 (5.0) D345a, F504L, A510V, A516G 
IX 50 (34) D345a, F504L, A510V, A516G, P551L 
XII 6 (4.0) D345a, F504L, A510V, A516G, P551S 
XIV 2 (1.5) D345a, F504L, A510V, A516G, H541N 
V 2 (1.5) D345a, F504L, A510V, A516G, G542S, I566V, N574a, A575V 
XXII 35 (24) D345a, F504L, A510V, A516G, H541N, P552V, K555Q, 
I556V, I566V, N574a, A575V 
XXXIV
d 
1 (0.7) P341S, S342A, P343T, R345Q, S352T, R373M, G375T,A376P, 
E377K, E385D,I388V, N406S, R411Q, P412K, A437V, 
V443E, L447V, Q457K, I461V, F462I, E464A, R468K, E469K, 
N472E, P480A, F504L, A510V, N512Y, H541N, G545S 
 
a: Mutation patterns were determined based on amino acid substitutions in the regions of AA340 to 
AA575 of N. gonorrhoeae PBP2. Two isolates were with WT PBP2. 
b: Two isolates were with WT transpeptidase domain. 
c: Pattern I, II, V, IX, XII, XIV, XXII had identical amino acid substitution in the region of 
AA340-AA540 of PBP2 which were compared to WT (M32091; Spratt 1998) transpeptidase 
domain.  
d: Pattern XXXIV mosaic PBP2. 
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Fig. 3.11 PBP2 mutation patterns in 146 N. gonorrhoeae isolates from Saskatchewan: 2003-2008. N. gonorrhoeae 
PBP2 has 581 amino acids. Mutations were determined based on amino acid substitutions in the transpeptidase domain of N. 
gonorrhoeae PBP2 between AA340 and AA575 (Dougherty et al 1980; Ito et al 2005; Whiley et al 2007a; Ohinishi et al 2011b). 
Pattern  II, V, IX, XII, XIV, XXII were identical from AA340-AA540 of PBP2. Pattern XXXIV is a mosaic PBP2 pattern.  
WT: Wild type PBP2. 
*: 345a- insertion after AA345. 
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Pattern I was significantly associated to ceftriaxone group 1 isolates (MIC range 0.0005-
0.016 mg/L; 39/123, 32%; P=0.045). Pattern XXII was mostly found in ceftriaxone group 1 
isolates (32/123, 26%). Patterns less common in this study i.e. II, XII, XIV, V and XXXIV (in 
total, n=20) were mostly found in ceftriaxone group 1 isolates (16/20). N. gonorrhoeae isolate 
with mosaic PBP2 pattern XXXIV (ceftriaxone MIC=0.06 mg/L; cefixime MIC=0.125 mg/L), 
was identified in ceftriaxone group 1 (Fig 3.12). 
 
Similar distribution patterns for PBP2 were observed with cefixime susceptibility. Pattern 
IX was significantly associated with cefixime susceptibility group 2 (MIC range 0.03-0.125 
mg/L; 16/23, 67%; P=0.006) and pattern I was associated with cefixime susceptibility group 1 
(MIC range 0.00025-0.016 mg/L; 39/122, 32%; P=0.045) isolates. There was no significant 
association in between cefixime MIC and any other PBP2 pattern and most isolates were from 
cefixime susceptibility group 1. 
 
ii) porB (PorB) Analysis 
(Please see table A.9 in appendix-I showing raw data on PorB mutations in N. 
gonorrhoeae isolates analyzed for resistance determinants of extended spectrum cephalosporins). 
 
Twelve mutation patterns were observed in porin protein, PorB (Fig 3.13).  Analysis of 
PorB showed that most (53%, 78/146) isolates carried double mutations at amino acid residues 
G120 and A121. Combined mutations at residues G120 and A121 with charged amino acids [Lys 
(K) at residue G120 and Asp (D) at residue A121] were significantly associated with N. 
gonorrhoeae ceftriaxone susceptibility group 2 (9/23, 39%; P=0.003) and cefixime susceptibility 
group 2 (9/24, 38%; P=0.001). Wild type (WT) PorB was identified in 63 isolates mostly from 
ceftriaxone (60/123, 49%; P=0.003) and cefixime (59/123, 48%; P=0.008) susceptibility groups 
1. The distribution of the PorB mutations was the same in ceftriaxone and cefixime susceptibility 
groups 1 and 2. 
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iii) ponA (PBP1) Analysis  
More than 60 % of the 146 N. gonorrhoeae isolates investigated (89/146, 61%) carried a 
L421P amino acid substitution in PBP1. This substitution was significantly associated with 
ceftriaxone and cefixime group 2 isolates
 
(20/23, 87%; P=0.01, data not shown).  
 
iv) mtrR (MtrR and its promoter) Analysis 
(Please see table A.10 in appendix-I showing raw data on mtrR mutations in N. 
gonorrhoeae isolates analyzed for resistance determinants of extended spectrum cephalosporins). 
 
The analysis of mtrR and its promoter revealed 12 different mutation patterns 
derived from mutations in different regions of MtrR (Fig 3.14). The frequencies of different 
mutation patterns in mtrR and its promoter were the same in ceftriaxone and cefixime 
susceptibility groups. Overall, among the 146 isolates tested, a G45D substitution in the 
MtrR DNA binding domain predominated (38%, 55/146), both in ceftriaxone susceptibility 
group 2 (13/23, 57%, P=0.072) and cefixime susceptibility group 2 (12/24, 50%, P=0.25). 
 
The substitution G45D coupled with an adenine deletion (A-) in the 13bp inverted 
repeat region of the promoter (A-/G45D) was present in 17% (25/146) of the analyzed 
isolates. The double mutation, A- coupled with H105Y substitution in the multimeric region 
of MtrR was also significantly associated with both ceftriaxone susceptibility group 2 (5/23, 
22%; P=0.008) and cefixime susceptibility group 2 (5/24, 21%, P=0.016) isolates. Wild type 
mtrR sequences were associated with ceftriaxone (37/123, 30%, P=0.005) and cefixime 
(36/123, 30%, P=0.018) group 1 isolates. 
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3.3.2 Analysis of Genes implicated in Azithromycin Resistance  
 
Fifty-two isolates were investigated for azithromycin resistance which included all 
resistant (MIC≥2.0 mg/L) isolates (n=2), 11 intermediately susceptible (MIC=1.0 mg/L) and 39 
susceptible (MIC= 0.03-0.5 mg/L) isolates (Fig 3.15). Both azithromycin resistant N. 
gonorrhoeae isolates had the C2611T mutation in all the four alleles of 23S rRNA and MtrR 
mutation G45D (P=0.001). Among intermediately susceptible (n=10/11, 91%) and susceptible 
(9/39, 23%) isolates only the MtrR mutation was detected. In N. gonorrhoeae isolates with 
intermediate susceptibility to azithomycin, mtrR mutations were A39T (n=1/11, 9%), A-/H105Y 
(n=1/11, 9%), G45D (n=3/11, 27%) and A-/G45D (5/11, 45%; P=0.0008). None of these 52 
isolates were with rRNA methylase genes (erm). 
 
3.3.3 Analysis of Quinolone Resistance determining Region 
 
In total, 41 isolates were investigated for ciprofloxacin
 
resistance mechanisms that 
included all 5 resistant (ciprofloxacin MIC≥1.0 mg/L) isolates recovered, 2 with 
intermediate susceptibility (MIC=0.5 mg/L) and 18 susceptible (MIC= 0.002-0.008 mg/L) 
isolates (Table 3.4).  
 
Ciprofloxacin
 
resistant isolates carried GyrA-S91F/D95G; ParC-S87R (n=4/5, 80%; 
P=0.0005) and GyrA-S91F/D95N; ParC-S87R (n=1) mutations. The intermediately 
ciprofloxacin susceptible isolates (n=2) carried mutations; GyrA-S91F/D95G; ParC-S87R and 
GyrA-S91F/D95N; ParC-S87R/S88P. Ciprofloxacin resistance was also significantly associated 
with mtrR mutation A-/H105Y (4/5, 80%; P=0.01) and ciprofloxacin intermediate susceptibility 
(2/2, 100%) was significantly linked with truncated mtrR (P=0.01). 
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Fig. 3.15 Mutations in MtrR and its promoter in 52 N. gonorrhoeae isolates with different azithromycin susceptibility. Amino 
acid substitutions in MtrR and its promoter were determined in azithromycin susceptible (AziS), azithromycin intermediately 
susceptible (AziI) and azithromycin resistant (AziR) isolates. 
*: P value < 0.05 was considered statistically significant. 
    * 
  * 
3
4
 
9
8
 
99 
 
 
Table 3.4 GyrA and ParC QRDR mutation patterns in 41 N. gonorrhoeae  
 
Mutation Pattern 
n (%) MIC (mg/L) GyrA ParC 
S91 D95 S87 S88 
F G R - 5 (12.2) 0.5
a
-8.0
* 
F N - P 1 (2.4) 4.0 
F N R P 1 (2.4) 0.5
a 
- - - - 34 (83) 0.002-0.008 
-: No mutation on these residues. 
a: Intermediate susceptibility 
*: P value<0.05 (MIC=2-8 mg/L). 
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3.3.4 Analysis of Genes implicated in Penicillin Resistance 
 
 High levels (96%) of penicillin susceptibility of gonococci were observed in this study. 
This is contrary to recent reports on penicillin susceptibility of N. gonorrhoeae from Canada and 
worldwide (CDC 2009; Cole et al 2010; Martin et al 2011; Allen et al 2011; WHO-WPR 2012; 
Starnino et al 2012). In view of low levels of penicillin resistance, molecular determinants of 
penicillin resistance were also investigated in this study. 
 
i) penA (PBP2) Analysis 
  PBP2 pattern IX was significantly associated with isolates which were both penicillin 
intermediately susceptible (Pen
I
, MIC=1) (34/67, 51%; P<0.0001)
 
and penicillin
 
resistant (Pen
R
,  
MIC ≥ 2mg/L) isolates (10/15, 67%; P<0.0001) (Table 3.5). Pattern I was significantly 
associated with penicillin susceptible (Pen
S
) isolates
 
(38/64, 59%; P<0.0001) while pattern XXII 
were predominant in Pen
S 
(15/64, 23%) and Pen
I
 (18/67, 27%) isolates (Fig 3.16). The N. 
gonorrhoeae isolate with pattern XXXIV (Pen MIC=0.5 mg/L) was present in a Pen
S
 category. 
 
ii) porB (PorB) Analysis  
 In PorB, a combination of aspartic acid (D) and asparagine (N) substitutions at G120 and 
A121 was significantly (21/67, 31%; P=0.0016) associated with Pen
I
 isolates (Table 3.6). Pen
R
 
was significantly associated (P<0.0001with charged amino acid substitutions at residue 120 and 
121; G120K and A121D (9/15, 60%). Sixty three isolates with WT PorB were mostly present in 
Pen
S 
(48/64, 75%; P<0.0001) and Pen
I 
(15/67; 22%) categories (Fig 3.17). 
 
iii) ponA (PBP1) Analysis 
 The L421P amino acid substitution in N. gonorrhoeae PBP1 was significantly associated 
with Pen
I 
(n=59/67, 88%; P< 0.001) and Pen
R
 (n=14/15, 93%; P<0.001, data not shown). 
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Table 3.5 Mutation patterns of PBP2 in 146 N. gonorrhoeae isolates with 
different penicillin susceptibility phenotypes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a: Mutation patterns were numbered as they have been previously referenced in  
the literature (Whiley et al, 2007a; Ohnishi et al 2011b).  
b: Penicillin category: Pen
S
: Pen susceptible (MIC=0.008-0.5mg/L); Pen
I
: Pen 
intermediate (MIC=1.0 mg/L); Pen
R: Pen resistant (MIC≥2; PPNG included). 
c: Includes PPNG.  
d: WT: wild type using wild type PBP2 sequence M32091 (Spratt 1988).  
*: P value<0.05 is considered statistically significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PBP2 pattern
a
 n 
Penicillin Category
b
 
Pen
S
 
n (%) 
Pen
I
 
n (%) 
Pen
R
 
n (%) 
IX 50 (34) 6 (12) 34 (51)
*
 10 (67)
*
 
I 41 (28) 38 (59)
*
 3 (4)
 
0 (0)
 
XXII 35 (24) 15 (23) 18 (27) 2 (13) 
II 7 (5) 0 (0) 6(9) 1 (7)
c
 
XII 6 (3.5) 2 (3) 2 (3) 2 (13)
c
 
XIV 2 (1.4) 0 (0) 2 (3) 0 (0) 
V 2 (1.4) 0 (0) 2(2) 0 (0) 
WT
d 
2 (1.4) 2 (3) 0 (0) 0 (0) 
XXXIV 1(0.7) 1(2) 0 (0) 0 (0) 
Total 146 64 (44) 67 (46) 15 (10) 
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Fig. 3.16 PBP2 mutation patterns in 146 N. gonorrhoeae isolates with different penicillin susceptibility. Amino acid 
substitutions between AA340 to AA575 were determined. PenS: penicillin susceptible (MIC=0.008-0.5mg/L); PenI: penicillin 
intermediate (MIC=1.0 mg/L); PenR: penicillin resistant (MIC≥2; PPNG were also included).  
*: P value < 0.05 was considered statistically significant. 
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Table 3.6 Mutation patterns in PorB in 146 N. gonorrhoeae isolates with different 
penicillin susceptibility phenotypes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a: Penicillin category: Pen
S
, Pen
I
 & Pen
R
: See Table 3.7. 
b: WT: wild type using porB sequence M21289 (Carbonetti et al 1987). 
c: Includes PPNG.  
*: P value<0.05 is considered statistically significant.  
 
 
 
 
 
 
 
Pattern 
number 
PorB mutation n 
Penicillin Category
a
 
Pen
S 
 
n (%) 
Pen
I 
 
n (%) 
Pen
R 
 
n (%) 
1 WT
b 
63 (43) 48 (75)
*
 15 (22) 0 (0) 
2 G120D;A121N 28 (19) 5 (8) 21 (31)
*
 0 (0) 
3 G120K;A121D 21 (14) 5 (8) 7 (10) 9 (60)
*
 
4 G120N;A121N 11 (7.5) 3 (5) 8 (12) 0 (0) 
5 G120K;A121N 6 (4) 1 (2) 5 (7) 0 (0) 
6 G120D;A121D 5 (3.5) 0 (0) 3 (4) 2 (13) 
7 A121S;N122K 5 (3.5 0 (0) 4 (6) 1 (7)
c 
8 A121G 2 (1.4) 2 (3) 0 (0) 0 (0) 
9 G120D 2 (1.4) 0 (0) 0 (0) 0 (0) 
10 G120K 1 (0.7) 0 (0) 1(1.5) 0 (0) 
11 G120K;A121G 1 (0.7) 0 (0) 0 (0) 1(7)
 
12 G120R;A121D 1 (0.7) 0 (0) 1 (1.5) 0 (0) 
 Total 146 64 (44) 67 (46) 15 (10) 
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Fig. 3.17 PorB mutation patterns in 146 N. gonorrhoeae isolates with different penicillin susceptibility. Amino acid 
substitutions at G120 and A121 were determined in PenS, PenI and PenR isolates. 
*: P value < 0.05 was considered statistically significant. 
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iv) mtrR (MtrR and its promoter) Analysis 
A G45D substitution in the DNA binding domain of the MtrR was significantly 
associated with Pen
I
 (55%, 37/67; P<0.0001) and Pen
R
 (9/15, 60%; P=0.0005) isolates (Table 
3.7). A-;G45D substitutions, in the mtrR promoter and DNA binding domain was also 
significantly associated with Pen
I
 (25%, 17/67; P=0.03) category. Wild type mtrR were 
associated with Pen
S
 (55%, 35/64; P<0.0001) isolates (Fig 3.18).  
 
3.3.5 penA, mtrR and porB mutation Combinations Detected in  N. gonorrhoeae Isolates 
Analyzed for Cephalosporin and Penicillin Susceptibility 
 
A total of 50 mutation patterns; PBP2 (penA)/MtrR (mtrR)/PorB (porB) were observed in 
146 isolates tested based on a combination of individual mutations in PBP2/MtrR/PorB (Table 
3.8). Isolates from ceftriaxone group 2 (n=23) had 18 mutation patterns whereas 39 mutation 
patterns were found in 123 isolates from ceftriaxone susceptibility group 1. None of the patterns 
had significant association with ceftriaxone susceptibility group 2 or isolates with higher 
ceftriaxone MICs (MIC≥0.03 mg/L). Pattern I/WT//WT was significantly associated with 
ceftriaxone (33/123, 26.8%; P=0.01) and cefixime (33/122, 27%; P=0.01) susceptibility groups 
1. Pattern IX/G45D/G120K;A121D (8/24, 33.3%) was significantly associated (P<0.0001) with 
cefixime susceptibility group 2 (Table 3.8).  
 
 Isolates from Pen
S
 (n=64) and Pen
I
 (n=67) categories had 25 and 30 PBP2/MtrR/PorB 
mutation patterns (Table 3.9). Penicillin resistant (n=15) isolates were classified into 6 
PBP2/MtrR/PorB mutation patterns. Pen
S
 isolates were significantly related to pattern I/WT/WT 
(30/64, 47%; P=0.0001). Pen
I 
was significantly related to patterns IX/G45D/G120D;A121N 
(12/67, 18%; P=0.0012)   IX/G45D/WT (9/67, 13.4; P=0.025). Patterns IX/G45D/G120K; 
A121D (7/15, 47%; P=0.007) and IX/G45D/G120D;A121D (2/15, 13.3%; P=0.04) had 
significant association with Pen
R
 isolates (Table 3.9).  
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Table 3.7 Mutation patterns of mtrR N. gonorrhoeae isolates associated with different 
penicillin susceptibility phenotypes 
 
a: Penicillin category: Pen
S
, Pen
I
 & Pen
R
: See Table 3.7. 
b: wild type using mtrR sequence Z25796 (Pan & Spratt 1994). 
c: Includes PPNG.  
d: MtrR coding sequence truncated at amino acid position 136. 
*: P value<0.05 is considered statistically significant.  
 
 
 
  
 
Pattern 
number 
MtrR mutation n 
Penicillin Category
a
 
Pen
S
  
n (%) 
Pen
I 
   
n (%) 
Pen
R 
   
n (%) 
1 WT
b
 37 (25) 35 (55)
*
 2 (3) 0 
2 G45D 55 (38) 9 (14) 37 (55)
* 
 9 (60)
*
 
3 A-;G45D 25 (17) 6 (9) 17 (25)
* 
 2 (13.0) 
4 A-;H105Y 10 (7) 2 (3) 5 (7.5) 3(20)
c 
5 Truncated MtrR
d
 4 (3) 4 (6) 0 0 
6 A39T 4 (3) 3 (4.5) 0 1(6.7)
c 
7 T86A;H105Y 3 (2) 1(1.5) 2 (3) 0 
8 A40D;D79N;T86A;H105Y 3 (2) 0 3 (4.5) 0 
9 D79N;T86A;H105Y 2 (1.4) 1(1.5) 1(1.5) 0 
10 A39T;H105Y 1 (0.7) 1(1.5) 0 0 
11 A- 1(0.7) 1(1.5) 0 0 
12 TT+ 1(0.7) 1(1.5) 0 0 
 Total 146 64 (44) 67 (46) 15 (10) 
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Table 3.8 Mutation pattern combination of PBP2/ MtrR /PorB associated with ceftriaxone susceptibility in 146 N . 
gonorrhoeae isolates 
 
a: Ceftriaxone susceptibility groups: 1: MIC range =0.0005-0.016 mg/L); 2: MIC range =0.03-0.06 mg/L. 
b: Cefixime susceptibility groups: 1: MIC range =0.0005-0.016 mg/L); 2: MIC range =0.03-0.125 mg/L. 
c: 35 isolates were with single unique combination of PBP2/MtrR/PorB. 
*
: P value<0.05 is considered statistically significant. 
Pattern 
numbers 
PBP2/MtrR/PorB mutation pattern n (%) 
Ceftriaxone susceptibility 
groups
a 
Cefixime susceptibility 
 groups
b
 
1 
n (%) 
2 
n (%)  
1 
n (%) 
2 
n (%) 
A I/WT/WT 33 (22.6) 33
*
 (26.8) 0 (0) 33
*
 (27) 0 (0) 
B IX/G45D/G120K;A121D 14 (10) 9 (7.3) 5 (22) 6 (5) 8
*
 (33.3) 
C IX/ G45D/G120D;A121N 11 (8) 9 (7.3) 2 (8.7) 8
 
(6.5) 3 (12.5) 
D IX/G45D/ G120D;A121D 4 (2.7) 3 (2.4) 1 (4.4) 4 (3.3) 0 (0) 
E IX/G45D/WT 10 (7) 9 (7.3) 1 (4.4) 9 (7.4) 1 (4.2) 
F IX/ A-;H105Y/G120K;A121D 2 (1.4) 1 (0.8) 1 (4.4) 1 (0.8) 1 (4.2) 
G XXII/A-,G45D/G120N;A121N 8 (5.5) 7 (6) 1 (4.4) 8 (6.5) 0 (0) 
H XXII/G45D/G120D;A121N 4 (2.7) 3 (2.4) 1 (4.4) 4 (3.3) 0 (0) 
I I/G45D/ WT 3 (2) 3 (2.4) 0 (0) 1 (0.8) 2 (8.3) 
J I/ truncated MtrR/WT 3 (2) 3 (2.4) 0 (0) 2 (1.6) 1 (4.2) 
K II/G45D/A121S;N122K 2 (1.4) 2 (1.6) 0 (0) 2 (1.6) 0 (0) 
L II/A40D,D79N,T86A,H105Y/G120D 2 (1.4) 2 (1.6) 0 (0) 2 (1.6) 0 (0) 
M XXII/WT/WT 2 (1.4) 2 (1.6) 0 (0) 2 (1.6) 0 (0) 
N XXII/A-,G45D/G120D;A121N 9 (6) 9 (7.3) 0 (0) 9 (7.4) 0 (0) 
O XXII/A-,G45D/G120K;A121N 4 (3) 4 (3.3) 0 (0) 4 (3.3) 0 (0) 
P
 
Other patterns
c
 35 (24) 24 (19.5) 11 (48) 27 (22) 8 (33.3) 
 Total 146 123 (84) 23 (16) 122 (83.5) 24 (16.5) 
1
0
8
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Table 3.9 Mutation pattern combination of PBP2/ MtrR /PorB associated with penicillin 
susceptibility in 146 N . gonorrhoeae isolates  
 
Pattern 
numbers 
PBP2/MtrR/PorB mutation pattern n (%) 
Isolates with different mutation 
patterns in penicillin categories 
Pen
S
 
n (%) 
Pen
I
 
n (%) 
Pen
R
 
n (%) 
A I/WT/ /WT 32 (22) 30 (47)* 2 (3) 0 
B IX/G45D/G120K;A121D 14 (10) 2 (3) 5 (7.4) 7 (47)
*
 
C IX/G45D/G120D;A121N 12 (8) 0 (0) 12 (18)
*
 0(0) 
D IX/G45D/G120D;A121D 4 (2.7) 0 (0) 2 (3) 2 (13.3)
*
 
E IX/G45D/WT 10 (7) 1 (1.5) 9 (13.4)
*
 0 (0) 
F IX/ A-, H105Y/G120K;A121D 2 (1.4) 1 (1.5) 0 (0) 1 (7) 
G XXII/ A-, G45D/G120N;A121N 8 (5.5) 3 (4.7) 5 (7.4) 0 (0) 
H XXII/ G45D/G120D;A121N 4 (2.7) 2 (3) 2 (3) 0 (0) 
I I/G45D/WT 3 (2) 2 (3) 1 (1.5) 0 (0) 
J I/ truncated MtrR/WT 3 (2) 3 (4.7) 0 (0) 0(0) 
K II/G45D/A121S;N122K 2 (1.4) 0 (0) 1 (1.5) 1 (7) 
L II/A40D;D79N;T86A;H105Y/G120D 2 (1.4) 0 (0) 2 (3) 0 (0) 
M XXII/WT/WT 2 (1.4) 2 (3) 0 (0) 0 (0) 
N XXII/G120D, A120N/A-;G45D 9 (6) 3 (4.7) 6 (9) 0 (0) 
O XXII/G120K, A120N/A-;G45D 4 (3) 0 (0) 2 (3) 2 (14) 
P Other patterns 35 (24) 15 (23) 18 (27) 2 (14) 
 Total 146 64 (44) 67 (46) 15 (10) 
 
a: Penicillin categories: See Table 3.5. 
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3.3.6 β-lactamase and tetM Plasmid Types 
 
Only 4 PPNG were detected during study period (2003-2011) (Fig 3.4). 2 of the 4 PPNG 
were with African type plasmids, other 2 from 2009 and 2011 could not be typed because of non 
availability of the isolates from 2009-2011.  
 
All (n=14) the TRNG observed in this study were Dutch type. TRNG prevalence was 5% 
(n=3) in 2004, 5.8% (n=3) in 2005, 12.7% (n=7) in 2006 and 2.2% (n=1) in 2007 (Fig 3.5).  
 
3.4  Phylogeny of Neisseria gonorrhoeae Strains from Saskatchewan Based on porB typing,  
NG-MAST and MLST 
3.4.1 porB DNA Sequence Analysis and Phylogeny 
 
Analysis of porB sequences differentiated 320 N. gonorrhoeae isolates (2003-2008) from 
SK into 70 strain types (Table 3.10) with an average of 4.5 isolates per porB ST. The index of 
discrimination (ID) of porB typing for 320 isolates was 0.94. Of 70 STs, 35 porB STs were 
associated with two or more N. gonorrhoeae isolates whereas 35 porB STs comprised individual 
isolates. porB STs were assigned numbers consistent with the typing criteria used in the Dillon 
laboratory (Liao et al 2008, 2009). porB STs identified in this study were numbered as ST-40, 
ST-71 and consecutively from ST-108 to ST-175. Of the 320 N. gonorrhoeae isolates, 54.4% 
(n=174/320) were clustered under 6 STs [109 (n=57, 18.0%), 108 (n=39, 12%), 114 (n=22, 7%), 
141 (n=22, 7%), 111 (n=21, 6.6%) and 120 (n=13, 4.0%)]. 
 
Isolates susceptible to all the tested antibiotics were significantly associated with ST 109 
(n=46/104, 44%; P<0.0001) (Table 3.10). CMTR gonococaal isolates had significant presence in 
STs; 108 (n=30/181, 17%; P=0.001), 114 (n=19/181, 10.5%; P=0.007) and 120 (n=12/181, 
6.6%; P=0.017). CMRNG and TRNG were significantly associated to ST 111 (n=9/13, 69%; 
P<0.0001) and ST 130 (10/13, 77%; P=0.0001). 
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Table 3.10 70 porB strain types with resistance phenotypes in 320 N.  gonorrhoeae isolates 
(2003-2008) 
 
 
porB STs in bold constitutes 54.4% (n=174/320) of the typed isolates 
*: P value<0.05 is considered statistically significant  
 
porB 
ST 
n 
Susce-
ptible 
CM 
TR 
CMR 
NG 
TR 
NG 
Other resistance phenotypes 
PP 
NG 
Cip
R
 Azi
R PPNG/ 
CMTR
 
TRNG/
Cip
R
 
CMTR/
Cip
R
 
CMTR/ 
Azi
R
 
109 57 46
* 
11 - - - - - -  - - 
108 39 6 30
*
 2 1 - - - - - - - 
114 22 3 19
* 
- - - - - - - - - 
141 22 5 17 - - - - - - - - - 
111 21 1 11 9
* 
- - - - - - - - 
120 13 1 12
* 
- - - - - - - - - 
146 12 6 6 - - - - - - - - - 
130 11 1 - - 10
* 
- - - - - - - 
134 8 5 3 - - - - - - - - - 
131 7 1 6 - - - - - - - - - 
132 7 1 6 - - - - - - - - - 
138 5 2 3 - - - - - - - - - 
110 4 3 1 - - - - - - - - - 
113 4 3 1 - - - - - - - - - 
122 4 4 - - - - - - - - - - 
157 4 1 3 - - - - - - - - - 
159 4 - 4 - - - - - - - - - 
40 3 - 3 - - - - - - - - - 
117 3 2 1 - - - - - - - - - 
118 3 1 2 - - - - - - - - - 
129 3 2 1 - - - - - - - - - 
148 3 - 3 - - - - - - - - - 
116 2 1 1 - - - - - - - - - 
119 2 1 1 - - - - - - - - - 
128 2 2 - - - - - - - - - - 
144 2 2 - - - - - - - - - - 
147 2 1 - - - - 1 - - - - - 
153 2 - 2 - - - - - - - - - 
154 2 - 1 - 1 - - - - - - - 
160 2 - 2 - - - - - - - - - 
161 2 - 1 - - - - - - - 1 - 
162 2 - 2 - - - - - - - - - 
167 2 - 2 - - - - - - - - - 
172 2 2 - - - - - - - - - - 
175 2 - 2 - - - - - - - - - 
Others 35 4 21 2 1 1 1 1 1 1 1 1 
Total 
(n=70) 
320 104 181 13 13 1 2 1 1 1 2 1 
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 Multiple sequence alignment was done to determine differences between all the 320 porB 
[765 base pairs (bp)] DNA sequences used in typing. porB sequences with ≤1% bp (7 bp) 
differences from the predominant porB ST were grouped together and the group was named after 
the ST with highest number of isolates (Table 3.11). On the basis of this classification, 12 porB 
(n=300, 93.8%) groups were identified with ID of 0.87. The major porB groups were 109, 108 
and 111.  
 
Group 109 was the largest porB group and 73 (22.8%) gonococcal isolates were clustered 
under this group (Table 3.11). This porB group in addition to porB ST 109 also had porB STs 
110 (n=4), 157 (n=4), 144 (n=2), 147 (n=2), 167 (n=2), 135 (n=1) and 165 (n=1). The STs 
grouped as porB group 109 differed in 1-6 bp between them. Group 109 had a significant 
association with susceptible isolates (n=53/73, 72.6%, P<0.0001).  
 
 porB group 108 accounted for 72 (22.5%) isolates. Group 108 had porB STs 108 (n=30), 
114 (n=22), 131 (n=7), 159 (n=4), 148 (n=3), 153 (n=2), 160 (n=2), 156 (n=1) and 142 (n=1) 
(Table 3.11). The difference in between STs clustered as porB group 108 ranged from 1 to 4 bp. 
Group 108 (n=57/181, 80.28%) was significantly (P<0.0001) associated with CMTR isolates.  
 
porB group 111 (n=34, 10.6%) comprised of porB STs 111 (n=21), 130 (n=11), 115 
(n=1) and 145 (n=1) with differences of 1 to 6 bp. This group had significant (P<0.0001) 
associations with CMRG (n=9/13, 69.23%) and TRNG (10/13, 77%) isolates. Group 141 was 
also associated with CMTR isolates (23/181, 12.7%, P=0.016). 
 
Isolates (n=104) susceptible to all the tested antibiotics were differentiated into 27 porB 
STs (Fig 3.19). Of the 104 susceptible N. gonorrhoeae isolates, 55.7% (n=58) were grouped 
under 3 STs; ST 109 (n=46, 44%), ST 108 (n=6, 5.7%) and ST 146 (n=6, 5.7%). Other 
predominant porB STs among susceptible isolates were, 141 (n=5, 4.8%) and 134 (n=5, 4.8%). 
Gonococcal isolates susceptible to all the antibiotics tested in this study had 7 porB ST groups 
(Fig 3.19). 51% (n=53) of the susceptible isolates were grouped under porB group 109. 
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Table 3.11  porB groups in N. gonorrhoeae isolates (2003-2008) from Saskatchewan for 
porB STs with ≥2 isolates  
 
porB groups in bold constitute 56% (n=179/320) of the typed isolates 
a: STs with ≤ 1% (n=1-7) base pair difference from predominant ST 
b: 20 isolates appear as single ST 
c: porB sequence used for porB typing was 765 bp long 
d: P value < 0.05 was considered significant 
 
 
 
 
 
porB Group
a 
n
b
 (%) 
Predominant 
ST (n) 
STs differ by within  
≤ 1% bp in  porBc (n) 
Significant association 
with resistance 
phenotypes 
109 73 (22.8) 109 (57) 110 (4), 157 (4), 144 (2), 147 (2), 
167 (2), 135 (1), 165 (1) 
Susceptible 
108 72 (22.5) 108 (30) 114 (22), 131 (7), 159 (4), 148 (3), 
153 (2), 160 (2), 142 (1), 156 (1)  
CMTR 
111 34 (10.6) 111 (21) 130 (11), 115 (1), 145 (1) CMRNG, TRNG 
141 29 (9) 141(22) 154 (2), 166 (1), 168 (1), 169 (1),  
171 (1), 173(1) 
CMTR 
132 18 (6) 132 (7) 122 (4), 119 (2), 161(2), 124 (1), 
 143 (1), 174 (1) 
 
113 13 (4) 113 (4) 118 (3), 129 (3), 116 (2), 112 (1)  
134 11 (3.4) 134 (8) 172 (2), 163 (1)  
40 6 (1.8) 40 (3) 136 (1), 140 (1), 164 (1)  
133 3 (1) 133 (1) 152 (1), 155 (1)  
162 3 (1) 162 (2) 158 (1)  
175 3 (1) 175 (2) 171 (1)  
71 2 (0.6) 71 (1) 139 (1)  
120 13 (4) 120 (13)  CMTR 
146 12 (3.8) 146 (12)   
138 5 (1.6) 138 (5)   
117 3 (1.3) 117 (3)   
Total 300 191 109  
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 Group 117 (n=3) 
 
Group 132 (n=7) 
 Group 134 (n=7) 
 
Group 113 (n=7) 
 
Group 108 (n=11) 
 Group 111 (n=2) 
 
Group 109 (n=53) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.19 porB STs associated with susceptible (n=104) N. gonorrhoeae isolates in 
Saskatchewan: 2003-2008. 
 
The predominant porB STs: 109 (n=46, 44%), 108 (n=6, 5.7%), 146 (n=6, 5.7%), 141 (n=5, 4.8%) and 
134 (n=5, 4.8%).  
 
7 gonococcal porB ST groups were observed in susceptible isolates with ≤1% (1-7 bp) difference in 
amplified porB (765 bp) DNA sequence fragment.  
 
51% (n=53) of the susceptible isolates were grouped under Group 109. 
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Phylogenetic analysis of porB STs showed clustering of CMRNG, TRNG and CMTR N. 
gonorrhoeae isolates. 4 STs were observed for CMRNG (n=13), ST-111(n=9, 69%), ST-108 
(n=2, 15%), ST-137 (n=1, 7.7%) and ST-164 (n=1, 7.7%) (Fig 3.20A). ST-111 and ST-108 had 
15 bp (≈2%) differences in porB.  
 
TRNG (n=13) were characterized as 4 porB STs; ST-130 (10/13, 77%), ST-108 (1/13, 
7.7%), ST-154 (1/13, 7.7%) and ST-149 (1/13, 7.7) (Fig 3.20B). porB ST-130 (10/11, 91%) was 
almost exclusively associated with TRNG (Table 3.13). One TRNG/Cip
R
 isolate observed in this 
study was identified as porB ST-151. This ST-151 had more than 100bp difference compares to 
other porB STs observed as TRNG in this study (data not shown). 
 
CMTR (n=181) N. gonorrhoeae isolates were resolved into 50 porB STs (Fig 3.21). Of 
these 50 porB strain types, 28 STs were associated with one isolate each. Of the 181 CMTR N. 
gonorrhoeae isolates, 55% (n=100) were grouped under 6 porB STs [ST-108 (n=30, 17%), ST 
114 (n=19, 10.5%), ST 141 (n=17, 9.4%), ST 120 (n=12, 6.6%), ST 109 (n=11, 6%) and ST 111 
(n=11, 6%)]. This analysis of porB sequences showed presence of 10 porB groups (≥5 isolates) 
in CMTR N. gonorrhoeae (Fig 3.21). 37% (n=67) and 13% (n=23) of CMTR N. gonorrhoeae 
isolates were grouped under two porB separate groups; 108 and 141.  
 
Among the 10 predominant porB STs observed in this study, 3 porB STs; 109, 108 and 
114 were present throughout the entire study period (2003-2008) (Fig 3.22).  Isolates appeared as 
ST 109 were significantly higher in 2003 (24/60, 40%, P<0.0001) and 2004 (17/59, 28.8%, 
P=0.024) and decreased in prevalence over the study period to 4.8% (2/41) of isolates in 2008. 
ST 114 (10/22, 45.5%, P=0.0008) predominated in 2006. The incidence of ST 111 (9/21, 42.8%, 
P=0.0071) was higher in 2004.  ST 108 was present through the study period but no significant 
association of this ST was observed with time period. Interestingly, porB STs 108 &114 were 
grouped together as porB group 108 and porB STs 111 and 130 were grouped under porB group 
111.   
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Fig. 3.20 porB STs associated with CMRNG (n=13) and TRNG (n=13) in Saskatchewan: 
2003-2008 
 
A. CMRNG, B. TRNG 
 
A. 69% (9/13) and 15% (2/13) of CMRNG were grouped as porB ST-111 and 108. porB ST-111 and 
108 had 15 bp (≈2%) difference. 
B. 77% (10/13) TRNG clusterd under porB ST-130. The bp difference between ST-130 and other TRNG 
STs ranged from 12 bp (ST-108) to 153 bp (ST-149). 
 
All the STs observed as CMRNG or TRNG were from different porB groups with >1% (> 7 bp) bp 
difference in the porB sequences. 
A .  B.  
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Fig. 3.21 porB STs associated with CMTR (n=181) N. gonorrhoeae isolates in 
Saskatchewan: 2003-2008. 
 
The predominant porB STs: 108 (n=30, 17%), 114 (n=19, 10.5%), 141 (n=17, 9.4%), 120 (n=12, 6.6%), 
109 (n=11, 6%) and 111 (n=11, 6%). 
 
10 gonococcal porB groups were observed in CMTR gonococcal isolates.  
 
37% (n=67) and 13% (n=23) of CMTR N. gonorrhoeae isolates were clustered under group 108 and 141. 
 
 
 
 
 
 
 
 
 
 
 
Group 141 (n=23) 
Group 132 (n=9)  
Group 134 (n=4)  
Group 175 (n=3) 
Group 113 (n=6) 
Group 162 (n=3) 
Group 40 (n=5) 
Group 109 (n=16) 
Group 111 (n=12) 
Group 108 (n=67) 
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Fig. 3.22 Distribution of predominant (≥ 10 isolates) porB STs of N. gonorrhoeae in Saskatchewan (2003-
2008).  NG-MAST STs 25, 3655 and  3654 has shown declining trend in the prevalence after 2003, 2006 and 2004 respectively.  
*: P value < 0.05 was considered statistically significant. 
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3.4.2 NG-MAST Analysis and Phylogeny 
 
NG-MAST resolved the 320 gonococcal isolates tested into 82 STs (Table 3.12) with an 
index of discrimination (ID) of 0.96. The average number of isolates per NG-MAST-ST was 3.9. 
42 NG-MAST STs were associated with two or more N. gonorrhoeae isolates and 40 STs were 
associated with individual isolates. Of the 320 N. gonorrhoeae isolates, 55.6% (178/320) of the 
isolates grouped under 10 NG-MAST STs [25 (n=46, 14.4%), 3655 (n=23, 7.2%), 3654 (n=21, 
6.5%), 3657 (n=15, 4.7%), 3672 (n=14, 4.4%), 921 (n=13, 4%), 3556 (n=13, 4%), 3711 (n=10, 
3.1%) and 508 (n=10, 3.1%)] (Table 3.12). 
 
Significant associations were observed between certain STs and antimicrobial resistance 
(AMR) profiles (Table 3.12). Susceptible isolates were significantly associated with STs 25 
(40/46, 87%, P<0.0001). The CMTR phenotype was significantly associated with STs 3655 
(22/23, 95.6%, P=0.0002), 3672 (12/14, 85.7, P=0.048) and 921 (12/13, 92.3%, P=0.0178). ST 
3711 was exclusively associated with TRNG. The majority (9/13; 69.2%) of CMRNG were 
grouped as ST 3654 (9/21, 42.9%, P<0.0001). 
 
The 82 STs identified were further grouped based NG-MAST STs which shared one 
identical porB or tbpB  allele and which differed by ≤1% (≤5bp difference in porB and ≤4bp in 
tbpB) in the other allele (Table 3.13). On the basis of this classification, 29 NG-MAST groups 
were identified with ID of 0.93. The NG-MAST groups were named after the most predominant 
ST present in each group. Using this refined grouping scheme, the majority (53.4%, 171/320) of 
the isolates were grouped under 6 NG-MAST groups [25 (n=52, 16.3%), 3655 (n=35, 11%), 921 
(n=27, 8.4%), 3654 (n=23, 7.2%), 3657 (n=20, 6.3%) and 3656 (n=14, 4.4%)]. NG-MAST STs 
508 and 3655 had a one base pair difference in their porB allele (365: 2195) and were grouped as 
NG-MAST group 3655. STs 921 and 3714 differed by only one base pair in NG-MAST porB 
allele (356: 2242) and appeared  as NG-MAST group 921 (Table 3.13). 
 
Group 25 in addition to NG-MAST ST 25 also contained NG-MAST STs 50 (n=2), 70 
(n=2) and 4674(n=2). STs clustered under NG-MAST group 25 had identical tbpB alleles and 
had 1 to 3 bp difference in porB (Table 3.13).  
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Table 3.12 82 NG-MAST strain types with resistance phenotypes in 320 N. gonorrhoeae 
isolates (2003-2008) 
 
 
NG-MAST STs in bold constitute 55.6% (178/320) of the typed isolates 
*: P value<0.05 is considered statistically significant 
 
NG-
MAST 
ST 
n 
Susce-
ptible 
CM 
TR 
CMR 
NG 
TR 
NG 
Other resistance phenotypes 
PP 
NG 
Cip
R
 Azi
R PPNG/ 
CMTR
 
TRNG/
Cip
R
 
CMTR/
Cip
R
 
CMTR/
Azi
R
 
25 46 40
* 
6 - - - - - - - - - 
3655 23 1 22
* 
- - - - - - - - - 
3654 21 - 12 9
* 
- - - - - - - - 
3657 15 5 10 - - - - - - - - - 
3672 14 2 12
* 
- - - - - - - - - 
3556 13 6 7 - - - - - - - - - 
921 13 1 12
* 
- - - - - - - - - 
3656 13 4 8 1 - - - - - - - - 
3711 10 - - - 10
*
 - - - - - - - 
508 10 1 8 1 - - - - - - - - 
3653 8 1 7 - - - - - - - - - 
3671 7 4 3 - - - - - - - - - 
3714 7 1 6 - - - - - - - - - 
4585 6 5 1 - - - - - - - - - 
210 5 2 3 - - - - - - - - - 
2 4 2 2 - - - - - - - - - 
12 4 3 1 - - - - - - - - - 
1109 4 1 3 - - - - - - - - - 
3676 4 3 1 - - - - - - - - - 
3713 3 2 1 - - - - - - - - - 
5 3 - 3 - - - - - - - - - 
238 3 1 2 - - - - - - - - - 
3652 3 - 3 - - - - - - - - - 
3663 3 - 3 - - - - - - - - - 
3670 3 2 1 - - - - - - - - - 
4222 3 1 2 - - - - - - - - - 
3660 2 - 2 - - - - - - - - - 
3661 2 - 2 - - - - - - - - - 
3662 2 - 2 - - - - - - - - - 
3666 2 - 2 - - - - - - - - - 
3669 2 - 2 - - - - - - - - - 
3673 2 - 1 - 1 - - - - - - - 
3677 2 - 2 - - - - - - - - - 
3712 2 - 2 - - - - - - - - - 
4228 2 1 1 - - - - - - - - - 
4674 2 2 - - - - - - - - - - 
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Table 3.12 continued……. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NG-
MAST 
ST 
n 
Susce-
ptible 
CM 
TR 
CMR 
NG 
TR 
NG 
Other resistance phenotypes 
PP 
NG 
Cip
R
 Azi
R PPNG/ 
CMTR
 
TRNG/
Cip
R
 
CMTR/
Cip
R
 
CMTR/
Azi
R
 
51 2 1 - - - - 1 - - - - - 
70 2 1 1 - - - - - - - - - 
365 2 2 - - - - - - - - - - 
3116 2 - 1 - - - - - - - 1 - 
3658 2 - 2 - - - - - - - - - 
3659 2 - 2 - - - - - - - - - 
Others 40 9 20 2 2 1 1 1 1 1 1 1 
Total 
(n=82) 
320 104 181 13 13 1 2 1 1 1 2 1 
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Table 3.13 NG-MAST groups in N. gonorrhoeae isolates (2003-2008) from Saskatchewan 
for NG-MAST STs with ≥2 isolates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NG-MAST groups in bold constitute 53.4% (171/320) of the typed isolates 
a: 22 isolates appear as single STs 
b: STs that share an identical tbpB allele but  porB allele varies by ≤1% 
c: STs that share an identical porB allele but tbpB allele varies by ≤1%  
d:
 
STs 508 and 3655 have  ≤1% difference in their  porB  (356:2195) alleles and  have identical tbpB  allele (28) 
ST 508 also shared porB (356) allele with 3566 and differed in tbpB allele (28:821) by ≤1%. Since ST 3655 was 
more predominant compared to ST3656 therefore ST 508 was placed in group 3655 
NG-MAST 
Group 
n
a
 (%) 
Predominant 
ST (n) 
STs which differ by ≤1%  for 
 porB
b 
ST (n) 
tbpB
c 
ST (n) 
25 52 (16.3) 25 (46) 51 (2), 70 (2), 4674 (2)  
3655  35 (11) 3655 (23) 508
d
 (10), 3658 (2)  
921 27 (8.4) 921 (13) 3662 (2), 3666 (2), 3675 (1), 
3712 (2), 3714 (7) 
 
3654  23 (7.2) 3654 (21) 4516 (1), 4670 (1)  
3657   20 (6.3) 3657 (15) 3660 (2), 3677 (2), 3667 (1)  
3656   14 ( 4.4) 3656 (13)  4584 (1) 
3653  10 ( 3) 3653 (8) 3673 (2)  
12   10 ( 3) 12 (4) 238 (3), 3670 (3)  
3671  8 ( 2.5) 3671 (7) 3678 (1)  
210   8 ( 2.5) 210 (5)  3663 (3) 
1109   7 ( 2.2) 1109 (4) 3659 (2), 4711 (1)  
5   5 (1.5) 5 (3) 3485 (1), 4673 (1)  
3669   3 ( 1) 3669 (2) 3664 (1)  
4228   3 ( 1) 4228 (2) 1650 (1)  
3116   3 (1%) 3116 (2) 3668 (1)  
4227   2 (0.6) 4227 (1) 4675 (1)  
225   2 (0.6) 225 (1) 4712 (1)  
64  2 ( 0.6) 64 (1) 359 (1)  
3672 14 ( 4.4) 3672 (14)   
3556 13( 4) 3556 (13)   
3711 10 ( 3) 3711 (10)   
4585 6 ( 2) 4585(6)   
3676 4 ( 1.3) 3676(4)   
2 4 (1.3) 2 (4)   
3713 3 (1) 3713 (3)   
3652 3 (1) 3652 (3)   
4222 3 ( 1) 4222 (3)   
365 2 ( 0.6) 365 (2)   
3661 2 (0.6) 3661 (2)   
Total 298 233 61 4 
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Group 3655 comprised of NG-MAST STs 3655(n=23), 508 (n=10) and 3658 (n=2) 
(Table 3.13). NG-MAST group 921 included NG-MAST STs 921 (n=13), 3662 (n=2), 3666 
(n=2), 3675 (n=1), 3712 (n=2) and 3714 (n=7) (Table 3.13). 
 
Susceptible isolates were significantly associated with NG-MAST group 25 (44/52, 
84.6%, P<0.0001) (Table 3.14). NG-MAST groups; 3655 (32/35, 91.4%, P<0.0001), 921 (25/27, 
92.6%, P=0.0002) and 3672 (12/14, 85.7%, P=0.048) were significantly associated with CMTR 
phenotype. CMRNG were significantly related to NG-MAST group 3654 (9/23, 39.1%, 
P<0.0001). NG-MAST group 3711 was exclusively associated with TRNG (P<0.0001) (Table 
3.14).  
Susceptible isolates (n=104) were resolved into 34 NG-MAST STs (Fig 3.23). More than 
50% of susceptible isolates (56/104, 53.8%) appeared as 4 NG-MAST STs; 25 (n=40, 38.5%), 
3556 (n=6, 5.7%), 3657(n=5, 4.8%) and 4585 (n=5, 4.8%). Forty-four (42.3%) susceptible 
isolates were clustered under group 25 (Fig 3.23). 
 
NG-MAST grouped CMRNG into 4 STs, as observed with porB typing (Fig 3.24A). The 
majority of CMRNG (n=9/13, 69%) were clustered as NG-MAST ST-3654. TRNG were 
grouped under 4 NG-MAST STs (Fig 3.24B). NG-MAST ST-3711(n=10, 77%) was exclusively 
associated with TRNG.  
 
N. gonorrhoeae CMTR isolates were grouped under 58 different NG-MAST STs (Fig 
3.25). Of the 181 CMTR N. gonorrhoeae isolates, 57.4% (n=104) were grouped under 9 NG-
MAST STs [3655 (n=22, 12.2%), 3654 (n=12, 6.6%), 3672 (n=12, 6.6%), 921 (n=12, 6.6%), 
3657 (n=10, 5.5%), 508 (n=8, 4.4%), 3656 (n=8, 4.4%), 3653 (n=7, 3.9%) and 3653 (n=7, 
3.9%). Twelve gonococcal NGMAST groups were observed in CMTR N. gonorrhoeae isolates. 
Twenty five (13.8%) CMTR isolates clustered under group 921. No clonality was detected with 
Cip or Azi resistant isolates. 
 
Significant associations were observed between different STs and time periods of the 
study (Fig 3.26). Among the 10 predominant STs observed in this study, only 3 STs; 25, 3654 
and 3655 were present throughout entire study period (2003-2008).  The numbers of ST 25 
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Table 3.14 Major NG-MAST groups with resistance phenotypes in 320 N. gonorrhoeae 
isolates from Saskatchewan 
 
 
*
: P value<0.05 is considered statistically significant  
 
 
 
 
 
NG-
MAST 
Group 
n 
Susce-
ptible 
CM 
TR 
CMR 
NG 
TR 
NG 
Other resistance phenotypes 
PP 
NG 
Cip
R
 Azi
R PPNG/ 
CMTR
 
TRNG/
Cip
R
 
CMTR/
Cip
R
 
CMTR/
Azi
R
 
25 52 44
*
 7 - - - 1 - - - - - 
3655 35 2 32
* 
1 - - - - - - - - 
921 27 2 25
* 
- - - - - - - - - 
3654 23 1 13 9
* 
- - - - - - - - 
3657 20 8 12 - - - - - - - - - 
3656 14 4 8 1 1 - - - - - - - 
3672 14 2 12
* 
- - - - - - - - - 
3556 13 6 7 - - - - - - - - - 
3711 10 - - - 10
*
 - - - - - - - 
3653 10 1 8 - 1 - - - - - - - 
12 10 6 4 - - - - - - - - - 
3671 8 4 4 - - - - - - - - - 
210 8 2 6 - - - - - - - - - 
1109 7 1 6 - - - - - - - - - 
4585 6 5 1 - - - - - - - - - 
5 5 - 4 1 - - - - - - - - 
3676 4 3 1 - - - - - - - - - 
2 4 2 2 - - - - - - - - - 
3713 3 2 1 - - - - - - - - - 
3116 3 - 1 - - - - - - - 2 - 
3652 3 - 3 - - - - - - - - - 
4222 3 1 2 - - - - - - - - - 
3669 3 - 3 - - - - - - - - - 
4228 3 1 2 - - - - - - - - - 
64 2 - - - - - - 1 - - - 1 
3661 2 - 2 - - - - - - - - - 
3677 2 - 2 - - - - - - - - - 
4227 2 - 2 - - - - - - - - - 
365 2 2 - - - - - - - - - - 
Others 22 5 11 1 1 1 1 - 1 1 - - 
Total 320 104 181 13 13 1 2 1 1 1 2 1 
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Fig. 3.23 NG-MAST STs associated with susceptible (n=104) N. gonorrhoeae isolates in 
Saskatchewan: 2003-2008. 
 
The predominant NG-MAST STs: 25 (n=40, 38%), 3556 (n=6, 5.7%), 3657(n=5, 4.8%) and 4585 
(n=5, 4.8%). 
Four gonococcal NGMAST groups were observed in susceptible (n=104) N. gonorrhoeae isolates. 
42.3% (n=44) of the susceptible isolates were clustered under group 25. 
 
 
 
 
 
Group 25 (n=44) 
Group 3656 (n=5) 
Group 921 (n=2) 
Group 12 (n=6) 
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Fig. 3.24 NG-MAST STs associated with CMRNG (n=13) and TRNG (n=13) in 
Saskatchewan: 2003-2008 
 
A. CMRNG, B. TRNG 
 
A. 69% (n=9) CMRNG grouped as ST-3654. 
B. 77% (n=10) TRNG were clustered under ST-3711 and this ST was exclusively associated with 
TRNG. 
 
All CMRNG and TRNG isolates were from different NG-MAST groups. 
 
 
 
 
 
A .  B.  
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Fig. 3.25 NG-MAST STs associated with CMTR (n=181) N. gonorrhoeae isolates in 
Saskatchewan: 2003-2008. 
 
The predominant NG-MAST STs: 3655 (n=22, 12%), 921 (n=12; 9.4%), 3654 (n=11, 6%), 3657 (n=10, 
5.5%). 
12 gonococcal NGMAST ST groups were observed in CMTR N. gonorrhoeae isolates. 13.8% of the 
CMTR isolates clustered under group 921. 
 
Group 921 (n=25) 
 Group 25 (n=7) 
 Group 3657 (n=15)  
 
 Group 5 (n=4) 
 
 Group 3655 (n=10) 
 
 Group 210 (n=6) 
 
   Group 3669 (n=3) 
 Group 12 (n=5)  
 Group 3653 (n=8) 
 Group 1109 (n=4)] 
Group 3654 (n=4)  
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Fig. 3.26 Distribution of predominant (≥ 10 isolates) NG-MAST STs of N. gonorrhoeae in Saskatchewan (2003-2008). 
NG-MAST STs 25, 3655 and  3654 has shown declining trend in the prevalence after 2003, 2006 and 2004 respectively.  
*: P value < 0.05 was considered statistically significant. 
1
2
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isolates was significantly higher in 2003 (31.7%, 19/60, p<0.0001) and 2004 (23.7%, 14/59, 
p=0.032) and steadily declined in prevalence over the study period to 2.43% (1/41) of isolates in 
2008. The prevalence of ST 3654 was significantly higher (15.3%, 9/59, p=0.0071) in 2004 and 
numbers decreased afterwards. ST 3655 (10/23, 43.5, p=0.0015) predominated in 2006. ST 3711 
was observed in 2004 (5%, 3/59), 2005 (3.8%, 2/52) and 2006 (9%, 5/55) with a significant 
incidence in 2006 (p=0.017). ST 3556 had high numbers in 2007 (11.3%, 6/53, p=0.023) and 
2008 (12.2%, 5/41, p=0.016). 
 
It is important to mention that 7 of the 10 predominant STs observed in this study shares 
porB or (ST 508: ST3656) or tbpB (ST25: ST3657; ST3654: ST3653; ST508: ST3655) alleles.  
 
3.4.3 MLST Analysis of N. gonorrhoeae 
 
193 N. gonorrhoeae isolates (2005-2008) were resolved by MLST into 29 different STs 
(ST1 to ST29) (Fig 3.27) with an average of 6.7 isolates per MLST-ST. The index of 
discrimination of MLST for 193 isolates was 0.89. Most notably, 3 distinct STs were responsible 
for 52% N. gonorrhoeae isolates examined. ST-1 accounted for 23.6% (n=46) of the isolates, 
followed by ST-3 (15.9 %, n=31) and ST-2 (12.3%, n=24) (Fig 3.27). Seventy three isolates 
were resolved into 11 STs (ST-4, ST-5, ST-6, ST-8, ST-11, ST-14, ST-15, ST-16, ST-20, ST-21, 
and ST-25); these STs accounted from 1.5% (n=3) to 7.2% (n=14) of the isolates examined. Four 
STs (ST-9, ST-10, ST-24, and ST-29) were represented by two isolates each.  
 
 MLST resolved TRNG (n=9) from 2005 to 2008 in 3 STs; ST-20 (n=7), ST-25 (n=1) and 
ST-1 (n=1) (Fig 3.28). Six CMRNG (2005-2008) were differentiated into four STs; ST-1 (n=3), 
ST-3 (n=1), ST-9 (n=1), ST-25 (n=1) by MLST. 133 CMTR (2005-2008) isolates were resolved 
into 24 STs by MLST. The major STs among CMTR were ST-1 (n=41, 30.6%), ST-2 (n=16; 
12%), ST-3 (n=26; 19%). 39 (2005-2008) susceptible isolates were clustered under 11 STs and 
predominant STs being ST-5 (n=9; 23%), ST-2 and 4 (n=7; 18%) and ST-3 (n=4; 10%). 
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Fig. 3.27 Longitudinal distribution of N. gonorrhoeae strains in Saskatchewan on the basis 
of MLST: 2005-2008 
 
A. Occurrence of the STs over a four-year period. Solid squares indicate the presence of certain STs, 
while open squares indicate their absence.  
B. The prevalence rate of the most predominant circulating strains compared to the prevalence rate of all 
other STs identified during 2005-2008 in Saskatchewan.  
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Fig. 3.28 Minimum spanning tree based on the multilocus sequence typing allelic profiles 
depicting antibiotic-resistant phenotype distribution across N. gonorrhoeae lineages and 
their clonal complexes in Saskatchewan: 2005-2008 
 
 Each circle represents unique ST. The number of isolates of each ST is directly proportional to the area 
of the circle. Blue circle represents the ST susceptible to all tested antibiotics, black indicates resistance to 
tetracycline alone, while brown color indicates resistance to penicillin and tetracycline, red resistance to 
ciprofloxacin and tetracycline and orange indicates resistance to azithromycin and tetracycline. Gray 
shadings represent the clonal complexes which consist of single locus variants.           
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 Among Cip
R
 (n=5) isolates, two Cip
R
 isolates were ST-6 and remaining three were as 
single STs; 6, 9 and 26. The majority of CMRNG (5/6) were found in circulating strains ST-1 
(n=3) and ST-3 (n=1). All Cip (n=5) and Azi (n=1) resistant isolates were found in sporadic 
sequence types. All these sporadic isolates were positioned on the edges of the minimum 
spanning tree (Fig 3.28).  
 
3.4.4 Comparison of porB Typing, NG-MAST and MLST  
 
Three typing methods used in this study, porB, NG-MAST and MLST were compared for 
193 N. gonorrhoeae isolates (Table 3.15). NG-MAST, porB typing and MLST differentiated 193 
isolates into 45, 43 and 29 STs, respectively. The indices of discrimination of the NG-MAST, 
porB typing, and MLST for these isolates were 0.97, 0.95, and 0.89.  
 
All typing schemes resolved CMRNG (n=6) into 4 STs. TRNG (n=9) were differentiated 
into 3 STs by MLST and into 4 STs each by porB typing and NG-MAST. 133 CMTR gonococci 
isolates were resolved into 24, 30 and 32 STs on the basis of porB typing, NG-MAST and 
MLST, respectively. 39 susceptible N. gonorrhoeae were differentiated to 11 MLST STs, 17 
porB STs and 18 NG-MAST STs.   
 
Forty-six N. gonorrhoeae isolates clustered as ST-1 by MLST were differentiated into 15 
and 16 STs through NG-MAST and porB typing (Fig 3.29). 16 NG-MAST observed in isolates 
clustered under MLST ST-1 had 13 porB and 3 tbpB sequence types.  MLST ST-2 (n=24) were 
resolved as 7 NG-MAST STs and 9 porB STs. 31 isolates associated with MLST ST-3 were 
grouped as 4 NG-MAST STs and 6 porB STs. Only porB ST-141 and NG-MAST ST-3653 
appeared in all the four years in isolates grouped under MLST ST-1. These observations were 
also made with MLST ST-2 and ST-3. porB ST-141 and NG-MAST ST-3657 were present for 
all the four years and were MLST-2. In MLST-3, porB ST-108 and NG-MAST ST-3656 were 
detected for all the four years (2005-2008).  
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Table 3.15 Strain types detected by porB, NG-MAST and MLST in 193  
N. gonorrhoeae isolates (2005-2008) 
 
Phenotype n 
Number of STs detected  
NGMAST porB MLST 
Susceptible 39 18 17 11 
CMRNG 6 4 4 4 
TRNG 9 4 4 3 
CMTR 133 32 30 24 
Cip
R 
2 2 2 2 
Azi
R 
1 1 1 1 
Cip
R
/TRNG 1 1 1 1 
Cip
R
/CMTR 2 2 2 2 
Total 193 45 43 29 
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Fig. 3.29 Differentiation of N. gonorrhoeae (n=46) isolates clustered under MLST ST-1 by 
porB typing and NG-MAST 
 
 
A. 46 isolates clustered as MLST ST-1 were resolved into 15 STs by porB typing. 
B. MLST ST-1 was differentiated into 16 STs by NG-MAST. 
 
 
porB and NG-MAST STs  with same isolates are boxed similarly colored box i.e. porB STs 148 and 111 
have same isolates as those of NG-MAST STs 3712 and 3659. 
 
porB ST-108 (n=10) was resolved into 3 NG-MAST  STs; 921 (n=8), 3665 (n=1) and 3677(n=1). porB 
ST-171 was NG-MAST ST-3677.  
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3.4.5 Association of Predominant NG-MAST and MLST STs with PBP2, MtrR and PorB 
Mutations 
 
N. gonorrhoeae isolates (n=146) analyzed for molecular mechanisms of resistance were 
classified into 51 STs; 6 STs (86/146; 59%) comprised ≥ 5 isolates, 10 STs included 2-4 isolates, 
and 35 STs contained 1 isolate (Table 3.16). These STs carrying specific combinations of 
mutation patterns were significantly related to certain resistance phenotypes. Isolates with 
NGMAST-ST 25 (33/36, 92%) were associated (P<0.0001) with PBP2 (penA)/MtrR 
(mtrR)/PorB (porB) pattern I/WT/WT (Fig 3.30) and with antibiotic susceptibility. NG-MAST 
ST 3654 was associated (P<0.0001) with penA/mtrR/porB pattern IX/G45D/G120K;A121D 
(n=13/17) and CMRNG (n=7) and CMTR (n=6) isolates. Isolates with chromosomal resistance 
to tetracycline were significantly associated (P<0.0001) with several STs and penA/mtrR/porB 
patterns including: ST 3655 (XXII/A-;G45D/G120N;A121N - n=8/12), ST 921 (pattern 
IX/G45D/G120D;A121N - n=6/9), ST 508 (XXII/G45D/G120D;A121N - n=6/6), and ST 3656 
(pattern XXII/A-; G45D/G120D;A121N – n=5/6). 24 isolates had higher cefixime MICs (0.03-
0.06 mg/L) and included 17 STs with penA pattern IX (n=17) and mtrR G45D (n=16) and porB  
G120K, A121D (n=12) mutations. Seven of these isolates were associated (P<0.0001) with ST 
3654 (pattern IX/G45D/G120K;A121D). 
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Table 3.16 Association of PBP2, MtrR and PorB mutations in major NG-MAST STs resistance phenotypes 
 
 
In total 14 isolates (9 susceptible, 3 CMTR, 2 TRNG) were grouped as 2 isolates per ST. Thirty five total 35 isolates (3 susceptible, 21 CMTR, 1 TRNG, 1 
PPNG, 2 CMRNG, 1PPNG/CMTR, 1 TRNG/Cip
R
, 2 CMTR/Cip
R
, 2 Cip
R
 and 1 Azi
R
 isolates) were grouped as single isolate per ST. 
*: 
P value <0.05
 
 considered significant. 
 
NG-MAST 
ST (total) 
n 
Patterns Resistance Phenotypes 
penA mtrR porB Susceptible CMTR CMRNG TRNG 
Higher 
ceftriaxone/cefixime 
MIC (≥0.03 mg/L) 
25 (36) 33
* I
 
WT WT 33
*
 0 0 0  
 1 IX G45D G120D; A121D 0 1 0 0  
 1 XXII WT WT 1 0 0 0  
 1 XXII A-/G45D WT 1 0 0 0  
3654 (17) 3
*
 IX G45D G120D; A121D 0 1 2 0  
 13
*
 IX G45D G120K; A121D 0 6* 7* 0 3/7* 
 1 XXII G45D G120K; A121D 0 1 0 0 1/0 
3655 (12) 8
*
 XXII A-/G45D G120N; A121N 0 8* 0 0 1/1 
 1 XXII A-/G45D G120D; A121N 0 1 0 0  
 1 XXII A-/G45D G120K; A121N 0 1 0 0  
 1 XII A-/G45D G120D; A121N 0 1 0 0  
 1 IX A-/G45D G120N; A121N 0 1 0 0  
921 (9) 6
*
 IX G45D G120D; A121N 0 6* 0 0 1/1 
 3 XXII G45D G120D; A121N 0 3 0 0  
508 (6) 6
*
 XXII G45D G120D; A121N 0 5* 1 0  
3656 (6) 5
*
 XXII A-/G45D G120D; A121N 0 4* 1 0  
 1 XXII G45D G120D; A121N 0 1 0 0  
3714 (4) 3
*
 IX G45D G120D; A121N 0 3
*
 0 0 2/2 
 1 IX G45D G120K; A121N 0 1 0 0  
3657 (4) 3
*
 I Truncated MtrR WT 3* 0 0 0 1/1 
 1 I A39T WT 1 0 0 0 1/0 
1109 (3) 3
*
 IX G45D WT 0 3
*
 0 0  
Total 97
 
   39 47 11 0  
1
3
6
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Fig. 3.30 Significant (P<0.05) associations between NG-MAST strain types and combination of mutations in PBP2, MtrR  
and PorB.  
 
Figures in parenthesis indicate the mutation pattern numbers with which significant associations were observed with specific antibiotic 
resistance phenotype in a specific NG-MAST ST.
 Susceptible 
CMTR, CMRNG,  
cef ixime  
susceptibility group  2  
CMTR 
       CMTR CMTR (6) 
1
3
7
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CHAPTER FOUR 
 
DISCUSSION 
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4.1 Prevalence of Antimicrobial Resistance in Neisseria gonorrhoeae in Saskatchewan 
 
Results of this research indicate that N. gonorrhoeae isolates from SK were highly 
susceptible (>95%) to antibiotics currently recommended (ceftriaxone, cefixime, azithromycin & 
ciprofloxacin) and previously (penicillin & spectinomycin) recommended for the treatment of 
gonorrhea in Canada. Aggregate resistance to all the tested antibiotics detected in this study 
(2003-2011) was below 5% except for tetracycline. AMR prevalence in N. gonorrhoeae in SK is 
much lower compared to Canadian national resistance rates (Martin et al 2011) and rates 
detected in other Canadian provinces (Ota et al 2009; Plitt et al 2009; Allen et al 2011). This 
might be attributed to the fact that these provinces have larger populations and are major national 
transit, economic and immigration hubs compared to SK. Such activities introduce new 
infections to naive populations from distant places.  
 
One of the challenges faced by the laboratories performing surveillance of antimicrobial 
resistance in N. gonorrhoeae is the shift from the use of cultures (required for antimicrobial 
susceptibility testing) to the NAATs for the diagnosis of gonorrhea. This has decreased the 
availability of bacterial cultures for antimicrobial susceptibility testing and may result in 
underestimations of AMR in N. gonorrhoeae (Dillon 2011). A few (n=8) isolates tested in this 
study were from the throat (n=5/427, 1.16%) and the rectum (n=3/427, 0.7%), common sites of 
infection in MSM. Antimicrobial susceptibility testing of lower number of N. gonorrhoeae 
isolates from MSM in this study may have also contributed to the underestimation of AMR in 
gonococcal isolates from SK. A higher prevalence of antimicrobial resistant N. 
gonorrhoeae strains has been reported in MSM (HPA 2008; Ota et al 2009; de Vries et al 2009; 
CDC 2009, 2011; Bola et al 2012).  The proportion of N. gonorrhoeae isolates in MSM with 
elevated MICs (cefixime ≥0.25 mg/L; ceftriaxone≥0.125mg/L) of extended spectrum 
cephalosporins in the USA have increased from 0.2% to 4.7% (24 fold) for cefixime and 0.0% to 
1.0% (10 fold) for ceftriaxone from 2006 through 2011 (Bolan et al 2012).  
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The majority of the resistant isolates in this study were from three major cities of the 
province, Saskatoon, Regina and Prince Albert. This can be attributed to the larger population of 
these cities which is also reflected in the higher number of isolates tested from these cities.  
 
N. gonorrhoeae has developed resistance to every class of antimicrobial used to treat 
gonorrhea since the introduction of sulphonamides in the early 1940s and has resulted in reduced 
treatment options for gonococcal infections (Lewis 2010; Dillon 2011). The emergence of PPNG 
in 1976 ended the use of penicillin as a drug of choice for gonorrhea treatment (Percival 1976) 
and the development of chromosomal resistance to tetracycline resulted in the removal of this 
antibiotic from treatment guidelines (Reyan et al 1958). Emergence of significant resistance to 
quinolones, specifically to ciprofloxacin in different parts of the world, resulted in the 
withdrawal of this class of antibiotics from gonorrhea treatment guidelines (CDC 2006, 2007, 
PHAC 2006, 2008b, 2010a,b). After the spread of QRNG strains worldwide, extended spectrum 
cephalosporins (cefixime & ceftriaxone) became the antibiotics of choice for the treatment of 
gonococcal infections (Wang & Zhang 2007; PHAC 2006; CDC 2006, 2007). Recent reports on 
N. gonorrhoeae  isolates with the reduced susceptibility or resistance to extended spectrum 
cephalosporins and gonorrhea treatment failures with extended spectrum cephalosporins has put 
a question mark on the longevity of this class of antibiotics as  single dose treatment of 
gonorrhea
 
(Tapsall et al 2009a; Lewis 2009; Bala et al 2010; Dillon 2011; Bolan et al 2012). 
Isolations of N. gonorrhoeae strains from Japan and Europe with high level resistance to 
cefixime, ceftriaxone and other antibiotics has initiated a broad discussion on the use of novel 
antimicrobials such as gentamicin and new antimicrobial combinations to treat gonorrhea 
(Golparian et al 2010, Ohinishi et al 2011; Unemo et al 2010; 2011a&b, 2012a&b; Cámara et al 
2012).  
 
In its new treatment guidelines, the Public Health Agency of Canada (PHAC, 2011c), 
recommends use of ceftriaxone (250 mg intramuscularly) or cefixime (800 mg
 
orally) to treat 
gonococcal infections.  Cefixime is not effective in treating pharyngeal gonorrhea, common in 
MSM (CDC 2012; Tapsall et al 2009b).  Ceftriaxone is now being recommended as the preferred 
treatment for gonococcal infections in MSM. These treatment guidelines also recommend use of 
one gram single oral dose of azithromycin along with recommended doses of extended spectrum 
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cephalosporins as an empirical treatment to treat Chlamydia and gonococcl co-infections. It is 
important to note that PHAC still recommends quinolones (ciprofloxacin 500 mg or ofloaxcin 
400 mg as single dose orally) as alternative treatment in those cases where quinolone 
susceptibility of gonococcal isolates is demonstrated through antimicrobial susceptibility testing 
or local resistance is under 5% with a test of cure can be done.   
  
4.1.1 Absence of N. gonorrhoeae Isolates with Reduced Susceptibility to Cephalosporins  
 
None of the 427 N. gonorrhoeae isolates tested from SK had reduced susceptibility 
(MIC=0.00025-0.25 mg/L) or resistance to cefixime and ceftriaxone. No drift towards higher 
MIC values was noted for oral (cefixime) or parentral (ceftriaxone) cephalosporins in the 
province. In Canada, none of the isolates tested for AMR between 2000 and 2009, were resistant 
to cefixime or ceftriaxone, but N. gonorrhoeae isolates with decreased susceptibility to cefixime 
(MIC 0.25 mg/L & 0.5 mg/L) and ceftriaxone (MIC 0.125 mg/L & 0.25 mg/L) were reported 
with a MIC shift to the right (Martin et al 2011). The proportion of N. gonorrhoeae isolates with 
an elevated MIC of cefixime (≥0.25 mg/L) and ceftriaxone (≥0.125mg/L) in the USA has 
increased by a factor of 17 (0.1% in 2006 to 1.7% in 2011) and 10 (0.05% in 2006 to 0.50% in 
2011) between 2006 and 2011, respectively (Bolan et al 2012). A recent report from Ontario, 
Canada observed that 9.4% of tested N. gonorrhoeae isolates had reduced susceptibility to 
cefixime (MICs = 0.125–0.25 mg/L), or ceftriaxone (MICs = 0.032–0.125 mg/L) (Allen et al 
2011).  
 
The National Gonococcal Isolate Surveillance Project (GISP), USA has reported 20 
isolates with decreased susceptibility to cefixime (MIC=0.5 mg/L) since 2000 (CDC 2009, 
2011). In 2010, 88.9% of gonococcal isolates with decreased susceptibility to cefixime were 
recovered from MSM (CDC 2011). GISP has reported four isolates with decreased susceptibility 
to ceftriaxone (MIC of 0.5 mg/L) in the USA since 1987. No isolates with reduced susceptibility 
to ceftriaxone (MIC ≥ 0.5 mg/L) were observed in 2010 (CDC 2011). However; the percentage 
of isolates with elevated ceftriaxone MICs increased from 0.1% to 0.3% during 2000 and 2010 
(CDC 2011) in the USA.  
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 Reduced cephalosporin susceptibility and high level of resistance to extended spectrum 
cephalosporins (cefixime and ceftriaxone) among N. gonorrhoeae has been reported from 
Europe (Martin et al 2006; Chisholm et al 2010; Cole et al 2010). These isolates were recovered 
from  Italy (Martin et al 2006), Spain (Vázquez et al 2007;  Cámara et al 2012), Greece (Tzelepi 
et al 2008), the UK (HPA 2008, 2009; Chisholm et al 2010), Norway (Unemo et al 2010), 
Sweden (Golparian et al, 2010), Austria (Unemo et al, 2011a), France (Unemo et al 2012a) and 
Slovenia (Unemo et al, 2012b). In Europe, 5% of tested N. gonorrhoeae isolates in 2009 
displayed decreased susceptibility (>0.125 mg/L) to cefixime (Cole et al 2011). No reduced 
susceptibility to ceftriaxone (>0.125 mg/L) in N. gonorrhoeae isolates was reported from Europe 
in 2009 (Cole et al 2011). In Portugal from 2004 through 2009, 4 isolates displayed decreased 
susceptibility to ceftriaxone (≥0.125mg/L ≤0.25 mg/L) (Florindo et al 2010).  
 
Early reports on reduced susceptibility or resistance to extended spectrum cephalosporins 
in N. gonorrhoeae isolates had appeared from Western Pacific region especially Japan 
(Ameyama et al 2002; Tanaka et al 2002, 2006; Ito et al, 2004; Ohnishi et al 2011a) and 
Australia (Tapsall et al 2008, Tapsall 2009). Such gonococcal isolates have also been isolated 
from Thailand (Clendennen et al 1992a), the Philippines (Clendennen et al 1992b), Hong Kong 
SAR (Lo et al 2008), India (Bala et al 2007), Vietnam (Cao et al 2008), South Korea (Lee et al 
2010) and China (Yang et al 2006; Liao et al 2011).  N. gonorrhoeae isolates with cefixime and 
ceftriaxone MICs as high as 2 mg/L or more were reported in Japan and China (WHO 2006; 
Guoming et al 2000; Ohnishi et al 2011a). The proportion of gonococci with decreased 
susceptibility to ceftriaxone in Western Pacific countries/regions in 2010 ranged from 1.3% in 
Singapore to 55.8% in China (WHO-WPR 2012). 
 
Limited data from Africa have not reported any isolates with reduced susceptibility and 
resistance to cefixime and ceftriaxone (Barry & Klausner 2009). Recently, Mehta et al (2011) 
had reported cefixime and ceftriaxone MIC creep in N. gonorrhoeae isolates from Kenya. 
 
N. gonorrhoeae isolates tested for antimicrobial susceptibility in 11 Latin American 
countries during 2000 and 2009 were ceftriaxone susceptible with the exception of 6% of isolates 
tested in Manaus, Brazil, in 2007 that had ceftriaxone MICs >0.25 mg/L (Starnino et al 2012).  
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Gonorrhea treatment failures with extended spectrum cephalosporins have been primarily 
reported with the use of oral cephalosporins such as cefixime (Barry & Klausner 2009). Initial 
reports of treatment failures with cefixime appeared from Japan (Ameyama et al 2002; Ito et al 
2004; Tanaka et al 2002, 2006; Takahata et al 2006) followed by Hong Kong (Lo et al 2008) and 
then from various European countries (Golparian et al 2010, Unemo et al, 2010, 2011a). 
Treatment failures with ceftriaxone, a parental cephalosporin has been reported from Australia 
(Tapsall et al, 2009b), Japan (Muratani et al, 2008; Ohnishi et al 2011a,b), Sweden (Golparian et 
al 2010, Unemo et al 2011b) and Slovenia (Unemo et al 2012b). These reports indicate that the 
current recommendations for the treatment of gonorrhea need to be reviewed and that an on-
going surveillance is highly warranted. In view of treatment failures with extended spectrum 
cephalosporins and detection of isolates resistant or with reduced susceptibility to this class of 
antibiotics, health agencies from various countries now are recommending ceftriaxone and 
azithromycin as dual therapy for treatment of gonorrhea
 
(CDC 2012; Bignell & Fitzgerald 2011; 
HPA 2011; PHAC 2011c). The trend of increased MICs for the extended spectrum 
cephalosporins in Canada and elsewhere is a critical public health concern. Therefore, an active 
surveillance i.e. incentive based surveillance is required to monitor emerging trends of cefixime 
and ceftriaxone reduced susceptibility or resistance in SK where N. gonorrhoeae susceptibility to 
this class of antibiotics is still very high.  
 
4.1.2 High Susceptibility to Azithromycin  
 
 High susceptibility of N. gonorrhoeae (99.4%) isolates from SK to azithromycin was 
observed. Azithromycin along with ceftriaxone as a combination therapy has been recommended 
for the treatment of uncomplicated gonorrhea (CDC 2012; Bignell and Fitzgerald 2011; HPA 
2011; PHAC 2011c). In Canada, 0.17% of N. gonorrhoeae isolates tested for AMR between 
2000 and 2009 were azithromycin resistant (MIC range 2-64 mg/L); however the modal MIC of 
azithromycin shifted from 0.25 mg/L in 2001 to 0.5 mg/L to 2009 in Canada (Martin et al 2011).  
 
Azithromycin resistant isolates have been detected in USA and the proportion of GISP 
isolates resistant to azithromycin has remained under 0.5% (CDC 2011; Wu et al 2011). In 2010, 
82.4% of gonococcal isolates with azithromycin MICs 8-16 mg/L were from MSM (CDC 2011). 
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Recently, N. gonorrhoeae isolates with high (MIC>512 mg/L) level of azithromycin resistance 
(Katz et al 2012) and treatment failure with 2 g of azithromycin has been reported from the USA 
(Soge et al 2012). 
 
In the Western Pacific region during 2010, no azithromycin resistance was recorded from 
Cambodia, Vietnam and India and very low rates (< 1%) of azithromycin resistance were 
reported from Australia. By contrast, 34% of tested N. gonorrhoeae isolates from Mongolia were 
resistant to azithromycin (WHO-WPR 2012). N. gonorrhoeae isolates with azithromycin MIC > 
16mg/L have been detected in Australia (Bates et al 2011). 
 
In Japan, no significant changes were observed in gonococcal susceptibility to 
azithromycin from 1993 to 2008 (Tanaka et al 2004, 2011). In Hong Kong SAR, 8% (39/485) N. 
gonorrhoeae isolates between 2005 and 2010 were classified as being resistant to azithromycin 
with an MIC range of 1-256 mg/L (Lo et al 2012). 5.3% (17/485) azithromycin resistance was 
observed in gonococcal isolates from Nanjing and Chongqing, China (Yuan et al 2011). 
Azithromycin resistance ranged between 8.2% (5/60) and 38% (20/53) in isolated collected from 
2002 through 2007 in Israel (Dan et al 2010). 
 
European Gonococcal Antimicrobial Surveillance Programme of the European 
Surveillance of Sexually Transmitted Infections (Euro-GASP of ESSTI) reported an increase in 
azithromycin resistance from 2% (24/1285) in 2008 to 13% (180/1366) in 2009 (Cole et al 2010, 
2011). Gonococcal isolates with high (MIC≥256mg/L) level of azithromycin resistance have 
been detected in Scotland (Palmer et al 2008), Italy (Starnino et al 2009), England and Wales 
(Chisholm et al 2010) and various parts of Europe (Cole et al 2010).   
 
In Africa, no azithromycin resistance has been detected in Malawi and Kenya in Africa 
(Brown et al 2010; Mehta et al, 2011). 
 
N. gonorrhoeae isolates with reduced susceptibility (azithromycin MIC=0.25-0.5 mg/L) 
and resistance (azithromycin MIC≥1mg/L) had been detected in Latin America and Caribbean 
countries during the 1990s (Dillon et al 2001a, b, 2006; Sosa et al 2003). Overall, aggregated 
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azithromycin resistance from 2000 through 2009  in 6 Latin American countries was 13% 
(1088/8373), ranging from 6% (39/646) of gonococcal isolates tested in 2000 to 23% (225/962) 
in 2009. Percentage of azithromycin resistant isolates in Argentina decreased from 10% in 2000 
to 3% in 2009. Chile reported 3% azithromycin resistance in gonococci tested in 2000 and 
increased to 46% in 2009 (Starnino et al 2012). 
 
4.1.3 Low Prevalence of Quinolone Resistant N. gonorrhoeae  
 
Development of high level of resistance to quinolones in N. gonorrhoeae isolates from 
Canada resulted in the replacement of quinolones as the recommended  treatment for gonorrhea 
in 2007 (Plitt et al 2009; PHAC 2008b, 2010b) by oral cefixime (Mann et al 2003; Sarwal et al 
2003; Ota et al 2009; Plitt et al 2009; PHAC 2010b).  
 
Aggregate ciprofloxacin
 
resistance in gonococcal isolates from SK over the nine year 
period tested in this study (2003-2011) was 4.4% (MIC 0.001-32 mg/L). The annual percentage 
of ciprofloxacin resistance in SK remained below 5% till 2009 and increased in 2010 (26%) and 
2011 (14%). Interestingly, 78% (n=7/9) of ciprofloxacin resistant isolates in 2010 were 
recovered from Regina and 80% (n=4/5) of ciprofloxacin resistant isolates in 2011 were from 
Saskatoon. These findings may indicate the presence of an outbreak of ciprofloxacin resistant N. 
gonorrhoeae isolates in the province. Since N. gonorrhoeae isolates had remained susceptible to 
ciprofloxacin for a long period (2003-2009), periodic surveys should be conducted to assess the 
ciprofloxacin susceptibility of N. gonorrhoeae in SK. This finding is interesting because PHAC 
still recommends quinolones (ciprofloxacin 500 mg or ofloaxcin 400 mg as single dose orally) as 
an alternative drug for the treatment of gonorrhea (PHAC 2011c).  
 
In Canada, the proportion of gonococcal isolates resistant to ciprofloxacin increased from 
1.3% in 2000 to 25.5% in 2009 with a peak of 30.2% in 2007 (Martin et al 2011). Similar trends 
of gonococcal ciprofloxacin resistance have been reported from Alberta (1.5% in 2001 to 27.7% 
in 2007; Plitt et al 2009) and Ontario (4% in 2002 to 27.8% in 2006; Ota et al 2009). In a recent 
study, 29% ciprofloxacin resistance was reported from Ontario, Canada (Allen et al 2011).  
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The proportion of GISP N. gonorrhoeae isolates identified as QRNG in the USA peaked 
in 2007 at 14.8% (CDC 2009). In the USA, the prevalence of ciprofloxacin resistance in 2010 
was 12.5% (CDC 2011). 
 
In many counties from the Western Pacific Region, rates of QRNG are in excess of 90% 
(WHO-WPR 2012). High prevalences of QRNG have been reported from China (98.7%, Yang et 
al 2006), Japan (70.7%, Tanaka et al 2011), Korea (86%, Lee et al 2011), India (78%-98%, 
Khaki et al 2007; Bala et al 2008; Sethi et al 2006) and Israel (27.1%, Dan et al 2010). 
Prevalence of ciprofloxacin resistant gonococcal isolates continued to increase despite the 
withdrawal of ciprofloxacin from treatment guidelines (Yang et al 2006). The proportion of 
isolates with ciprofloxacin resistance in the Western Pacific countries/regions in 2010 ranged 
between 29.2% (New Zealand) and 100% (India & Vietnam) (WHO-WPR 2012). A high 
prevalence rate of ciprofloxacin resistant gonorrhoeae isolates has been reported from various 
parts of Europe (Florindo et al 2010; Cole et al 2011; Glazkova et al 2011; Carannante et al 
2012); ciprofloxacin resistance in Europe in 2009 was 63% and increased by 12% between 2008 
and 2009 (Cole et al 2011). The burden of ciprofloxacin resistance remains disproportionately 
high in MSM worldwide (HPA 2009; Ota et al 2009; CDC 2009, 2011). 
 
In Africa, most studies on isolates collected before 2000 showed that N. gonorrhoeae 
remained susceptible to the flouroquinolones (Dan 2004; WHO 2001). However, recent studies 
have shown that QRNG have emerged and spread in various parts of Africa. For example, the 
prevalence of ciprofloxacin resistance was 7% in Cape Town in 2004 and 11% in Johannesburg, 
whereas in 2007, percentages of resistant isolates were 27% in Cape Town and 32% in 
Johannesburg (Lewis et al 2008), respectively. In a recent study, a high prevalence of 
fluoroquinolone resistance (53.2%) was recorded in N. gonorrhoeae isolates from Kenya (Mehta 
et al 2012). A high level of gonococcal ciprofloxacin susceptibility had been reported from 
Mozambique (100%) and Malawi (99%) (Apalata et al 2009; Brown et al 2010).   
 Gonococcal quinolone resistance in Latin America and Caribbean countries was rare in 
the 1990s although low level resistance was noted in several regions previously (Dillon et al 
2006; Dillon et al 2001b; Ison et al 1998; Swanston et al 1997), which reflected the limited use 
of these drugs in the region (Dillon & Pagotto 1999; Dillon et al 2001a, b). However, aggregate 
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ciprofloxacin resistance in 11 reporting countries from Latin America increased from 2% in 2000 
to 31% in 2009. Significant increases ingonococcal ciprofloxacin resistance has been reported 
from Argentina (1% in 2000 to 23% in 2009), Chile (1% in 2004 to 46% in 2009) and Peru (8% 
in 2000 and 60% in 2006) during the last decade (Starnino et al 2012).  
 
4.1.4 Sporadic Prevalence of N. gonorrhoeae Resistant to Penicillin  
 
 It is interesting to note that penicillin resistance levels in N. gonorrhoeae isolates from 
SK are much lower compared to national Canadian penicillin resistance rates (Martin et al 2011). 
The overall burden (2003-20011) of N. gonorrhoeae resistance to penicillin (MIC ≥ 2.0 mg/L) 
was 4% in SK. It seems that prevalence of penicillin resistance has not changed in SK over the 
past two decades since in a national study conducted in 1988-89, low (0-0.9%) penicillin 
prevalence was recorded from SK (Dillon 1989). This can be attributed to the removal of the 
penicillin from treatment guideline of the gonorrhea in mid 1980s (PHAC 2006) and limited 
introduction of penicillin resistant isolates from outside the province. 
 
In Canada, the nationwide prevalence of penicillin resistance in N. gonorrhoeae isolates 
decreased between 2000 and 2003 from 14.2% to 5.6% and then increased to 18.7% by 2009 
(Martin et al 2011). In a recent study from Ontario, Canada, 12.2 % penicillin resistance was 
reported (Allen et al 2011). 
 
In the USA, GISP reported approximately 10% penicillin resistance in N. gonorrhoeae 
isolates for each year since the late 80s (CDC 2009). 
 
The proportion of gonococci with penicillin resistance in Western Pacific 
countries/regions in 2010 ranged between 18.1% (New Zealand) and 96.7% (Thailand) (WHO-
WPR 2012). High prevalences of penicillin resistant gonococcal isolates have been reported 
fromChina (93.1%, Yang et al 2006), Japan (16.1%, Tanaka et al 2011) and Korea (74% to 91%, 
Lee et al 2011).  
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 The Euro-GASP of ESSTI demonstrated an overall burden of 21% penicillin resistance 
during 2006 and 2008 (Cole et al 2010). In Portugal, penicillin resistance during 2006 and 2009 
was 79.1% (Florindo et al 2010).  
 
In Latin America and the Caribbean in the 1990s, percentages of penicillin resistant 
gonococcal isolates (MIC ≥ 2.0 mg/L) varied between 48.5% in 1993 and 25.3% of isolates 
tested in 1999 (Dillon et al 2006).  Overall, aggregate resistance percentages to penicillin in 11 
countries of Latin America during 2000 and 2009 decreased from 35% to 26%. In 2009, the 
prevalence of penicillin resistance in Latin America ranged from 16% in Uruguay to 87% of 
isolates tested in Venezuela (Starnino et al 2012). 
 
The emergence of high-level, plasmid-mediated, penicillinase-producing resistance to 
penicillin was first reported in 1976 (Percival et al 1976; CDC 1976; Dillon et al 1978b). The 
overall prevalence of PPNG in SK was 0.9%; 24% of total penicillin resistance in SK. By 
comparison  the number of PPNG strains isolated in Canada 1976-1984 comprised < 1% of all 
gonococcal isolates (Dillon et al 1986), it increased to 5% in 1985 and was 9.6% in 1990 (Yeung 
et al 1990, 1991). PPNG isolates carrying the Asia type (80.2%), Africa type (15.8%) and 
Toronto type (4%) β-lactamase plasmids have been reported from Canada (Dillon et al 1986). 
The Asia, Africa and Toronto types of β-lactamase producing plasmids have been associated 
with epidemic outbreaks of gonorrhea (Dillon & Yeung 1989). The prevalence PPNG isolates in 
Canada decreased from 3.0% in 2000 to 0.9% in 2009. During this period, Africa type plasmids 
(78.8%) were the most common type among PPNG in Canada followed by the Toronto type 
(13.8%) and Asia type (6.1%) (Martin et al 2011). A decline in prevalence of PPNG was 
recorded in the USA from an annual peak of 11.0% in 1991 to 0.4% in 2007 (CDC 2009).  
 
The proportions of PPNG in Western Pacific countries/regions in 2010 ranged from 5.9% 
in Malaysia to 96.6% in China (WHO-WPR 2012). A PPNG prevalence of 37.8% (2004-2005) 
and 21% (2006) has been reported from China and Korea (Yang et al 2006; Lee et al 2011). 
34.1% of the tested N. gonorrhoeae isolates in Bangladesh were PPNG and all of these were 
African type (Alam et al 2012).   
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The overall prevalence of PPNG in Europe for 2009 was 12% (Cole et al 2011). The 
proportions of PPNG isolates in Portugal (2004-2009) and Italy (2006-2010) were 15.5% and 6% 
(Florindo et al 2010; Carannante et al 2012). Plasmid-mediated penicillin resistance was 65% in 
Mozambique (2005) and Kenya (2002-2009) (Apalata et al 2009; Mehta et al 2011). 97% of the 
PPNG detected in Kenya were Africa type and 3% were of Asia type (Mehta et al 2011). 25.8% 
of the tested N. gonorrhoeae isolates in South Africa were PPNG carrying Africa-type (35.2%), 
the Toronto-type (44.4%), and a new, Johannesburg type (20.3%) plasmid, related to the Asia-
type (Fayemiwo et al 2011).  
 
High percentages of PPNG had been noted in Latin America and Caribbean countries 
during 1990s, ranging from 17.9% to 38.8% (Moreno et al 1987; Dillon et al 2006). A recent 
survey, in the 7 countries from Latin America, reported an overall PPNG prevalence of 21% 
(Starnino et al 2012). A significant decrease in PPNG isolates was observed from 31% in 2000 to 
20% in 2009 in this region (Starnino et al 2012). 
 
4.1.5 High Prevalence of Tetracycline Resistant N. gonorrhoeae  
 
The total burden of tetracycline resistance (MIC ≥ 2.0 mg/L) in SK was 51% (2003-
2011). High levels of tetracycline
 
resistance in SK can be attributed to the selective pressure 
exerted through the doxycycline which remains one of the recommended drugs to treat C. 
trachomatis infections (Dillon and Pagotto 1999; PHAC 2010b). By comparison, in a 1988-89 
study, tetracycline resistance in SK ranged between 0 to 2.7% (Dillon 1989). Interestingly 
enough, no resistance to tetracycline was observed in 2009 and 2010 and tetracycline resistance 
levels were around 5% (2/37) in 2011.  
 
 High-level, plasmid-mediated resistance to tetracycline (TRNG, tetracycline MIC ≥16 
mg/L) was first recorded in mid-1980s (CDC 1985; Roberts et al 1988). The first TRNG isolated 
in Canada was reported in 1986 (Shaw et al 1986).  In this study, TRNG constituted 3.3% of 
total tetracycline resistance and all the TRNG were Dutch type. The prevalence of tetracycline 
resistant isolates increased from 14.3% in 2003 to 24.7% in 2009 in Canada whereas proportion 
of TRNG in Canada has decreased from 3.4% in 2000 to 1.6% in 2009 (Martin et al 2011). 
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Between 1986 and 1997, 29.1% of N. gonorrhoeae isolates tested for antimicrobial susceptibility 
in Canadian laboratories were TRNG with predominance of Dutch (79.3%) type tetM plasmids 
over  the American (20.7%) type tetM plasmids (Greco et al 2003).  
 
In the USA, GISP reported that approximately 10% of N. gonorrhoeae isolates were 
resistant to tetracycline since the late 80s (CDC 2007). The prevalence of TRNG in USA was 
5.6% in 2007 (CDC 2009). 
 
 In Shanghai, tetracycline resistance between 2004 and 2005 was 56.5% which included 
6.3% TRNG (Liao et al 2006). The proportion of TRNG has remained high in the countries of 
the Western Pacific region for many years with range a of 10% to 100% (WHO-WPR 2012). The 
rates of tetracycline resistant N. gonorrhoeae isolates in Japan (2008) and Korea (2000-2006) 
were 28.1% and 97% (Tanaka et al 2011, Lee et al 2011). TRNG prevalence in Korea from 2000 
through 2006 increased from 3% to 9% (Lee et al 2011).  
 
Euro-GASP of ESSTI reported tetracycline resistance of 60% during 2006 and 2008 and 
TRNG prevalence fairly stable at 16% (Cole et al 2010). Tetracycline resistant isolates (2006-
2010) in Italy were 38% (Carannante et al 2012).  
 
Studies in Latin America and the Caribbean  in the 1990s reported that the total burden of 
tetracycline resistance  in the region ranged from 28.6% (1994) to 52.5% (2003) (Dillon et al 
2006; Dillon et al 2001b; Sosa et al 2003). In a recent 2009 survey, in Latin American the 
prevalence of tetracycline resistant gonococcal isolates was 35% compared to 60% in 2000 
(Starnino et al 2012). Plasmid-mediated tetracycline resistance was 97% in Kenya (Mehta et al 
2011) and 77% in Mozambique (Apalata et al 2009).  
 
 All the TRNG observed in this study were Dutch type. A higher prevalence of Dutch 
type plasmids in TRNG than the American type has been reported in Canada, China and 
Bangladesh (Greco et al 2003; Yang et al 2006; Alam et al 2012). In South Africa, the America 
type was 3-fold more frequent as compared with the Dutch type (Fayemiwo et al 2011). The 
overall percentage of TRNG (2000-2009) in five Latin American countries was 10% (Starnino et 
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al 2012). No isolate with combined plasmid-mediated resistance of PPNG and TRNG 
(PP/TRNG) resistance was identified in this study. PP/TRNG is common in Canada (Carballo et 
al 1990; Dillon and Carballo 1990; Martin et al 2011). 455 PP/TRNG strains were detected in 
Canada between 2000 and 2009 (Martin et al 2011). PP/TRNG strains have been reported from 
various parts of the world (Yang et al 2006; Bala et al 2008 HPA 2008). The prevalence of 
PP/TRNG in the USA has continued to be low (0.5%) since 1999 to 2007 (CDC 2009).  
 
4.1.6 Absence of Spectinomycin Resistance in N. gonorrhoeae in Saskatchewan 
 
Spectinomycin can be an alternative regimen for treating urogenital gonorrhea in patients 
who do not tolerate cephalosporins. However, spectinomycin has limited effectiveness for the 
treatment of pharyngeal infections (CDC 2006). High levels of resistance developed when this 
antimicrobial was widely used in South-East Asia such as Korea in the mid-1980s (Boslego et al 
1987).  
 
We did not observe spectinomycin resistant isolates (MICs ≥ 128.0 mg/L; CLSI, 2009) in 
SK. However, 3.3 % of isolates with intermediate levels of susceptibility (MIC = 64.0 mg/L; 
CLSI 2009) were observed. In Canada, one PPNG isolate which was also resistant to 
spectinomycin has been previously reported (Dillon et al 1978b, 1981). Since the 1990s, 
spectinomycin resistant gonococcal isolates have not been reported in Canada (Martin et al 
2011).  
 
All N. gonorrhoeae isolates tested in 2010 from USA were susceptible to spectinomycin. 
GISP has reported in all five spectinomycin resistant isolates from the USA since 1988 (CDC 
2011). 
 
In the mid-1980s, clinical treatment failures caused by spectinomycin resistant N. 
gonorrhoeae strains were observed in US military personnel in the Republic of Korea (Boslego 
et al 1987). Sporadic gonococcal isolates (12 or less) with in vitro resistance or decreased 
susceptibility to spectinomycin have been reported from Mongolia, China, Bhutan and 
Bangladesh (WHO-WPR 2012; Ahmed et al 2010). Sporadic spectinomycin resistant isolates 
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were identified in the Venezuela and Colombia during the 1990s (Dillon et al 2006). All N. 
gonorrhoeae isolates from 2000 through 2009, tested for antimicrobial susceptibility to 
spectinomycin from 5 Latin American countries were susceptible (Starnino et al 2012). No 
spectinomycin resistant N. gonorrhoeae isolates have been identified in Europe according to 
published reports (Cole et al 2010, 2011; Starnino et al 2008; Florindo et al 2010; Glazkova et al 
2011; Carannante et al 2012).  
 
4.1.7 Conclusions 
 
AMR is an ongoing problem in N. gonorrhoeae all over the world. Effective 
antimicrobial treatment along with early detection of infection or cases is the cornerstone for 
controlling the disease since no vaccine is available against the disease. 
 
This research provides longitudinal (2003 to 20011) information on the antimicrobial 
susceptibility of N. gonorrhoeae isolated in SK, Canada. This study shows a high prevalence N. 
gonorrhoeae susceptible to currently recommended ceftriaxone and azithromycin; alternatively 
recommended cefixime and ciprofloxacin and traditionally used but no longer recommended 
penicillin for treating gonococcal infections in Canada and elsewhere. The susceptibility to these 
antimicrobials was more than 95%, an accepted definition for an antimicrobial to be used for 
gonococcal treatment. Recent investigations show that N. gonorrhoeae penicillin, ciprofloxacin 
and azithromycin resistance rates and reduced susceptibility to ceftriaxone in the Northern 
Territory, Australia are below the WHO threshold of 5.0% (Lahra 2012; Goire et al 2011) . 
These observations relate to continuous monitoring for AMR and formulation of regional 
treatment policies based on AMR characteristics of N. gonorrhoeae population in an area. The 
presence of high susceptibility of N. gonorrhoeae to penicillin and ciprofloxacin in SK 
underscores the importance of designing regional surveillance programs to monitor trends of N. 
gonorrhoeae AMR so that antimicrobials can be prudently used to ensure high cure rates for this 
treatable infection.  
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4.2 Molecular Mechanisms of Antimicrobial Resistance in Neisseria gonorrhoeae 
 
Mechanisms of antibiotic resistance in N. gonorrhoeae are of two types, i.e. chromosomally 
mediated (CMR) and plasmid-mediated resistance (Dillon & Pagotto 1999). Multiple resistance 
determinants may act synergistically to confer resistance to a single or a number of different 
antibiotics (Tapsall 2001). Plasmid-mediated resistance in N. gonorrhoeae is conferred by 
acquisition of β-lactamase-producing plasmids (PPNG) or by tetM-containing plasmids (e.g. 
TRNG) (Dillon & Pagotto 1999). 
 
4.2.1 PBP2 Pattern IX, PorB Mutations G120K,A121D and a Combination of mtrR 
Mutation in Promoter (A-) and Multimeric Region (H105Y) are Associated with Reduced 
Susceptibility to Cephalosporins in N. gonorrhoeae 
 
146 N. gonorrhoeae isolates from SK collected during 2003 and 2008 were investigated 
to determine molecular mechanisms of reduced susceptibility to cephalosporins. Sequencing and 
bioinformatic analysis was performed to determine the associations of mutations in PBP2, MtrR 
and its promoter, PorB and PBP1 with gonococcal susceptibility to cephalosporins.  
 
The transpeptidase domain of gonococcal PBP2 (penA) was polymorphic and exhibited 8 
mutation patterns, including the “mosaic” PBP2 pattern XXXIV (cefixime MIC=0.125 mg/L; 
ceftriaxone MIC=0.06 mg/L), which has been reported to be associated with reduced 
susceptibility to extended spectrum cephalosporins (Pandori et al 2009; Allen et al 2011; Unemo 
2011, 2012a,b). The predominant penA mutation patterns for all isolates combined (n=146) were 
patterns IX, I and XXII. The most common penA mutation patterns in isolates from Sydney, 
Australia were patterns XII, X and XIII (Whiley et al 2007a, b). In this study, of the majority 
(24/28, 85.7%) of isolates with penA pattern XII had high susceptibility to ceftriaxone (MIC≤
0.0008-0.03 mg/L), whereas pattern X (10/11, 91%) and XIII (11/11, 100%) were associated 
with higher ceftriaxone MICs (0.06-0.12 mg/L) (Whiley et al 2007a).  In Korea, pattern XIII was 
most common and was present exclusively (28/28, 100%) in isolates with ceftriaxone MICs 
0.06-0.25mg/L (Lee et al 2010). In this study, no isolate with penA pattern XIII was observed. 
This pattern has been reported to be one of the predominant penA patterns in isolates with higher 
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MICs to ceftriaxone by others (Whiley et al 2007a; Lee et al 2010). The most common PBP2 
mutation patterns in isolates from Shanghai, China were V, XXI and XXVII (Liao et al 2011). 
Isolates carrying penA patterns; V (7/10, 70%), XXI (8/11, 72.7%) and XXVII (5/8, 62.5%) were 
susceptible to ceftriaxone (MIC 0.004-0.016 mg/L) (Liao et al 2011). In Saskatchewan, 
gonococcal isolates with pattern IX were predominant in isolates with cefixime (16/24, 67%) and 
ceftriaxone (14/23, 61%) susceptibility group 2 (cefixime and ceftriaxone MIC ≥0.03 mg/L). 
Other predominant penA patterns observed in this study, I and XXII were almost exclusively 
present in isolates in cefixime and ceftriaxone susceptibility group 1 [(pattern I: cefixime, 39/41, 
95%; ceftriaxone, 39/41, 95%) and (pattern XXII: cefixime 33/35, 93.3%; ceftriaxone 32/35, 
91.4%)].  
 
It has been reported that PBP2 mutations G542S, P551S and P551L are associated with 
increased ceftriaxone MICs (0.016-0.6 mg/L) (Whiley et al 2010). Structural homology 
modeling of gonococcal PBP2 have shown that P551S along with F504L, decreases the 
penicillin acylation rates and may also contribute to reduced susceptibility to cephalosporins 
(Powell et al 2009). Amino acid substitutions P551S and P551L along with F504L were present 
in PBP2 patterns IX and XII observed in this study. F504L was also observed in patterns without 
P551S/L; PBP2 patterns (II, V, XIV, XXII and XXXIV) not associated with isolates with higher 
MICs (≥0.03 mg/L) to extended spectrum cephalosporins.  This observation supports the role of 
P551S/L in imparting reduced susceptibility to cephalosporins to N. gonorrhoeae as reported by 
others (Powell et al 2009; Whiley et al 2010). 
 
Mosaic penA pattern XXXIV observed in this study had N512 and G545S substitutions 
contributing to reduced susceptibility to cephalosporins but A501substitution, vital to raise 
cephalosporin MICs above break points was absent (Tomberg et al 2010). A501V substitution is 
present only in penA non-mosaic patterns (Ohnishi et al 2011b).  The introduction of A501V by 
transformation has been shown to increase the ceftriaxone and cefixime MICs of recipient N. 
gonorrhoeae to levels above break points (Tomberg et al 2010). This is attributed to the bulkier 
side chain of amino acid valine which prevents the active site binding of the cephalosporins by 
interacting with the alkayl side chain, R1 substituent of the cephalosporin (Tomberg et al 2010).  
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 N512Y substitution in PBP2 contributes to decreased susceptibility to extended spectrum 
cephalosporins and reversion of substitution N512Y to wild type N512 decreases resistance to 
cephalosporins (Tomberg et al 2010). N512 is relatively distant from the cephalosporin binding 
active site but is located along with mutations that are known to be important for resistance to 
penicillin in non-mosaic PBP2 patterns with spontaneous mutations (Powell et al 2009; Tomberg 
et al 2010). PBP2 mutations I312M, V316T and G545S mutations in PBP2 are also reported to 
contribute to higher extended spectrum cephalosporin MICs indirectly in the presence of other 
PBP2 mutations (Tomberg et al 2010). These mutations have been classified as epistatic 
mutations which are permissive substitutions of no immediate consequence but stabilize specific 
elements of the protein and allow it to tolerate subsequent function-switching changes (Ortlund 
et al 2007). The reversion of these mutations back to the wild type; I312, V316 and G545 
decreases the cephalosporin MICs (Tomberg et al 2010). penA fragments amplified in this study 
were between AA 340 and 570, therefore presence of substitutions at amino acid positions I312 
and V316 was not observed. Other studies have demonstrated the presence of I312M and V316T 
substitutions along with G545S in pattern XXXIV (Pandori et al 2009; Ohnishi et al 2011b).  
 
PBP2 pattern IX (D345a, F504L, A510V, A516G, P551L), the predominant patterns 
observed in this study was significantly associated with decreased susceptibility to ceftriaxone 
(0.03-0.06 mg/L) and cefixime (0.03-0.125 mg/L) (Susceptibility group 2 isolates). Population 
studies on gonococcal extended spectrum cephalosporins susceptibility have reported presence of 
penA pattern IX with ceftriaxone MIC 003-0.06 (Whiley et al 2007a) and 0.12-0.25 mg/L (Liao 
et al 2011).  Pattern IX has F504L and P551L substitutions decreasing the acylation of active site 
but does not contain A501V, N512Y, I312M, V316T and G545S substitutions which have been 
associated with reduced cephalosporin susceptibility (MIC≥0.25 mg/L) (Powell et al 2009; 
Tomberg et al 2010; Whiley et al 2010). The elevated MICs (0.03-0.06 mg/L) of cefixime and 
ceftriaxone of isolates carrying pattern IX can be attributed to decreased acylation of active site 
due to F504L and P551L substitutions.  
 
Analysis of mtr repressor (mtrR) and its promoter revealed 12 different mutation patterns 
derived from mutations in different regions of MtrR. Predomiant mtrR mutation patterns 
observed in this study were  G45D, A-; G45D and A-; H105Y.  
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The most commonly reported mtrR mutation is a single base pair deletion (A-) located in 
the inverted repeat that is between the -10 and -35 the mtrR promoter (Lucas et al 1997; 
Zarantonelli et al 1999; Xia et al 2000; Ng et al 2002; Cousin et al 2004; Tanaka et al 2006). 
Hagman and Shafer (1995) had proposed that the promoter mutation abrogates mtrR 
transcription. N. gonorrhoeae strains containing a single-base-pair adenine deletion (A-) in a 13-
bp inverted repeat within the mtrR promoter show elevated mtrCDE transcription (Lucas et al 
1997). Due to this deletion mtrR RNA polymerase cannot interact with the mtrCDE promoter 
that partially overlaps with the mtrR promoter at the -35 region (Lucas et al 1997). Population 
studies have shown the presence of A- in a high proportion of N. gonorrhoeae isolates with 
reduced susceptibility to extended spectrum cephalosporins (Lindberg et al 2007; Lee et al 2010; 
Allen et al 2011).  
 
Twenty three percent of ceftriaxone and cefixime susceptibility group 1 isolates and 
approximately 4% in susceptibility group 2 N. gonorrhoeae isolates contained an “A” deletion in 
the 13bp inverted repeat sequence of the mtrR promoter. Among all the mtrR mutations observed 
in this study, only A-; H105Y was found associated with both ceftriaxone and cefixime 
susceptibility group 2 N. gonorrhoeae. This combination has not been previously reported in 
isolates with reduced susceptibility to cephalosporins. The H105Y mutation probably inhibits 
MtrR dimerization and subsequently further reduce MtrR DNA binding (Shafer et al 1995; 
Warner et al 2008), or it could enhance binding of antibiotic to MtrR which could then serve as a 
sink for the antibiotic (Liao et al 2011).  
 
A39T and G45D substitutions abrogate MtrR binding to the target DNA upstream of 
mtrCDE and enhance gonococcal resistance to hydrophobic antimicrobials (Hagman and Shafer 
1995; Shafer et al. 1995). In this study, 53% isolates from ceftriaxone and cefixime susceptibility 
group 1 were with G45D substitution whereas approximately 65% isolates in ceftriaxone and 
cefixime susceptibility group 2 had this mutation. In this study, no significant association was 
observed between A39T, G45D or A-/G45D in mtrR with any of the cefixime and ceftriaxone 
susceptibility groups. 
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PorB, a porin, allows the passage of small molecules, such as β-lactams and tetracyclines, 
through the outer membrane (Danielsson et al 1986). Mutations at amino acid 120 and/or 121 in 
PIB alter the conformation of loop3 to decrease the influx of antibiotics into the periplasmic 
space (Olesky et al 2002). Eleven different mutation patterns in PorB at G120;A121 and one at 
A121S;N122K were observed in this study. Double mutations in PorB, G120D;A121K have 
been associated with reduced susceptibility of N. gonorrhoeae isolates to extended spectrum 
cephalosporins (Lindberg et al 2007; Zhao et al 2009; Lee et al 2010, 2011; Martin et al 2012). I 
also found this to be the case with the isolates studied from SK and gonococcal isolates with 
G120D;A121K was associated with extended spectrum cephalosporins group 2 isolates. The 
distribution of PorB mutations observed in gonococcal isolates from SK was different from that 
reported from Canada in other studies. Population studies on gonococcal AMR from Canada 
(Allen et al 2011; Martin et al 2012) showed predominance of G120K;A121N in N. gonorrhoeae 
isolates with reduced susceptibility to extended spectrum cephalosporins. This pattern was 
present in 1% (ceftriaxone) to 2% (cefixime) of cephalosporin susceptibility group 2 isolates.  
 
It has been reported that the L421P mutation in PBP1 is present in N. gonorrhoeae 
isolates which have reduced susceptibility to extended spectrum cephalosporins (Takahata et al 
2006; Lindberg et al 2007; Allen et al 2011; Martin et al 2012). But genetic studies had shown 
that the L421P mutation in PBP1 does not contribute to reduced susceptibility to extended 
spectrum cephalosporins since PBP1 is not a target for the action of extended spectrum 
cephalosporins as with penicillin (Zhao et al 2009). A significant association was observed 
between the L421P mutation in PBP1 and isolates with cefixime and ceftriaxone MICs 
≥0.3mg/L.  
 
4.2.2 PBP2 Pattern IX and DNA Binding Domain Mutation G45D in mtrR are Associated 
with Penicillin Resistance in N. gonorrhoeae 
 
  Not many studies have related PBP2 patterns with penicillin susceptibility. Individual 
contributions of different PBP2 patterns except for pattern I, X and penAH041 (mosaic penA allele) 
to gonococcal penicillin resistance were not determined (Ropp et al, 2002; Zhao et al 2009; 
Ohnishi et al 2011b). penAH041 is present in N. gonorrhoeae isolate H041, recently isolated in 
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Japan with high level of penicillin, ciprofloxacin, cefixime and ceftriaxone resistance (Ohnishi et 
al 2011b). A significant association was observed between penA allele IX and Pen
R
 (MIC=2-
4mg/L) and Pen
I
 (MIC=1mg/L). This PBP2 pattern has been reported by others to be present in 
gonococcal isolates with penicillin MICs of 2-128 mg/L (Whiley et al 2007a; Liao et al 2011). 
PBP2 pattern I was significantly associated with Pen
S
 gonococci as reported by Whiley and 
others (2007a). The isolate with mosaic pattern XXXIV was Pen
I
 (MIC=0.5mg/L). Gonococcal 
isolates with this pattern have been reported to have Pen
I
 (MIC=1mg/L) (Allen et al 2011; 
Unemo et al 2012a) or Pen
R
 (MIC=2mg/L) (Allen et al 2011).  
 
Analysis of mtrR mutations for penicillin resistance revealed the association of mtrR 
mutations G45D and A-;G45D with Pen
I
 whereas only G45D was significantly linked to Pen
R
. 
This suggests that the substitution G45D plays an important role in the development of 
gonococcal penicillin resistance. mtrR mutation combination A-;H105Y which was significantly 
associated with  cefixime and ceftriaxone susceptibility group 2 had no association with Pen
R
. 
 
A high proportion (31%) of the isolates with intermediate susceptibility to penicillin 
carried G120D and A121N mutations whereas the majority of Pen
R
 (60%) isolates carried 
G120K and A121D mutations. This is in agreement with earlier transformation studies which 
demonstrated that PIB at positions G120 and/or A121 with charged amino acids such as Lys (K), 
Arg (R), His (H) and Asp (D) are capable of conferring antibiotic resistance in N. gonorrhoeae. 
Substitution with Asp at either position 120 or 121 conferred only partial resistance to penicillin 
(Olesky et al 2002). 
 
The L421P mutation of PBP1 is also present in N. gonorrhoeae isolates resistant to 
penicillin (Shigemura et al 2005; Lee et al 2010). PBP1 is one of the targets for penicillin action 
although compared to PBP2, a 10-fold higher concentration of penicillin is required to act on 
PBP1 to inhibit penicillin susceptible gonococcal strains (Barbour, 1981).  A significant 
association was observed between Pen
I
 and Pen
R
 and the L421P mutation in PBP1as did Lee et 
al (2010) and Ropp et al (2002). 
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4.2.3 Association of GyrA, ParC and MtrR Mutations with Ciprofloxacin Resistance in N. 
gonorrhoeae 
 
The combinations of the amino acid substitutions in GyrA and ParC of gonococcal 
QRDRs form diverse mutation patterns (Uehara et al 2011; Starnino et al 2010; Chen et al 2010; 
Yang et al 2006; Giles et al 2004; Su& Lind 2001; Yoo et al 2004; Ng et al 2002b; Trees et al 
1999, 2001). Four QRDR mutation patterns were observed in ciprofloxacin resistant (MIC≥ 
1mg/L) and intermediately susceptible (MIC≥ 0.5mg/L) isolates in this research. The majority of 
the reported QRDR mutation patterns have a double mutation in GyrA (Ser91Phe and 
Asp95Gly/Asn), combined with a single mutation (Ser-87Arg) in ParC (Starnino et al 2010; 
Chen et al 2010; Ng et al, 2002). In this study, mutations in gonococcal ParC (Ser87Arg and 
Ser87Arg and Ser88Pro) were present in 2 isolates with intermediate susceptibility (MIC=0.5 
mg/L) to ciprofloxacin. This is contrary to some studies in which ParC mutations have been 
correlated with high level of quinolone resistance (Belland et al 1994; Tanaka et al 1998).           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
Bacterial efflux pumps that export antibiotics can have important implications for the 
efficacy of antibiotic treatment of infections (Nikaido 1994). Mutation in genes encoding drug 
efflux pumps also contribute to resistance along with  mutations in enzymes GyrA and ParC 
(Ilina et al 2008; Marcusson et al 2009). In this study, ciprofloxacin
 
resistance was also 
significantly associated with mtrR mutation, A-;H105Y and both the isolates with ciprofloxacin 
intermediate susceptibility were linked with truncated mtrR. These mtrR alterations, A-;H105Y 
and truncated mtrR have not been reported in earlier studies  investigating  the role of mtrR 
mutation in imparting ciprofloxacin  resistance to gonococci (Starnino et al 2010; Chen et al 
2010). 
It has been suggested that high percentages of ciprofloxacin resistant isolates can be 
maintained in a population because of the fitness advantage provided by mutations in GyrA 
(Kunz et al 2012; Dillon & Parti 2012, Sadiq et al 2010). But this advantage can be abrogated by 
a mutation in parC, which confers a high level of resistance and fitness can be restored by 
compensatory mutations in mtrR and GyrA. The survival fitness of ciprofloxacin resistant 
gonococci in Saskatoon since the gonococcal isolates after 2008 were not available for DNA 
sequence analysis. Ciprofloxacin resistant isolates detected in our study had mutation in GyrA, 
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ParC and mtrR but at residues different from those investigated in survival fitness (Kunz et al 
2012; Dillon & Parti 2012). QRNG may last for years even though selection pressure has been 
removed by dropping ciprofloxacin from treatment guidelines for gonorrhea (Kunz et al 2012; 
Dillon & Parti 2012). Therefore, continued surveillance of QRNG is required in SK where 
QRNG are emerging much later compared to other parts of the world. 
 
4.2.4 Role of mtrR and 23SrRNA Mutations in Azithromycin Resistance in N. gonorrhoeae 
 
Azithromycin belongs to the macrolide-lincosamide-streptogramin family and can be 
administered orally in a single dose to treat gonorrhea (WHO 2003). Multiple mechanisms of 
resistance to azithromycin have been recorded. These involve A-, TT+ (dinucleotide insertion in 
mtrR promoter), A39T, R44H and A-;H105Y in mtrR and C2611T and C2599T in 23S rRNA 
(Galarza et al 2010; Wu et al 2011; Soge et al 2012). Two azithromycin resistant N. gonorrhoeae 
(MIC=2mg/L & 8mg/L) detected in this study had C2611T mutation in all four alleles of 23S 
rRNA along with a G45D in mtrR DNA binding domain.    
 
In this study, all isolates with  azithromycin MIC 1.0 mg/L had mtrR mutations; A39T, 
G45D, A-/G45D and A-/H105Y. We did not find 23S rRNA methylase genes (ermA, ermB, 
ermC and ermF) in any of the gonococcal isolates investigated for molecular mechanisms of 
azithromycin resistance. 
 
The detection and isolation of strains with resistance to azithromycin is of concern 
especially in the context of the emergence of cephalosporin resistance among N. gonorrhoeae 
and recommendation of azithromycin along with ceftriaxone for treatment of gonococcal 
infections. Emergence and spread of strains of N. gonorrhoeae with azithromycin resistance will 
further limit the treatment options available for N. gonorrhoeae infections. 
 
High-level azithromycin resistance (≥256 mg/L) develops rapidly with a single mutated 
allele of 23S rRNA. It presents the possibility that high-level azithromycin resistance could 
develop from an apparently sensitive isolate in vivo under a selection pressure. This can occur 
easily in gonorrhea patients prescribed azithromycin to treat C. trachomatis co-infection. 
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(Chisholm et al 2010). The development of N. gonorrhoeae strains with high level of 
azithromycin resistance by a point mutation in the 23S rRNA highlights the importance of 
treating gonorrhea with recommended therapies to prevent selection and dissemination of 
gonococcal strains with high levels of azithromycin resistance. 
 
4.2.5 Specific Combinations of Individual Mutations penA, mtrR and porB are Associated 
with Gonococcal Cephalosporin and Penicillin Susceptibility  
 
The combined mutation patterns in penA, mtrR and porB were associated with 
gonococcal susceptibility to extended spectrum cephalosporins and penicillin. Ilina and others 
(2008) demonstrated the presence of penA, porB, ponA, mtrR, gyrA and parC mutations 
implicated in gonococcal AMR in N. gonorrhoeae isolates susceptible to penicillin, tetracycline 
and ciprofloxacin. penA/mtrR/porB combined mutation pattern I/WT/WT and was significantly 
associated with  N. gonorrhoeae isolates susceptible to extended spectrum cephalosporins and 
Pen
S
. In this study, isolates with higher cefixime MICs (0.03-0.125; Group 2) were found to be 
significantly associated with pattern IX/ G45D/ G120K;A121D. Penicillin resistance was 
significantly associated with combined mutation patterns, IX/ G45D/G120K;A121D and 
IX/G45D/G120D;A121D.  
 
These findings indicate that certain combined mutation patterns may be predictive of 
antimicrobial susceptibility. Increasing use of NAATs for the diagnosis of gonorrhea on clinical 
specimens (urine) had resulted in lesser recoveries of N. gonorrhoeae clinical isolates. Thus MIC 
determination on clinical isolates has become impossible in most cases. Therefore, molecular 
methods of diagnosis based on combined mutation patterns can detect antimicrobial resistance 
and predict trends and emergence of AMR from non invasive specimens. 
 
4.2.6 Conclusions 
 
This research systemically examined mutations in various loci in association with 
gonococcal resistance to different antibiotics. It is the first report with regards to molecular 
mechanisms of resistance to various antibiotics including extended spectrum cephalosporins in 
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N. gonorrhoeae isolates from Saskatchewan. Results of this study show that the molecular 
factors associated with high MICs of cefixime and ceftriaxone include a PBP2 pattern IX, 
simultaneous mutations (A-; H105) in MtrR promoter and multimeric region, and PorB 
substitution at G120 and A121 with charged amino acids. The correlation of A-/H105 in higher 
extended spectrum cephalosporins (cefixime and ceftriaxone) was demonstrated for the first time 
in this study. Penicillin resistance was correlated to G45D substitution in MtrR DNA binding 
domain mutations and combination of adenine deletion in mtrR promoter and G45D (A-; G45D). 
This study is the first to identify the occurrence of multiple mutations in azithromycin resistant 
isolates from Canada. Investigation of molecular determinants of resistance i.e. PBP2, MtrR, and 
PorB revealed that specific combination of mutations involving individual alterations in these 
genes are associated with different cefixime and penicillin susceptibility and resistance 
phenotypes. 
 
4.3 Population Dynamics and Evolution of Antimicrobial Resistance in Neisseria 
gonorrhoeae in Saskatchewan 
 
This study confirms that both porB DNA sequence analysis and NG-MAST analysis have 
high discriminatory powers sufficient to distinguish N. gonorrhoeae isolates and to identify 
circulating clusters of strains. The indices of discrimination recorded in this study for modified 
(765bp; ≈77% of porB sequence) porB typing and NG-MAST were 0.94 and 0.96. These 
findings are in line with the recent studies comparing these two typing schemes (Liao et al 2009; 
Ilina et al 2010; Heymans et al 2011). 
 
  NG-MAST appears to be a leading method for N. gonorrhoeae typing (Martin et al 
2004; Unemo & Dillon 2011) with an index of discrimination (ID) ≥95% (Liao et al 2009; Ilina 
et al 2010; Heymans et al 2012; Kushnir et al 2012).  
 
It has been suggested that porB typing is less expensive and more rapid than sequencing 
the entire porB gene and NG-MAST and provides comparable ID (Liao 2009). The modified 
porB typing requires single PCR reaction and 2 DNA sequencing reactions. To obtain sequences 
of the entire porB gene, four DNA sequencing reactions for each strand are often needed to 
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achieve unambiguous sequence results (Liao et al 2009). NG-MAST typing also involves two 
PCR and four DNA sequencing reactions.  
 
The index of discrimination of MLST scheme based on seven housekeeping genes used 
in this study for N. gonorrhoeae isolates (2005-2009) was 0.89. Ilina et al (2010) had reported ID 
value of 0.91 by MLST with seven housekeeping genes. The discriminatory ability of the present 
MLST schemes, examining seven housekeeping loci, is suboptimal (<0.9). Therefore, it has been 
suggested that to differentiate clonal populations detected by MLST, the loci sequenced should 
also include more rapidly evolving loci in addition to housekeeping genes (Urwin & Maiden 
2003). A higher ID value of 0.953 has been reported for MLST using 10 housekeeping loci 
(Vidovic et al 2011).  
 
porB typing and NG-MAST have high ID but result in over discrimination of N. 
gonorrhoeae. In my study, this observation was  highlighted from the fact that 3 major MLST-
STs (ST-1, ST-2 and ST-3) comprising 101 (2005-2008) isolates were differentiated into 26 STs 
each by porB typing and NG-MAST. MLST ST-1, ST-2 were ST-3 resolved into 15 and 16 STs, 
9 and 7 STs and 6 and 4 STs by porB typing and NG-MAST. This has also been observed by 
others for porB typing and NG-MAST (Ilina et al 2010; Mavroidi et al 2011). It has been 
suggested that distorting effects among genetically related isolates can arise in typing schemes 
that are based on the hyper-variable genes. For example, porB and tbpB DNA sequence can be 
subjected to frequent mutation and recombination, this may lead to a failure to identify the 
predominant related strains of N. gonorrhoeae that circulate within community (Vidovic et al 
2011). MLST which is based on concatenated sequences of house- keeping has the ability to 
provide a buffer against the distorting effects of mutations and recombinations resulting in the 
maintenance of clonal stability of N. gonorrhoeae isolates.  
 
4.3.1 Clustered Distribution of Antimicrobial Resistance/Susceptibility in N. gonorrhoeae 
Revealed by porB-based Typing, NGMAST and MLST Analysis  
 
All the three typing schemes i.e. modified porB typing, NG-MAST and MLST used in 
this study revealed that antibiotic resistant and susceptible N. gonorrhoeae isolates in SK belong 
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to different clusters. Three predominant STs observed through porB typing and NG-MAST 
accounted for 36% and 28% of 320 gonococcal isolates typed with these schemes. Both for porB 
typing and NG-MAST more that 50% of isolates were grouped under ≤10 STs.  
 
  The average number of isolates per NG-MAST ST was 3.9 and the number of isolates per 
porB ST was 4.5. The average number of isolates per ST observed through porB typing and NG-
MAST in this study was higher compared to those reported by others (Unemo et al 2007; Olsen 
et al 2008; Ilina et al 2010). The reported number of isolates per porB-ST ranged from 1.24 
(Unemo et al 2003) to about 2.0 isolates (Unemo et al 2007; Olsen et al 2008; Liao et al 2009; 
Ilina et al 2010) and for NG-MAST the range was 1.7 (Unemo et al 2007; Olsen et al 2008; Ilina 
et al 2010) to 2.4 isolates per ST (Martin et al 2004; Palmer & Young 2006; Abu-Rajab et al 
2009; Liao et al 2009). Large gonococcal clusters were identified by the porB-based typing and 
NG-MAST. For example, 57 isolates exhibited an identical porB ST 109, and 46 of these isolates 
also displayed a single NG-MAST ST 25. Identification of a large group of isolates as single ST 
and high average number of isolates per porB and NG-MAST ST implies that N. gonorrhoeae 
isolates in SK are related by genotype.  
 
  Molecular epidemiological studies can provide novel information on the emergence and 
dissemination of antimicrobial resistant gonococcal clones. Tetracycline resistance was present 
across the majority of STs detected through porB typing and NG-MAST in this study. TRNG 
(tetracycline MIC ≥16 mg/L and β-lactamase negative) had a clustered distribution and were 
exclusively associated with porB ST-130 and NG-MAST ST-3711. The endemic presence of 
tetracycline resistance may be attributed to the history of tetracycline and doxycycline use in the 
co-treatment of chlamydial infections as these antibiotics are not recommended for the primary 
treatment of gonorrhoea in Canada (PHAC 2010b). CMRNG (69%) observed in this study 
appeared as porB ST-111 and NG-MAST ST-3654.  
 
All the isolates resistant to ciprofloxacin (n=5) and azithromycin (n=2) appeared as single 
porB and NG-MAST STs suggesting a sporadic presence of AMR to these antimicrobials. 
Around 40 % of the isolates susceptible to all the tested antimicrobials in this study were 
grouped as porB ST-109 and NG-MAST ST-25. 
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Several studies have shown a clustered distribution, as ascertained by NG-MAST 
analysis, of N. gonorrhoeae isolates which are resistant to ciprofloxacin, azithromycin orwith  
reduced susceptibility to extended spectrum cephalosporins (Palmer et al, 2005; Palmer & 
Young 2006; Moodley et al 2006; Palmer et al 2008; Starnino et al 2008, 2009; Monfort et al 
2009; Martin et al 2012; Heymans et al 2012; Buono et al 2012) and  porB typing (Liao et al 
2008) or both (Lundback et al, 2006; Unemo et al 2007; Lindberg et al 2007; Ilina et al 2010). 
Not many studies have shown clusters of N. gonorrhoeae isolates resistant to penicillin and 
tetracycline as determined using NG-MAST or other molecular typing methods.  
  The grouping of predominant porB and NG-MAST STs and on the basis of <1% bp 
difference from predominant STs indicated that the gonococal population in SK is related. The 
grouping of predominant porB and related porB STs (STs with 1-7 bp difference from 
predominant porB ST) together stratified 320 isolates into 13 groups with ID of 0.87. porB 
groups 109 and 108 were the most prevalent groups followed by porB group 111. porB groups 
108 and 141 were the major groups in CMTR isolates. porB group 109 was the predominant 
group in susceptible isolates. The classification of the NG-MAST STs (NG-MAST group), 
sharing one identical allele (porB or tbpB) and differing by ≤ 1% bp at the other NG-MAST 
allele identified 29 NG-MAST groups with an ID of 0.93. The major NG-MAST groups were 25, 
3655 and 921. In CMTR isolates, 12 NG-MAST groups were observed. NG-MAST group 25 
was predominant in susceptible isolates.  
 
One isolate in this study appeared as NG-MAST ST1407, ciprofloxacin MIC 8.0 mg/L, 
ceftriaxone MIC 0.125 mg/L, cefixime MIC 0.06 mg/L in this study. NG-MAST ST1407 carried 
PBP2 mosaic pattern XXXIV, was recovered in 2006 from SK, and was first identified in 
Scotland in 2007. This strain type has been marked as one of the most successfully distributed N. 
gonorrhoeae strain types all over the world and with resistance to penicillin, tetracycline 
(TRNG), ciprofloxacin and reduced susceptibility to extended spectrum cephalosporins (Florindo 
et al 2010; Golparian et 2010; Tapsall et al 2010; Eastick 2010; Tanaka et al 2011; Unemo et al 
2012; Martin et al 2012; Hess et al 2012; Chisholm et al 2013). ST1407 has been reported from 
Canada (Martin et al 2012), but only one such isolate was observed in this study involving 
screening of 320 isolates obtained over a period of 6 years (2003-2008). The prevalence this NG-
MAST ST is needed to be determined in the province after 2008, since isolates from 2010 and 
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2011 had shown a substantial increase in ciprofloxacin resistance commonly associated with 
ST1407, along with reduced susceptibility to extended spectrum cephalosporins.  
 
  The average number of isolates per MLST ST was 6.7 whereas 3.4 and 9.8 N. 
gonorrhoeae isolates per MLST-ST were observed using different MLST schemes from the one 
used in this study (Ilina et al 2010; Mavroidi et al 2011). Three predominant STs were observed 
through MLST accounting for 52% of the 193 gonococcal isolates typed. The predominant 
MLST ST-1 was found as an ancestor of the major clonal complex, suggesting that this 
circulating strain has been present in SK for a long period. With MLST, 46 N. gonorrhoeae 
isolates were ST-1 and these same isolates exhibited 15 and 16 STs through NG-MAST and 
porB typing. All the TRNG in MLST appeared as MLST ST-20 which is not associated with any 
other antibiotic resistant and susceptible isolates. In MLST, CMRNG were observed among the 
major gonococcal lineages, further suggesting that this phenotype was probably acquired in SK 
as a result of spontaneous mutations in established lineages (ST-1, ST-3 and ST-25). The clonal 
complexes with SLV observed through MLST and eBURST analysis had two to five STs with 
the number of gonococci ranging from two to 52 isolates. The depiction of ciprofloxacin 
resistance across the gonococcal lineages on the minimum spanning tree suggests that 
ciprofloxacin resistance was acquired independently from genetically distant lineages rather than 
by clonal expansion. All gonococcal lineages resistant to ciprofloxacin were positioned at the 
edges of the minimum spanning tree, indicating a very distant genetic relatedness to the major 
gonococcal lineages and further suggesting that ciprofloxacin resistance was most likely 
introduced from outside of the province.  In MLST, susceptible isolates were grouped under 
MLST ST-29 and had a SLV from MLST ST-24.  
 
This study for the first time demonstrated clonal expansion of resistance determinants of 
N. gonorrhoeae on the basis of NG-MAST. Specific PBP2/MtrR/PorB mutation combinations 
were found to be associated with NG-MAST STs. Isolates with NG-MAST ST 25 were 
associated with PBP2 (penA)/MtrR (mtrR)/PorB (porB) pattern I/WT/WT and with antibiotic 
susceptibility. NG-MAST ST 3654 was associated with penA/mtrR/porB pattern 
IX/G45D/G120K;A121D and resistance phenotype CMRNG, CMTR isolates and isolates of 
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cefixime susceptibility group 2.  Isolates with chromosomal resistance to tetracycline were 
significantly (P<0.05) associated with several STs and penA/mtrR/porB patterns.  
 
This is the first approach where regional AMR data along with molecular typing has been 
used to determine dissemination of molecular determinants of resistance. This can provide 
enhanced surveillance of AMR in gonorrhoea since the presence of different STs from a region 
can be correlated with occurrence of AMR to specific antibiotic(s). Future studies involving 
higher number of gonococcal isolates recovered from larger populations will help in establishing 
more reliable and better correlation between occurrence of AMR and STs. 
 
4.3.2 porB Typing and NG-MAST is a Useful Tool for Short Term Epidemiological Studies 
in  N. gonorrhoeae  
 
Short term epidemiological or microepidemiological analysis focuses on the 
identification of community epidemics; strains in an entire population over a limited time (6 
months to on year); strains from sexual networks; identifying the emergence and transmission of 
individual (e.g., antimicrobial-resistant) strains; confirmation or discrimination of presumed 
epidemiological connections in suspected clusters of infection; contact tracing, and the 
characterization of bacterial clones. It has been suggested that full- or extended length porB 
sequence analysis and NG-MAST which are based on hyper-variable loci are more suitable for 
microepiemiological studies (Unemo & Dillon 2011). Both porB typing and NG-MAST methods 
can identify clusters of circulating strains and their epidemiological links (Choudhury et al 2006; 
Liao et al 2009).  
 
The porB ST-108, the second most predominant ST observed in this study had a single bp 
difference from ST 114 and 131. Two bp differences were observed between ST-114 and 131. 
All these STs were grouped as porB group 108 on the basis of <1% bp difference in amplified 
porB sequence. This means that a large cluster of similar isolates i.e porB group 108 was divided 
into 3 different STs; 108, 114 and 131 due to minor alterations in a hyper-variable gene, porB.  
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Major NG-MAST STs detected during this study shared either porB (508:3656) or tbpB 
alleles (25:3657; 3654:3653 & 508:3655). tbpB alleles of NG-MAST ST-508 (tbpB 28) and NG-
MAST ST-3656 (tbpB 821) had only one bp difference and appeared as CMTR and CMRNG in 
this study. STs 508 and 3655 NG-MAST STs were predominantly associated with CMTR N. 
gonorrhoeae isolates and had only one bp difference in porB (356:2195) and grouped as NG-
MAST group 3655.  
 
 These finding clearly show that minor variations in hyper-variable genes utilized in porB 
typing NG-MAST prevented assigning new STs to the similar gonococcal strains.  This suggests 
that large clusters of N. gonorrhoeae isolates observed over the years have been classified to 
different strain types. These STs gradually diminish and appear as new STs owing to mutations 
in porB and tbpB. This suggests that porB typing and NG-MAST is a better scheme for 
molecular epidemiological studies on N. gonorrhoeae isolates.  
 
4.3.3 MLST Analysis is Useful in Determining the Long Term Epidemiological Studies and 
Evolution of Antimicrobial Resistance in N. gonorrhoeae 
 
Macroepidemiology, or long-term or global epidemiology involves the study of bacterial 
population dynamics over many years or decades. Therefore, a typing scheme used for studying 
macroepidemiology should be based on several conserved and evolutionarily neutral genes 
(Unemo & Dillon 2011). Genetic relatedness of a bacterial population is more certain through 
MLST genotyping, method based on housekeeping genes than genotyping methods based on 
antigen-encoding genes such as porB and tbpB in N. gonorrhoeae.  These antigen-encoding 
genes are under positive selection pressure and change rapidly over the short term (Urwin & 
Maiden 2003; Vidovic et al 2011).  
 
MLST appears to be more suitable for long-term epidemiological studies than is NG-
MAST and porB typing. This conclusison was drawn on analyzing  major MLST-STs (STI-1, 
ST-2, ST-3 and ST-5) present in all the four years (2005-2008), and their comparison with NG-
MAST and porB STs.  Forty-six N. gonorrhoeae isolates clustered as ST-1 by MLST were 
differentiated into 15 and 16 STs through NG-MAST and porB typing. MLST ST-2 (n=24) were 
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resolved as 7 NG-MAST STs and 9 porB STs. 31 isolates associated with MLST ST-3 were 
grouped as 4 NG-MAST STs and 6 porB STs. Only one porB and NG-MAST ST appeared for 
all the four years in isolates grouped under MLAST STs; 1, 2 and 3. This shows that porB typing 
and NG-MAST, which are based on hyper-variable genes, have less genetic stability i.e. more 
genetic variation between similar STs. Therefore, typing schemes such as MLST, which are 
based on conserved housekeeping genes, are more suitable for macroepidemiological studies, 
and the typing schemes revealing hyper-variable loci are more useful with short-term studies. 
 
4.3.4 Conclusions 
 
This research used three different typing methods i.e., porB typing NG-MAST and 
MLST and established a clustered distribution of gonococci in SK.  The STs identified by typing 
schemes based on hyper-variable genes, modified porB based typing and NG-MAST were 
further grouped into MLST strain types, a typing scheme based on housekeeping genes. The 
MLST scheme used in this study was able to demonstrate that the gonococcal population in SK 
has evolved within the province with very little intrusion from outside. It is suggested that 
molecular epidemiological studies based on conserved genetic markers along with those based 
on hyper-variable loci will provide a desired balance of genetic stability and ability to 
discriminate. 
 
Significant associations were observed between mutation pattern combinations in penA, 
mtrR and porB and STs. This indicates that certain combined mutation patterns can be predictive 
of antimicrobial susceptibility, and are useful for molecular diagnosis. 
 
The predominant porB and NG-MAST STs observed in this study differed by minor 
variations in DNA sequences. The predominant STs detected through MLST were present 
throughout the study period. It is concluded that MLST is a better epidemiological tool for long 
term studies, whereas NG-MAST and porB typing are more suited for short term studies. It is 
important that standardized guidelines are established for using the  porB based typing scheme, 
which has a sufficient index of discrimination and is cheap and less time consuming, compared 
to NG-MAST and full length porB typing. A porB based DNA sequence database for N. 
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gonorrhoeae should be established comparing molecular epidemiology of N. gonorrhoeae 
worldwide. 
 
This study shows a clear association between AMR and STs. The molecular 
epidemiological tools used in this study have demonstrated clustered distribution of AMR among 
gonococcal isolates from SK. This highlights the potential of molecular epidemiological typing 
as a tool to predict AMR. 
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Gonorrhea, caused by the Gram-negative bacterial pathogen N. gonorrhoeae, remains a 
global public health problem. Control of gonorrhea relies on comprehensive public health 
strategies, including safe sex, early diagnosis combined with effective treatment of the infection, 
partner notification, and the identification of sexual networks and high-risk populations in order 
to implement control and effective prevention programs. In the absence of a vaccine, antibiotic 
treatment is the cornerstone of gonorrhea control programs. The number of different antibiotics 
that can be used to treat gonococcal disease is increasingly restricted due to the resistance of N. 
gonorrhoeae isolates to most antibiotic classes such as β-lactams and quinolones.  
 
Currently, gonococcal infections are mostly treatable with extended spectrum 
cephalosporins alone or in combination with azithromycin. However, increasingly numerous 
reports of N. gonorrhoeae strains with reduced susceptibility or resistance to extended spectrum 
cepalosporins and treatment failures with these agents, especially with oral cephalosporins (e.g. 
cefixime), have highlighted the urgent need to discover and assess new therapeutic regimens and 
antimicrobial agents. For this reason, the World Health Organization (WHO) issued a global 
alert on potentially untreatable gonococcal infections and calling for a variety of measures to 
combat drug resistance, including increased antimicrobial susceptibility surveillance.  
 
This research provides temporal (2003 to 2011) and spatial information on gonococcal 
AMR in SK, Canada. It is the first study investigating the antimicrobial susceptibility, 
mechanisms and molecular epidemiology of AMR, and the population dynamics of N. 
gonorrhoeae isolates in the province. Tetracycline resistance was widespread in the gonococcal 
population in SK. N. gonorrhoeae isolates in SK are highly susceptible (>95%) to extended 
spectrum cephalosporins and azithromycin, currently the recommended antibiotics for gonorrhea 
treatment, and to ciprofloxacin and penicillin, antibiotics which are no longer recommended to 
treat gonorrhea. According to the accepted definition of gonococcal treatment efficacy, a cure 
rate of over 95% is required for an antibiotic to be recommended for gonorrhea treatment. Thus, 
an antibiotic should not be used in situations where resistance is observed in greater than 5% of 
gonococcal isolates tested. The low levels (<5%) of gonococcal resistance to penicillin and 
ciprofloxacin observed in this research emphasizes the need to develop regional surveillance 
programs and treatment guidelines for the prudent and possibly extended use of antibiotics. Such 
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antibiotic susceptibility in N. gonorrhoeae as found in SK is rare and has been noted in only a 
few regions; the Northern Territory, Australia and Western Pacific Islands of Tonga, New 
Caledonia and Papua New Guinea.  
 
  As a result of evolutionary changes, bacteria have developed various ways to counter the 
actions of antimicrobials through development of resistance to one or multiple drugs. 
Gonococcal resistance to antimicrobial agents can be plasmid-mediated, chromosomally 
mediated resistance or both. In gonococci, plasmid-mediated resistance confers high levels of 
resistance to penicillin (i.e. PPNG) or tetracycline (i.e. TRNG). Mutations at various loci, 
singularly or in combination, are associated with chromosomally mediated resistance. The 
accrual of chromosomal mutations can confer resistance to multiple antibiotics or higher levels 
of resistance to single antibiotics. The potential array of molecular determinants for antimicrobial 
resistance in N. gonorrhoeae include the quinolone resistance determining regions in gyrA and 
parC for quniolones and various mutations in penA, mtrR, porB and ponA for penicillin, 
tetracycline and extended spectrum cephalosporin. Azithromycin resistance in N. gonorrhoeae is 
the result of alterations in 23S rRNA and mtrR and acquisition of erm encoding rRNA 
methaylases.  
 
This research systemically examined mutations in various loci in gonococcal isolates 
from SK resistant to penicillin, ciprofloxacin, azithromycin and with higher MICs (>0.03 mg/L) 
to cefixime and ceftriaxone. It is the first report on emerging molecular mechanisms of resistance 
in N. gonorrhoeae isolates from the province. This study revealed that the gonococcal 
antimicrobial susceptibility/resistance to extended spectrum cephalosporins and penicillin is 
associated with simultaneous  presence of specific mutations in PBP2 (penA), PorB and MtrR. 
This is the first study to establish the association of PBP2 mutation pattern IX (D345a, F504L, 
A510V, A516G and P551L) and MtrR mutation A-/H105Y (i.e.an adenine deletion (A-) in the 
mtrR promoter and a H105Y susbstituion in dimerization domain of MtrR with gonococcal 
isolates with higher MICs to cefixime and ceftriaxone).  
 
 Gonorrhea transmission occurs through groups of people called core groups and bridging 
populations, with the individuals in the bridging group acting as a link between the infected core 
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groups and the general population.
  
Therefore, effective identification of core groups is critical 
for the successful control of gonorrhea transmission. Molecular epidemiology, combinational 
application of molecular tools such as DNA sequence based typing and traditional 
epidemiological studies may be applied for this purpose. DNA sequence based typing (porB 
based typing, NG-MAST and MLST) for N. gonorrhoeae isolates can identify isolates with 
common molecular characteristics, grouping them into STs, and thereby providing insight into 
presumptively linked cases. The DNA sequence based typing methods have high resolution 
power, and coupled with phylogenetic analysis they provide comprehensive information on the 
genetic relatedness of different strains.  
 
Using porB-based typing, NG-MAST and MLST, novel patterns of gonococcal strain 
distributions were revealed. porB based typing and NG-MAST are based on hyper-variable loci 
and classify the large cluster of similar N. gonorrhoeae isolates with minor (1 bp) variations 
under different STs over the period of time. These typing methods have high discriminating 
ability but less genetic stability, and are better suited for molecular epidemiological studies of N. 
gonorrhoeae isolates collected over short period of time. This research shows that predominant 
STs in SK differ over time and across geographical locations. The gonococcal population 
isolated from major locations in SK is genetically and phenotypically different as compared to 
other Canadian provinces. Further, porB groups and NG-MAST groups, (STs with less than ≤1% 
bp difference), revealed that the gonococcal population in SK is highly related.  
 
MLST is based on internal DNA sequence fragments of conserved house-keeping genes, 
which are evolutionarily relatively neutral genes. MLST revealed that the gonococcal population 
over time in SK is related with very little incursion from imported strains. MLST analysis of 
AMR demonstrated that ciprofloxacin and azithromycin resistances in N. gonorrhoeae in SK 
evolved through convergent acquisition and were distantly related to predominant MLST 
gonococcal lineages observed in SK. Penicillin and tetracycline resistance in SK were the result 
of spontaneous mutations in already established lineages. Certain porB and NG-MAST STs were 
clustered under MLST STs. This underscores that typing schemes, such as MLST, which are 
based on conserved housekeeping genes, are more suitable for macroepidemiology or long term 
epidemiological studies. Based on three typing methods used in this study, the best approach to 
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achieve desired balance of genetic stability and discrimination power in molecular 
epidemiological studies can be using a combination of conserved genetic markers and hyper-
variable loci. In many studies, only a single method is used. 
 
Significant associations were observed between different resistance phenotypes and 
specific mutation pattern combinations in PBP2, MtrR and PorB and specific NG-MAST STs. 
This indicates that certain STs with specific combined mutation patterns be predictive of 
antimicrobial susceptibility and is useful for molecular diagnosis. 
 
Based on this research and previous research an international database of gonococcal 
porB sequences is being established. porB typing (756 bp) is less expensive compared with other 
DNA base typing schemes (full length porB typing, 987bp; NG-MAST and MLST) available for 
N. gonorrhoeae strain typing and has good (>90%) resolution power. This will help in globally 
tracking the strain distribution and transmission of N. gonorrhoeae.  
 
This research has been communicated to the SDCL, Regina as well as various other 
authorities in the STI field provincially, nationally and internationally. High levels of 
antimicrobial susceptibility in N. gonorrhoeae will impact formulation of disease control 
strategies and treatment guidelines/options for gonorrhea. The findings of this study stress the 
need to develop regional policies on treatment guidelines for N. gonorrhoeae infections and 
gonococcal AMR surveillance programs. The significant associations between antimicrobial 
resistance phenotypes/genotypes and specific STs observed in this study suggest that such 
observations can aid in molecular diagnosis of antimicrobial susceptibility in gonococci. This 
means that the population studies based on molecular typing that did not involve determination 
of antimicrobial susceptibility and molecular determinants of resistance in gonococcal isolates 
can still provide information on resistance phenotype of N. gonorrhoeae. This finding is relevant 
in the present context of gonococcal diagnosis when NAATs are used for the confirmation of N. 
gonorrhoeae infections and less use is made of culture identification methods for the 
determination of antimicrobial susceptibility. 
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Table A.1 Penicillin susceptibility of 427 N.  gonorrhoeae isolates from Saskatchewan (2003-2011)
a
 
 
a: 
 
Interpretative criteria for MIC classification were those described by the CLSI (CLSI 2009).  
b: The MICs of 320 N. gonorrhoeae  isolates from 2003-2008 were determined as part of this thesis. The antimicrobial susceptibility testing of 107 
N. gonorrhoeae isolates from 2009-2011 was done at the SDCL, Regina, Canada.  
c: PPNG isolates- 1/60 isolates 2003, 1/52 isolates 2005, 1/36 isolates 2009 and 1/37 isolates 2011. 
 
 
 
 
 
 
 
 
Year
b 
n 
% Susceptible 
(n) 
% Intermediate 
(n) 
% Resistant 
(n) 
MIC range 
(mg/L) 
MIC50 
(mg/L) 
MIC90 
(mg/L) 
2003 60 13 (8) 80 (48) 7 (4)
c 
0.06-16.0 0.25 1.0 
2004 59 31 (18) 63 (37) 7 (4) 0.016-4.0 0.25 1.0 
2005 52 12 (6) 76 (40)  12 (6)
c 
0.016-32.0 0.5 2.0 
2006 55 20 (11) 80 (44) 0 (0) 0.008-1.0 0.125 1.0 
2007 53  17 (9) 83 (44) 0 (0) 0.008-1.0 0.5 1.0 
2008 41  17 (7) 81 (33) 2 (1) 0.008-2.0 0.25 1.0 
2009 36 50 (18) 47  (17) 3 (1)
c 
0.001-8.0 0.06 0.25 
2010 34 32 (11) 68 (23) 0 (0) 0.001-1.0 0.125 0.5 
2011 37 46 (17) 51 (19) 3 (1)
c 
0.008-8.0 0.125 0.5 
Total 427 25 (105)  71 (305) 4 (17) 0.001-32.0 0.25 1.0 
2
1
5
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Table A.2 Tetracycline susceptibility of 427 N. gonorrhoeae isolates from Saskatchewan (2003-2011)
a
 
a: 
 
Interpretative criteria for MIC classification were those described by the CLSI (CLSI 2009).  
b: MIC of 320 N. gonorrhoeae  isolates from 2003-2008 were determined were determined as part of this thesis.  
The antimicrobial susceptibility testing of 107 N. gonorrhoeae isolates from 2009-2011 was done at the SDCL, Regina, Canada.  
c: TRNG isolates- 3/59 isolates 2004, 3/52 isolates 2005, 7/55 isolates 2006, 1/53 isolates 2007. 
 
 
 
 
 
 
 
Year
b 
n 
% Susceptible 
(n) 
% Intermediate 
(n) 
% Resistant 
(n) 
MIC range 
(mg/L) 
MIC50 
(mg/L) 
MIC90 
(mg/L) 
2003 60 22 (13) 27 (16) 51(31) 0.125-8.0 2.0 8.0 
2004 59 36 (21) 22 (13) 42 (25)
c 
0.125-128.0 1.0 4.0 
2005 52 15 (8) 25 (13)  60 (31)
c 
0.125-128.0 2.0 4.0 
2006 55 5.4 (3) 5.4 (3) 89.1 (49)
c 
0.06-256.0 4.0 16.0 
2007 53 4 (2) 9 (5) 87 (46)
c 
0.06-16.0 4.0 8.0 
2008 41 5 (2) 22 (9) 73 (30) 0.03-8.0 2.0 8.0 
2009 36 67 (24) 33 (12)  0 0.008-0.5 0.25 0.5 
2010 34 82 (28) 18 (6) 0 0.016-1.0 0.125 1.0 
2011 37 73 (27) 22 (8)  5 (2) 0.008-16.0 0.125 0.5 
Total 427 30 (128) 20 (85) 50 (214) 0.008-256.0 1.0 8.0 
2
1
6
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Table A.3 Ciprofloxacin susceptibility of 427 N.  gonorrhoeae isolates from Saskatchewan (2003-2011)
a
 
a: 
 
Interpretative criteria for MIC classification were those described by the CLSI (CLSI 2009).  
b: MIC of 320 N. gonorrhoeae  isolates from 2003-2008 were determined were determined as part of this thesis.  
The antimicrobial susceptibility testing of 107 N. gonorrhoeae isolates from 2009-2011 was done at the SDCL, Regina, Canada.  
 
 
 
 
 
 
 
 
 
Year
b 
n 
% Susceptible 
(n) 
% Intermediate 
(n) 
% Resistant 
(n) 
MIC range 
(mg/L) 
MIC50 
(mg/L) 
MIC90 
(mg/L) 
2003 60 100 (60) 0 (0) 0 (0) 0.002-0.016 0.008 0.016 
2004 59 100(59) 0 (0) 0 (0) 0.002-0.016 0.004 0.008 
2005 52 100 (52) 0 (0) 0 (0) 0.002-0.016 0.004 0.008 
2006 55 94 (52) 2 (1) 4 (2) 0.002-8.0 0.008 0.016 
2007 53 96 (51) 0 (0) 4 (2) 0.004-4.0 0.008 0.008 
2008 41 94 (39) 3 (1) 3 (1) 0.002-4.0 0.004 0.016 
2009 36 100 (36) 0 (0) 0 (0) 0.001-0.008 0.001 0.004 
2010 34 74 (25) 0 (0) 26 (9) 0.001-32.0 0.002 4.0 
2011 37 86 (32) 0 (0) 14 (5) 0.001-16.0 0.002 4.0 
Total 427 95 (406) 0.5 (2) 4.5 (19) 0.001-32.0 0.004 0.016 
2
1
7
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Table A.4 Azithromycin susceptibility of 427 N.  gonorrhoeae isolates from Saskatchewan (2003-2011)
a
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a: 
 
Interpretative criteria for MIC classification were those described by the GISP (CDC 2010b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year
 
n 
% Susceptible 
(n) 
% Resistant 
(n) 
MIC range 
(mg/L) 
MIC50 
(mg/L) 
MIC90 
(mg/L) 
2003 60 100 (60) 0 (0) 0.03-0.5 0.125 0.5 
2004 59 100 (59) 2 (1) 0.016-8.0 0.125 0.5 
2005 52 98 (51) 0 (0) 0.06-1.0 0.25 0.5 
2006 55 100 (55) 0 (0) 0.03-1.0 0.25 0.5 
2007 53 98 (52) 2 (1) 0.03-2.0 0.25 0.5 
2008 41 100(41) 0 (0) 0.03-1.0 0.5 0.5 
Total 320 99.5 (318) 0.5 (2) 0.016-8.0 0.25 0.5 
2
1
8
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Table A.5 Spectinomycin susceptibility of 427 N.  gonorrhoeae isolates from Saskatchewan (2003-2011)
a
 
a: 
 
Interpretative criteria for MIC classification were those described by the CLSI (CLSI 2009).  
b: MIC of 320 N. gonorrhoeae  isolates from 2003-2008 were determined were determined as part of this thesis.  
The antimicrobial susceptibility testing of 107 N. gonorrhoeae isolates from 2009-2011 was done at the SDCL, Regina, Canada. 
 
 
 
 
 
 
 
 
Year
b 
n 
% Susceptible 
(n) 
% Intermediate 
(n) 
% Resistant 
(n) 
MIC range 
(mg/L) 
MIC50 
(mg/L) 
MIC90 
(mg/L) 
2003 60 100 (60) 0 (0) 0 (0) 8.0-32.0 16.0 16.0 
2004 59 81(48) 19 (11) 0 (0) 8.0-64.0 16.0 64.0 
2005 52 100 (52) 0 (0) 0 (0) 8.0-32.0 16.0 16.0 
2006 55 100 (55) 0 (0) 0 (0) 8.0-32.0 16.0 32.0 
2007 53 94 (50) 6 (3) 0 (0) 4.0-64.0 16.0 32.0 
2008 41 100 (41) 0 (0) 0 (0) 8.0-32.0 16.0 16.0 
2009 36 100 (36) 0 (0) 0 (0) 4.0-16.0 8.0 16.0 
2010 34 100 (34) 0 (0) 0 (0) 4.0-16.0 8.0 16.0 
2011 37 100 (37) 0 (0) 0 (0) 4.0-16.0 8.0 16.0 
Total 427 97 (413) 3 (14) 0 (0) 4.0-64.0 16.0 32.0 
2
1
9
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Table A.6 Cefixime susceptibility of 427 N.  gonorrhoeae isolates from Saskatchewan (2003-2011)
a
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a: 
 
Break points are not defined (CLSI 2009).  
b: MIC of 320 N. gonorrhoeae  isolates from 2003-2008 were determined were determined as part of this thesis. 
Antimicrobial susceptibility testing of 107 N. gonorrhoeae isolates from 2009-2011 was done at the SDCL, 
Regina, Canada. 
 
 
 
 
 
 
 
 
Year
b 
n 
MIC range 
(mg/L) 
MIC50 
(mg/L) 
MIC90 
(mg/L) 
2003 60 0.004-0.03 0.016 0.03 
2004 59 0.0005-0.06 0.008 0.03 
2005 52 0.002-0.06 0.008 0.03 
2006 55 0.001-0.125 0.008 0.03 
2007 53 0.0005-0.016 0.008 0.016 
2008 41 0.0005-0.03 0.016 0.016 
2009 36 0.008 0.008 0.008 
2010 34 0.008 0.008 0.008 
2011 37 0.008 0.008 0.008 
Total 427 0.0005-0.125 0.008 0.016 
2
2
0
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Table A.7 Cetriaxone susceptibility of 427 N.  gonorrhoeae isolates from Saskatchewan (2003-2011)
a
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a: 
 
Break points are not defined (CLSI 2009).  
b: MIC of 320 N. gonorrhoeae  isolates from 2003-2008 were determined were determined as part of this thesis. 
Antimicrobial susceptibility testing of 107 N. gonorrhoeae isolates from 2009-2011 was done at the SDCL, 
Regina, Canada. 
Year
b 
n 
MIC range 
(mg/L) 
MIC50 
(mg/L) 
MIC90 
(mg/L) 
2003 60 0.002-0.06 0.008 0.03 
2004 59 0.00025-0.03 0.004 0.016 
2005 52 0.0005-0.03 0.008 0.03 
2006 55 0.001-0.06 0.016 0.03 
2007 53 0.0005-0.06 0.008 0.016 
2008 41 0.002-0.06 0.016 0.03 
2009 36 0.001-0.016 0.004 0.008 
2010 34 0.001-0.125 0.004 0.016 
2011 37 0.001-0.25 0.004 0.016 
Total 427 0.00025-0.25 0.008 0.03 
2
2
1
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Table A.8 Mutation patterns of PBP2 in 146 N. gonorrhoeae isolates  susceptible to 
extended spectrum cephalosporins   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a: Mutation patterns were numbered as they have been previously referenced in the literature 
(Whiley et al, 2007a; Ohnishi et al 2011b).  
b: Ceftriaxone susceptibility groups: 1: MIC =0.0005-0.016 mg/L; 2: MIC =0.03-0.06 mg/L. 
c: Cefixime susceptibility groups: 1: MIC =0.0005-0.016 mg/L; 2: MIC =0.03-0.125 mg/L. 
d: WT: wild type using wild type PBP2 sequence M32091.  
*: P value<0.05 is considered statistically significant.  
 
 
 
 
 
 
 
 
PBP2 pattern
a
 n (%) 
Ceftriaxone susceptibility  
groups
b 
Cefixime   susceptibility 
groups
c
 
1 
n (%) 
2 
n (%) 
1 
n (%) 
2 
n (%) 
IX 50 (34) 36 (29) 14 (61)
* 34(30) 16 (67)
* 
I 41 (28) 39 (32)
* 2 (9)
 
39 (32)
* 2 (8)
 
XXII 35 (24) 32 (26) 3 (13) 33 (27) 2 (8.3) 
II 7 (5) 7  (6) 0 (0) 7  (6) 0 (0) 
XII 6 (4.0) 4 (3.3) 2 (9) 4 (3.3) 2 (8.5) 
XIV 2 (1.4) 2 (2) 0 (0) 2 (2) 0 (0) 
V 2 (1.4) 1 (1) 1(4) 1 (1) 1(4) 
WT
d 
2 (1.4) 2 (2) 0 (0) 2 (2) 0 (0) 
XXXIV 1 (0.7) 0 (0) 1(4) 0 (0) 1(4) 
Total 146 123 (83) 23 (17) 122 (84) 24 (16) 
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Table A.9 PorB mutations in 146 N. gonorrhoeae isolates susceptible to extended 
spectrum cephalosporins 
 
a: Ceftriaxone susceptibility groups: See Table 3.11. 
b: Cefixime susceptibility groups: See Table 3.11. 
c: WT: wild type using porB sequence M21289 (Carbonetti et al 1987). 
 
 
 
 
 
 
 
Pattern 
number 
PorB mutation n (%) 
Ceftriaxone susceptibility  
groups
a
 
Cefixime susceptibility  
groups
b
 
1 
n (%) 
2  
n (%) 
1  
n (%) 
2  
n (%) 
1 WT 
c 
63(43) 60 (49)
*
 3 (13) 59 (48)
* 
 4 (17) 
2 G120D; A121N 28 (19) 24 (20) 4 (17) 24 (20) 4 (17) 
3 G120K; A121D 21(14) 12 (10) 9
 
(39)
*
 12 (10) 9
 
(38)
* 
 
4 G120N; A121N 11(7.5) 8 (7) 3 (13) 8  (7) 3  (13) 
5 G120K; A121N 6 (4) 5 (4) 1 (4) 4 (3) 2 (8) 
6 G120D; A121D 5 (3.5) 4 (3) 1(4) 5 (4) 0 (0) 
7 A121S; N122K 5 (3.5) 4 (3) 1(4) 4 (3) 1 (4) 
8 A121G 2 (1.4) 2 (2) 0 (0) 2 (2) 0 (0) 
9 G120D 2 (1.4) 2 (2) 0 (0) 2 (2) 0 (0) 
10 G120K 1 (0.7) 1(0.8) 0 (0) 1(0.8) 0 (0) 
11 G120K; A121G 1 (0.7) 1 (0.8) 0 (0) 1 (0.8) 0 (0) 
12 G120R; A121D 1 (0.7) 0 (0) 1(4) 0 (0) 1(4) 
 Total 146 123 (83) 23 (17) 122 (84) 24 (16) 
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Table A.10 mtrR mutations in 146 N. gonorrhoeae isolates susceptible to extended spectrum 
cephalosporins 
 
 
a: Ceftriaxone susceptibility groups: 1: See Table 3.11. 
b: Cefixime susceptibility groups: 2: See Table 3.11. 
c: WT: wild type using mtrR sequence Z25796 (Pan & Spratt 1994). 
e: MtrR coding sequence truncated at amino acid position 136. 
 
 
 
 
 
 
 
 
 
Pattern 
number 
MtrR mutation n (%) 
Ceftriaxone 
susceptibility groups
a
 
Cefixime susceptibility 
groups
b
 
1 
n (%)
 
2 
n (%) 
1 
n (%)
 
2 
n (%) 
1 WT
c
 37 (25) 37 (30)
*
 0 36 (30)
*
 1 (4) 
2 G45D 55 (38) 42 (34) 13 (57) 43 (35) 12 (50) 
3 A-;G45D 25 (17) 23 (19) 2 (9) 22 (18) 3 (12) 
4 A-;H105Y 10 (7) 5 (4) 5 (22)
* 5 (4) 5 (21)
*
 
5 Truncated MtrR
 e
 4 (3) 4 (3) 0 (0) 4 (3) 0 (0) 
6 A39T (4) 4 (3) 2 (1.5) 2  (9) 2 (2) 2 (8) 
7 T86A;H105Y 3 (2) 3 (2.5) 0 (0) 3 (2.5) 0 (0) 
8 
A40D;D79N; 
T86A;H105Y 
3 (2) 3 (2.5) 0 (0) 3 (2.5) 0 (0) 
9 D79N;T86A;H105Y 2 (1.4) 2 (1.5) 0 (0) 2 (2) 0 (0) 
10 A39T;H105Y 1 (0.7) 1(0.8) 0 (0) 1 (0.8) 0 (0) 
11 A- 1(0.7) 0 (0) 1 (4.5) 0 (0) 1 (4) 
12 TT+ 1(0.7) 1(0.8) 0 (0) 1 (0.8) 0 (0) 
 Total 146 123 (83) 23 (17) 122 (84) 24 (16) 
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Bacterial transformation 
 
Transformation experiments to assess the role of penA mutations in imparting reduced 
susceptibility to extended spectrum cephalosporins and penicillin were carried out as described 
by Sarubbi et al (1974) and Ropp et al (2002). Bacterial strains used in transformations studies 
were FA19, WHO K, Ng 9, Ng 22 and Ng 34 (Table 2.1).  
 
penA genes were amplified with primers penF and penR
  
(Ohnishi et al 2011b; Table 2.3) 
from strains FA19, WHO K, Ng 9, Ng 22 and Ng 34. The PCR mixtures were incubated for 2 
min at 96°C, followed by 30 cycles of 10 s at 96°C, 10 s at 65°C, and 2 min at 72°C (Ohnishi et 
al 2011b). All amplicons were analyzed by agarose gel electrophoresis and purified as described 
in Section 2.3.2. Amplicons were transformed individually into strain FA19, as described 
previously (Sarubbi et al 1974; Ropp et al 2002). The transformation protocol was standardized 
using penA with mosaic penA pattern X, amplified from reference strain WHO K. FA19 was 
transformed with penA patterns IX, XXII and mosaic pattern XXXIV, amplified from strains Ng 
9 Ng 22 and Ng 34, respectively.   
 
 Piliated colonies (Sarubbi et al 1974) of N. gonorrhoeae recipient strain FA19 were 
passaged on a fresh GCMBK plate with an inoculation loop and were grown for 12 to 16 h at 
35°C in a humidified 5% CO2 atmosphere. All cells were scrapped from these plates with an 
inoculation loop and were resuspended in prewarmed gonococcal broth with 1% Kellogg’s 
supplement, 20 mM bicarbonate and 10 mM MgCl2. N. gonorrhoeae cells were diluted to an 
optical density of 0.18 (at 560 nm). 20μl (~ 10 μg DNA) of  purified  PCR product was added to 
0.9 ml cell suspension and the mixture was incubated for 5 hours at 37°C in a CO2 (Ropp et al 
2002). An aliquot (10 μl) was then inoculated onto GCMBK plates containing cefixime (0.004-
0.125 mg/L) and penicillin (0.004-0.125 mg/L) in two-fold dilutions. Plates were incubated for 
20-24 hours at 35
o
C in a humidified 5% CO2 atmosphere.  Cell suspensions of the untransformed 
parental strain N. gonorrhoeae FA19 (cefixime MIC= 0.002-0.004 mg/L) were also plated on the 
same antibiotic series as the negative control. Untransformed strains Ng 9, WHO K, Ng 22 and 
Ng 34 suspensions were plated as positive controls for penA patterns IX, X, XXII and XXXIV, 
respectively. Colonies growing on cefixime and penicillin containing GCMBK plates and not 
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which did show growth of FA19, were subcultured on GCMBK plates without antibiotics. Single 
isolated colonies were subcultured three times on GCMBK plates containing cefixime (0.016 
mg/L) to ensure the purity of the culture. 
 
 The antimicrobial susceptibility profiles of the generated isogenic N. gonorrhoeae strains 
were determined in duplicate using the agar dilution assays
 
(CLSI 2009)
 
and compared to those 
of wild type FA19. Recombinants showing 3-4 fold increase in the cefixime MIC values were 
compared to wild type FA19 and were stored to verify the transformant genotype through DNA 
sequencing. DNA sequencing of FA19 and FA19 transformants of penA pattern IX, X, XXII and 
XXXIV was performed as described in Section 2.5.3 previously using primers penA_SF1, 
penA_SF2, penA_SF3, penA_SR1, penA_SR2, penA_SR3 and penA_SR4 (Table 2.3) . 
 
Results 
 Transformation with penA pattern XXXIV from strain Ng 34 resulted in three fold (0.004 
to 0.03 mg/L) increase in cefixime MICs of the recipient strain FA19 (Table A2.1). A fourfold 
(0.004 to 0.06 mg/L) increase in cefixime MICs of FA19 was observed when transformed with 
penA pattern X from WHO strain K.  Transformations with penA mosaic penA patterns IX and 
XXII from strain Ng 9 and Ng 22 did not change the cefixime MICs of FA19.  
 
DNA sequencing of FA19 and FA19 transformants of penA pattern IX, X, XXII and 
XXXIV was done at using primers penA_SF1, penA_SF2, penA_SF3, penA_SR1, penA_SR2, 
penA_SR3 and penA_SR4 (Table 2.3). The sequencing reactions were done using Applied 
Biosystems 3730x1 DNA Analyzer (Plant Biotechnology Institute, National Research Council of 
Canada, Saskatoon, SK). The sequencing reactions were done twice but I could not align the 
whole penA from the FA19 and FA19 transformants because of the poor quality of the 
sequences. This work will be done in future since increase in the 3 to 4 fold increase in MICs of 
recipient strains observed after transforming mosaic penA patterns in recipient strain indicates 
that  whole or partial penA has been inserted in penA of FA19. 
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Table A2.1 Increase in cefixime MIC values of recipient wild type N. gonorrhoeae FA19 
transformed with penA mosaic patterns X and XXXIV but not with non-mosaic pattern IX 
and XXII 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strains and penA patterns Cefixime MIC (mg/L) Fold MIC increase 
FA19 (wild type, recipient) 0.004 0 
WHO K (X) 0.5 0 
Ng 9 (IX) 0.06 0 
Ng 22 (XXII) 0.03 0 
Ng 34 (XXXIV) 0.125 0 
FA19 + normal saline 0.004 0 
FA19 + penA X (WHO K) 0.06 4 
FA19+ IX 0.004 0 
FA19+XXII 0.004 0 
FA19 + penA XXXIV (Ng 34) 0.03 3 
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